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Glioblastoma is a WHO grade IV tumor with high mortality rate. In order to 
identify the underlying biological causation of this disease, a comparative genomic 
hybridization dataset generated from 170 patients’ tumor samples was analyzed. Of 
many available segmentation algorithms, I focused mainly on two most acceptable 
methods: Homogeneous Hidden Markov Models (HHMM) and Circular Binary 
Segmentation (CBS). Simulations show that CBS tends to give better segmentation 
result with low false discovery rate. HHMM failed to identify many obvious 
breakpoints that CBS identified. On the other hand, HHMM succeeds in identifying 
many single probe aberrations.  
 Applying other statistical algorithms revealed distinct biological fingerprints 
of Glioblastoma disease, which includes many signature genes and biological 
  
pathways. Survival analysis also reveals that several segments actually correlate to 
the extended survival time of some patients.  
In summary, this work shows the importance of statistical model or algorithms 
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Chapter 1: Introduction 
Cancer is a class of diseases in which a group of cells display uncontrolled 
growth, invasion, and sometimes metastasis (http://en.wikipedia.org/wiki/Cancer). 
More than 200 different types of cancers have been identified so far and all these 
cancers account for 13% of all human deaths across the whole world. 
Cancer could start from any tissue of human body, and many factors have 
been found to contribute to the development of the disease. These include 
environmental factors (pollution, smoking, food, ultraviolet radiation from the sun, et 
al.), genetic factors, as well as other factors such as infections from viruses. 
Genetically, the direct consequences of the effects of all these factors are the 
alteration of genetic information including the uncontrolled gene expression of the 
oncogenes or inhibition of the activity of tumor suppression genes. 
The human genome contains 23 pairs of chromosomes with 22 pairs of 
autosomal chromosomes and 1 pair of sex chromosomes (XX for female and XY for 
male). There are about 3 billion base pairs of nucleotides for the entire human 
genome, which contains about 20-30 thousands protein-encoding genes. In fact, only 
1.5% of the entire human genome sequence encodes protein-coding information, 
while the function of most of the remaining sequence remains unknown. 
Cancer is the result of the accumulation of multiple genetic changes 
(Armitage and Doll 1954), which potentially become cytogenetically visible with the 
development of the cancer. Comparative Genomic Hybridization (CGH) is the study 
of chromosome aberrations and their correlations to human diseases. The common 




Numerical aberration mainly involves the changes of chromosome numbers 
(Aneuploidy) and it is believed that some cancers are involved in the aneuploidy (Sen 
2000). Structure aberration refers to copy number variations (copy number gains or 
losses) of some segments of chromosomes. Many tumors have shown to be related to 
chromosome aberration, for instance renal cell carcinoma (chromosome positions 
3p13-21) (Mulshine, et al. 1988), lung adenocarcinoma (chromosome positions 3p13-
23) (Mulshine, et al. 1988), etc. 
Traditionally, due to the limitation of human genome sequence information, 
staining has been the main method to study the karyotypes of human genome, usually 
using dyes, such as Giemsa, which results in the G-banding method. For this method, 
chromosomes are first stained by Giemsa and then followed by digestions with 
trypsin. In this way, the chromosomes show a series of lightly and darkly stained 
bands (Figure 1.1). The dark regions tend to be heterochromatic, late-replicating and 
AT rich, and the light regions are euchromatic, early replicating and GC rich. Usually 
G-banding can produce 300-400 bands in a normal human genome, with the average 
resolution around 10M base pairs (bp). FISH or Fluorescence In-Situ Hybridization is 
a rapid reliable technique in molecular cytogenetics (Celep, Karaguzel, Ozgur and 
Yildiz 2003) and can be used to identify isolated abnormal cells among a large group 
of normal cells. It is also a method to locate a specific gene on the chromosome or to 
study translocations of a known gene. As with G-banding methods to detect genomic 
variation, the main problems of FISH are also slowness, low throughput and low 





Figure 1.1 Chromosome spread and the karyotypes stained by the G-banding method. 
Chromosomes shown here are from a normal male. 
Array-based comparative genomic hybridization (aCGH) is similar to the 
traditional karyotyping methods but with the advantages of high throughput and high 
resolution. For this method, hundreds of thousands of oligonucleotides based on 
human genome sequences are spotted on an area of roughly 1cm2 on a 1”x 3” glass 
slide and tumor and reference samples labeled with different dyes are hybridized to 
the chip. Genomic gains and losses can be analyzed genome widely by comparing 
sample genomic DNA (in our case, tumor samples) to reference genomic DNA 
sample in one experiment; this will be discussed in detail in the experimental section. 
The ultimate goal of this thesis is to study the underlying causes in the 
genomic level of human cancer Glioblastoma by using the array CGH method. Since 
we are dealing with millions of data points, in order to get more reliable biological 
results, we will apply various statistical methods to process the data set and compare 








All the data used are downloaded from the Cancer Genome Atlas 
(“cancergenome.nih.gov”). The Agilent array platform – Human Genome CGH 244k 
chip – is used in this study. On each chip, 244,000 probes are spotted with 236,000 
distinct biological features. There are also 1000 replicated biological features and 
5045 internal quality control features. Each feature represents one 60mer 
oligonucleotide designed based on human genome sequence. The average distance on 
the chromosomes between two features is about 6.4kb. Brain Glioblastoma samples 
collected from 170 patients were analyzed by CGH at Broad Institute/Dana-Farber 
Cancer Institute. In addition, 24 normal samples were analyzed by CGH at Broad 
Institute and this data set is used as control in this analysis. Table 2.1.1 lists brief 
clinical information about the 170 patients. Detailed sample information can be 
obtained from the published paper (TCGA 2008) (also see supplementary file Table 
S2.1.1. For the array CGH experiment (hybridization), individual patient’s genomic 
DNA and a common reference genomic DNA are labeled with two different 
fluorescence dyes (which emit red and green light after laser ignition) and hybridized 
to the Human Genome CGH 244k chips. Figure 2.1.1 shows the brief procedures to 





total patients with tumor 170 
gender FEMALE: 67; MALE:103 
pretreatment history No: 148; Yes: 19 
histological type Treated primary GBM: 15; Untreated primary (De Nova) GBM:154 
vital status1 DECEASED:159; LIVING: 10 
vital status2 ALIVE: 15; DEAD: 155 
days to birth Min.: -31627; Q1: -24502; Median: -20931; Mean: -20375; Q3: -17080; Max.: -5303; NA's: 1 
days to death Min.: 8.0; Q1: 209.0; Median: 370.0; Mean: 516.7; Q3: 597.0; Max.: 3040.0; NA's: 11.0 
days to last follow up Min.: 3.0; Q1: 161.0; Median: 357.0; Mean: 519.6; Q3:578.0; Max.: 3040.0; NA's: 1.0 
age at diagnosis Min.: 14.00; Q1:46.00; Median: 57.00; Mean: 55.32; Q3: 67.00; Max.: 86.00; NA's: 1.00 
day to progression Min.: -1409.0; Q1: 88.0; Median: 183.0; Mean: 269.1; Q3: 334.0; Max.: 2339.0; NA's: 61.0 
days to recurrence Min.: 7.0; Q1: 113.0; Median: 283.0; Mean: 523.7; Q3: 524.0; Max.: 2296.0; NA's: 144.0 
secondary or recurrent No: 149; Rec: 16; Sec: 5 
race AMERICAN INDIAN OR ALASKAN NATIVE: 1; ASIAN: 1; BLACK OR AFRICAN AMERICAN: 2; UNK: 88; WHITE: 78 
age at procedure Min.: 15.00; Q1.: 47.00; Median: 57.00; Mean: 55.68; Q3: 66.50; Max.: 86.00; NA's: 3 
age at death Min.:15.00; Q1: 49.25; Median: 58.00; Mean: 56.82; Q3: 68.00; Max.: 87.00; 
 
Table 2.1.1: Summarized information for all 170 patients used in this study. The WHO 
categories for all patients are grade IV and the median survival rate is approximately one year 
as states in the published paper (TCGA 2008). All the date information is relative to the zero 
date when patients seek treatment. The “AGE at DIAGNOSIS” indicates patient’s age at 
initial pathologic diagnosis. “Day to progression” stands for “days to tumor progression”, and 
“Day to recurrence” for “days to tumor recurrence”. There are two vital status columns 
available in the table. The discrepancy is due to the inconsistent information from published 






Figure 2.1.1 Schematic description of array CGH experiments. First the sample genomic 
DNA is isolated from patients’ tissue samples (in this study, glioblastoma tumor) and then 
fragmented to yield the desirable around 200 bp short DNA population. The reference 
genomic DNA purchased from commercial sources is also processed in the similar way. After 
then, both the fragmented tumor DNA and the reference DNA are labeled with Cy5 and Cy3 
dyes respectively and the mixture of these two samples is hybridized onto the human genome 
CGH 244k chip, which is followed by the scanning procedure. Cy5 and Cy3 dyes can 
generate red and green light, respectively, upon the excitation by laser light, and the 
intensities of the two dyes of all features are measured for further data analysis. 
2.2 Data Structure 
 After hybridization, the chip is scanned and the intensities of red and green 
colors as well as the corresponding background intensities for each spot are recorded. 
The log2 transformed Ratio of the two background-subtracted fluorescent dyes of the 




As mentioned above, each chip (from each patient out of a total 170 patients) could 
yield 236k distinct data sets (each set includes Cy3 and Cy5 intensities, the 
corresponding backgrounds, as well as other data information). In addition, there are 
also another 24 normal samples from 24 patients. But only four patients have both 
tumor samples and normal samples in our analyzed data set. Each sample (tumor or 
normal) is used to perform hybridization on the chip and the collected data sets are 
used for data processing and analysis.  
 
2.3 Data processing and analyzing method 
 The data processing mainly relies on the R software “BioConductor” 
packages (www.bioconductor.org). Specifically, for the CGH part, the “snapCGH” 
package developed by Smith (Smith 2006) was used. For the survival analysis, 
“survival” package developed by Therneau (Terry Therneau 2009) and “KMsurve” 
package by Yan (Yan 2010) were used. The main codes for these analyses are listed 
as supplementary file. Many other R packages were also being called in the above 
individual package in order for the full functioning. These R packages include 
LIMMA (Gordon K. Smyth 2010), and aCGH (Willenbrock and Fridlyand 2005). 
Another powerful computation tool used in the data processing is Perl scripts and 
other R functions. Occasionally other commercially available software such as 




Chapter 3: Literature Review 
 
3.1 Copy number variation 
 Array CGH is a high throughput technology to study the chromosome 
aberration of target samples. Specifically, suitable segmentation methods are used to 
identify the breakpoint of the DNA copy numbers and to assign gains, losses or no 
change to all segments based on the log2(Ratio) and the cutoff criteria applied. For 
diploid cells, there are 2n numbers of chromosomes. In human cells, especially 
somatic cells, this n is 23. Theoretically, the copy number variation is inferred by the 
log2(Ratio) of intensities of tumor samples vs. reference sample. For instance, one 
copy number loss would yield log2(1/2) = -1. Table 3.1.1 lists the relations of copy 
number variation and log2(Ratio). Practically, due to many random and systematic 
errors involved in each experiment, the observed log2(Ratio) values of copy number 
variation are far from their theoretical values. Nevertheless, we can still derive the 













Table 3.1.1 the relations of copy number variation with the observed log2(Ratio) in the 
idealized situation of the diploid genome. In this study, we assume that the reference sample 
has a perfect diploid genome that is represented by “AA” in the denominator position. The 
numerator positions represent the ploidy situations of individual sample (or segments within 
the chromosome regions). For instance, “00”, stand for homozygous deletions and “A” 
indicates that only one copy of the diploid segment remains, which suggests heterozygous 
deletion. “AA” at the numerator shows no copy number changes, “AAA” indicates one copy 
gain and “AAAA” indicated 2 copy number gains. It is possible to have multiple copy 
number gains for some genes or segments. 
3.2 Segmentation methods 
During the past several years, many segmentation algorithms have been 
developed, for instance, Homogeneous Hidden Markov Models (HHMM) (Fridlyand 
et al. 2004) and Heterogeneous Hidden Markov Modes (BioHMM) (Marioni, Thorne 
and Tavare 2006), assign probes to underlying segments or states, which represent 
different copy numbers. Circular Binary Segmentation (CBS) (Olshen, et al., 2004) is 
a non-parametric change point method based on the original work of Sen and 
Srivastava (1975). Hupe proposed a Gaussian model-based algorithm (GLAD) (Hupe 
2004) and Hsu suggested a wavelet approach (Hsu, et al. 2005). There are still some 
Example Copy number variation Ratio log2(Ratio) 
00/AA two copy losses 0 -! 
A/AA one copy loss 1/2 -1 
AA/AA no change 1 0 
AAA/AA one copy gain 3/2 0.58 




other approaches such as hierarchical cluster based methods (CLAC) (Wang, Kim, 
Pollack, Narasimhan and Tibshirani 2005), Shifting Level Model (SLM) (Magi, et al. 
2009), and the Bayesian based model of Daruwala (Daruwala, et al. 2004), et al. In 
this section, I will briefly introduce some of the segmentation methods and some pros 
and cons involved in some of the major methods.  
 
3.2.1 Homogeneous Hidden Markov Models (HHMM) 
The following description of HHMM segmentation method is taken mainly from 
Fridlyand et al. (2004). Since each segment could be treated as a state with equal 
copy number and the total numbers of segments or states is unknown but fixed, the 
hidden Markov models could be used as a suitable statistical model for the 
identification of all the unknown states. In this model, each state is reachable from 
any other state and the state emission distributions are Gaussian with state specific 
mean and common variance. The initial state distribution and the transition state 
probability distributions comply with Markov Chain modeling requirement as shown 
below (cited mainly from Fridlyand et al., 2004): 
a) The number of states, K, is unknown but fixed. The Markov chain is assumed 
irreducible with individual states space S = {S1, S2, …, SK} and the state at 
location l is Sl, where 1 " l " L. 
b) The initial state distribution is ! = { !k} where !k = P{s1 = Sk}, 1 " k "K. 
c) The state transition probability matrix is A=[amp] where amp=P{sl+1=Sp|sl=Sm}, 




d) The distribution of emission bk is Gaussian with unknown mean and variance:    
bk ~ N(#k, !k2) for 1 " k " K 
A forward-backward procedure is used to calculate the likelihood of 
parameters (Lik(!|"), where ! is the parameter vector for the model and " represents 
the sequence of observed values on a given chromosome. The number of states K is 
estimated using the parameter correction penalty function #(K) similar to Akaike’s 
Information Criterion (AIC) (Akaike 1969) or Bayesian Information Criterion (BIC) 
(Schwarz 1978) as shown below: 
#(K) = -log(Lik(!|")) + qKD(L)/L. 
Briefly, for k = 1 to Kmax, where Kmax = 5 (based on the observation from real 
data sets), first fit the k-state HHMM model and calculate the penalized negative log-
likelihood #(k). Choose the model corresponding to the number of states with the 
smallest #(k), and so that K = argmink#(k). If K = 1, then stop the modeling. 
Otherwise, perform merge states test by calculating the absolute median differences 
of two states and compare to a cutoff threshold. If the difference is smaller than the 
cutoff threshold, merge the two states and also set K = K-1. Repeat the same testing 
until no merging is possible.  
3.2.2 Heterogeneous Hidden Markov Models (BioHMM) 
 In homogenous hidden Markov models, the spatial information (the distances 
between the adjacent probes) is not taken into account. But in fact, due to specific 




it is very hard to design suitable probes for the array CGH study. Therefore the 
distances between two adjacent probes vary significantly. This uneven tiling of 
probes on the chromosome reflects the biological properties embedded in each 
chromosome. BioHMM (Marioni, et al. 2006) is a segmentation method constructed 
based on the HHMM algorithm, but adding probe distance as an additional factor in 
the transition probabilities. Practically, the distance is defined as differences between 
two adjacent probes and this information is incorporated into the transition 
probabilities as shown below: 
 
where fi = xir, xi is the vector containing the distance information and r belongs to R 
with initial value as 1. Detailed algorithms for this method can be found in the cited 
paper (Marioni et al., 2006). 
3.2.3 Circular Binary Segmentation (CBS) method 
 
 CBS was proposed by Olshen (Olshen et al., 2004) based on the binary 
segmentation model proposed Sen and Srivastava (1975). The underlying framework 
for this model is that the gains and losses are discrete events and the aberrations occur 
in contiguous regions of the chromosomes. Segmentation is in fact a process to find 
the change points or breakpoints along the chromosome. For the binary segmentation 
method proposed by Sen and Srivastava, the third breakpoint located within the two 
known breakpoints will split the original segment into two segments. Both segments 
were assumed to follow normal distributions with equal variance but unknown means. 




likelihood ratio statistics for testing the null hypothesis is given by   Zb = max1<i<n|Zi|, 
where  Zi = {1/i+1/(n-i)}-1/2{Si/i-(Sn-Si)/(n-i)} and Si = X1+X2+Xi, 1<i<n. 
 One problem with the binary segmentation method is that it can only detect one 
breakpoint each time. Olshen et al. (2004) proposed a modified test called the 
Circular Binary Segmentation (CBS) method. Instead of finding one breakpoint 
suggested by binary segmentation method, CBS assumes the original two breakpoints 
were linked together to form a cycle and then trying to assign two additional 
breakpoints on the cycle following the similar procedures as shown in binary 
segmentation method. In this case, the maximum likelihood ratio statistic for testing 
the null hypothesis is modified to  Zc = max 1"i<j"n|Zij|, in which  
          Zij={1/(j$i)+1/(n$j+i)}$1/2{(Sj$Si)/(j$i)$(Sn$Sj+Si)/(n$j+i)}  
where 1<i<j<n, Sn = X1 + X2+…+Xn and Xi denotes log2(Ratio) of ith probe. Similar 
to the binary segmentation method, the critical value is also derived by Monte Carlo 
simulation (Siegmund 1986). This procedure is applied recursively until all change 
points are identified. 
 
3.2.4 Gain and Loss Analysis of DNA (GLAD) method 
 GLAD is a breakpoint detection method developed by Hupe et al. (Hupe 2004), 
mainly based on the adaptive weights smoothing (AWS) procedure proposed by 
Polzehl (Polzehl and Spokoiny 2000), which is “an iterative, data adaptive smoothing 
technique that was designed for smoothing in regression problems involving 
discontinuous regression function” (Hupe 2004). The statistical model for the GLAD 




where $i are i.i.d with N(0, !2) distribution. (Xi, Yi) are independent observations, Xi 
determines the chromosome locations of each individual probe or feature and the 
corresponding Yi is the measured log2(Ratio). AWS is applied to find the maximal 
possible neighborhood around location Xi based on the local likelihood model in 
which #(Xi) is constant. The regression function of Yi = #(Xi) + $ could be estimated 
by using the weighted maximum-likelihood estimate of local probes. The “contrasts” 
and the “edges” generated from AWS on the chromosomes provide potential 
segmentation (breakpoint) and its copy number information. 
3.2.5 Cluster Along Chromosomes (CLAC) method  
 
 The basic idea of CLAC (Wang, et al. 2005) is to build hierarchical cluster trees 
along each chromosome arm and assign the gains or losses based on the information 
associated with each node, such as the height of the node in the tree, the size of the 
sub-tree and the mean value of the sub-tree. Unlike the standard agglomerative 
clustering method, for the CGH data set, the order of the probe sequences of the 
chromosome are fixed, and so is the order the cluster. In order to compare the 
different measurement of two adjacent nodes, the authors proposed of using “relative 
difference” to measure the similarity of two adjacent sub-tree. If there are n probe on 
one chromosome with {x1, x2, …, xn} represent the log2(Ratio) of each probe. The 
relative difference (rd) for two contiguous probes is defined as: 
 




the height of the cluster, span on the chromosome as well as number of the probes), 
we can assign gains or losses to each segment. A brief clustering procedure within 
each chromosome is listed as follows: 
 1). Start clustering using all probes with one probe in each cluster. 
 2).Merge the two adjacent clusters with the smallest value of relative difference. 
 3). Repeat 2) until one big cluster is formed. 
3.2.6 Bayesian model 
 
 In this Bayesian model, some assumptions are made. First, all probes on the 
chromosomes are categorized into two groups. One group contains all “regular 
probes”, whose copy numbers are not affected by the disease, and whose log2 
transformed ratios follow a Gaussian distribution with mean µr and standard deviation 
!r. In the other group, which includes the deviated probes, the log2(Ratio) values also 
follow the Gaussian distribution but have unknown mean µb and unknown standard 
deviation !b. Another assumption is that the segments that have copy number 
variation (gains or losses) follow the Poisson distribution with parameter pbN, where 
N is the total number of probes. The segmentation algorithm is to find all the potential 
breakpoints on the chromosome, or equivalently, to subdivide all the probes along the 
chromosome into k non-overlapping intervals. Probes within the same interval follow 
the same distribution with same mean (or same copy number variations) and standard 
deviation. Specifically, for the j-th interval, the copy number values follow the 
Gaussian distribution N(µj, !j2). The parameter related to this interval is Ij = (µj, ij, !j) 
where ij is the position of the last probe in the interval. In this Bayesian model, we 




 In this model, the prior distribution is constructed based on both the Poisson 
distribution to model the number of intervals with Poisson parameter pbN and the 
Bernoulli trial where pr represents the probability that a given probe is a “regular” 
probe. 
 
where “#regular” denotes the number of unchanged probes and “#deviated” denotes 
the number of which assign gains or losses. The likelihood function of the first n 
probe is:  
 
with posterior likelihood function: 
. 
3.2.7 Comparisons of different segmentation methods 
 
 Even though many segmentation algorithms have been proposed during the past 
several years, only a few papers perform comparisons among some of the algorithms. 
In the recent paper of Willenbrock and Fridlyand (2005) three methods (HHMM, 
CBS and GLAD) are compared. Of these three methods, CBS yields the best 
operational sensitivity and lowest false discovery rate compared to the HHMM and 
GLAD segmentation methods. The drawbacks of this method are its slow 




contrary, the HHMM algorithm is fast and identifies many single probe aberrations. 
The problem is its low sensitivity to the breakpoint, since it fails to identify many big 
segments of aberrations.  GLAD is said to be superior to HHMM in identifying wide 
aberration. Lai, et al. (2005) compared 11 different segmentation methods, even 
though many of these methods are gradually becoming obsolete in current data 
analysis. Some of their results are very consistent with the conclusions of 
Willenbrock and Fridlyand. In general, Lai et al. found that CBS performed better in 
general than most of the other algorithms. The detailed results can be found in the 
published paper (Lai et al., 2005). As mentioned above, different methods have their 
own pros and cons. After many years of development, HHMM and CBS have been 
recommended as more reliable in identifying potential breakpoints on the 
chromosome in general (Willenbrock and Fridlyand 2005). Based on the nature and 
goal of this thesis, we choose to use HHMM and CBS to perform the data processing 
and to compare the segmentation results by using both simulated and real tumor data 
sets. 
3.3 Segment merging methods 
Since most of the segmentation methods work on the individual chromosome 
level, which means each chromosome is segmented independently, this poses a 
potential danger that aberration segments located on different chromosomes are 
incomparable. In some cases, this can cause information losses when the whole 
chromosome is deleted or amplified, which is the case in many tumor tissues. Even in 
the same chromosome segmentation profile, numerous segments with many different 




merging algorithm is used to merge those comparable segment values with 
insignificant differences into a common value. In GLAD algorithm, the adaptive 
weights smoothing (AWS) algorithm is used to remove the excessive breakpoints 
(Hupe 2004). Another merging algorithm was proposed by Willenbrock and 
Fridlyand (2005). Specifically, in this algorithm, if the difference between the 
log2(Ratio) values of two segments is not statistically significantly different, then 
these two segments are assigned to the same predicted value. In detail, the distances 
calculated based on the predicted (or segmented) values of log2(Ratio) values from 
any segments are ordered. From the smallest distance, using Wilcoxon rank sum test 
based on the observed log2(Ratio) of all probes within each segment to test whether 
both segments values are statistically different by using p < 0.0001 as threshold or if 
the distance is less than a give threshold if the probe number within one or both 
segments contain less than 3. If the predicted values of two segments are not 
significantly different or the distance is less than the cutoff threshold, these two 
segments are merged and the above process is repeated until no more segments can be 
merged together. If only 3 or fewer probes exist on one segment, then only the 
distance cutoff threshold will apply.  
In order to determine the cutoff threshold, the above steps are repeated with 
increased threshold and compare the current residual (current merged values minus 
observed log2(Ratio)) with the original residual (original merged value minus 
observed log2(Ratio)). The Ansari-Bradley two-sample test for equality of dispersion 




the largest threshold such that the Ansari-Bradley 2-sample test has p value > 0.05. 
The above test is repeated until no more segments can be merged together. 
3.4 Centering methods 
 DNA copy number gains or losses are defined relative to some common 
baseline agreed to represent the “normal” or “no changes” condition. Centering 
means calibrating the “normal” DNA copy number to a standard value, such as zero 
for the log2(Ratio) values. Different centering methods have been proposed, many of 
them based on different assumptions. Traditionally, the overall mean or median is 
used as the center value and all other log2(Ratio) values are shifted accordingly. But 
this method fails in highly aberrant genomes such as the tumor samples shown in 
Figure 3.4.1. Other methods, such as minimum aberration location, the segment 
intensity with the longest run length probe or using the highest mode of the intensities 
have also been suggested (Chen, et al. 2008). The first two methods require the pre-
segmentation while the last one doesn’t. Since the female X chromosome always has 
one copy number gain aberration in many studies with male genome references, sex 
chromosomes are always excluded from the calculation when define the centering 
values. In this analysis, after segmentation, we assume the mode of the predicted 






Figure 3.4.1 Genome aberration of Small Cell Lung Cancer samples shows the highly 
aberrant patterns across the whole genome. The y-axis represents the log2(Ratio) values of all 
probes and the black dotted line indicates the predicted segment values. 
3.5 Chromosome Gains and Losses assignment 
 After finding all potential breakpoints, the next question is to decide which 
segments represent chromosome gains or losses. As discussed in Section 3.1, due to 
all kinds of systematic and random errors involved in each experiment, the predicted 
segmentation values are far different from the standard, ideal log2(Ratio) of copy 
number variation as shown in Table 3.1.1. After suitable data processing steps, 
finding the chromosome gains or losses becomes a question of setting the reasonable 
cutoff thresholds for the predicted segmentation values. In some papers (Veltman, et 
al. 2003, Nakao, et al. 2004), a series of normal vs. normal hybridizations is 
performed in addition to the tumor sample hybridization. Ideally, all the log2(Ratio) 




errors are involved in the experiment. So the log2(Ratio) values in the normal vs. 
normal comparisons actually represent the noise information from the similar 
experiments. From the distribution of the log2(Ratio) of this controlled experiment, 
the cutoff thresholds could be decided by using 2 or 3 folds standard deviations of 
mean of log2(Ratio) values.   
 Derivative Log Ratio (DLR) is the difference between the log2(Ratio) values of 
consecutive probes along the chromosomes. Derivative Log Ratio spread (DLRs) can 
be used to estimate the probe-to-probe noise information. Based on the IQR of the 
DLRs, we can set a suitable cutoff threshold to estimate the noise level of the specific 
array CGH experiment. 
3.6 Literature review of the molecular biology background for 
Glioblastoma disease 
Glioma is a type of tumor that starts mostly in the brain. It is the most 
common primary brain tumor in adults. Histopathologically, Glioma has been 
subtyped into four categories, WHO grade I to IV, with grade I indicating a more 
benign tumor and grade IV being malignant featuring uncontrolled cellular 
proliferation, and resistance to apoptosis and high invasiveness. Glioblastoma is the 
most common grade IV brain tumor and is also a deadly disease with average survival 
time approximately one year. More than two decades of research work by many labs 
worldwide has revealed many molecular mechanisms about this disease. A detailed 
review of this research appears in the paper published on Gene & Development 
(Furnari, et al. 2007). Briefly, some genes or gene products have been shown to play 




to, phosphatase and tensin homolog (PTEN), retinoblastoma protein (RB1), TP53, 
epidermal growth factor receptor (EGFR). PTEN, Rb1, and TP53 have been classified 
as tumor suppressor genes, all of them involving cell cycle regulations. For instance, 
PTEN is involved in the regulation of the cell cycle, preventing cells from growing 
and dividing too rapidly (Chu and Tarnawski 2004). Rb1 is a protein that helps to 
prevent excessive cell growth by inhibiting cell cycle progression (Murphree and 
Benedict 1984). Like PTEN and Rb1, the protein product of TP53, p53, acts as a 
checkpoint regulator at the G1 to S phase (Furnari, et al. 2007). Loss of these 
functions through either mutations or deletions may cause the cancer cells to grow 
uncontrollably. Many molecular pathways have also been identified for the 
development of Glioblastoma. These pathways include PTEN/PI3K/AKT (Cantley 
and Neel 1999), TGF-Beta pathway (Xu and Kapoun 2009), and EGFR regulated 
pathway (Comincini, et al. 2009). Many other potential molecular pathways have also 





Chapter 4: Data simulation 
 
 
Simulated data sets have been widely used in evaluation of the performance of 
different CGH segmentation algorithms (Hupe 2004, Hsu, et al. 2005, Lai, et al. 2005, 
Willenbrock, et al. 2005, Huang, et al. 2007). The basic requirement is that the 
artificially generated data set should closely mimic the real data set, which includes 
probe tiling information on the chromosomes, breakpoint information, simulated 
intensity distribution, and even sample contamination information. In this analysis, in 
order to get a rough idea of segmentation properties of HHMM and CBS algorithms 
and also for the purpose of further comparison using the real data set, we perform a 
simulation study using the algorithm embedded in the R “snapCGH” package (Smith 
2006) mainly based on the simulation method proposed by Willenbrock and 
Fridlyand (2005). First thing we need to consider for the simulation is the array 
numbers. Sample numbers always determine the statistical testing power. In order to 
reflect the condition in our data set, we should use comparable data set numbers for 
our simulation. Second, chromosome information is also considered. Human genome 
contain 22 pairs of euchromosomes, each pair has different length. Each chromosome 
also contain one short arm and one long arm separated by the centromere, this 
information has also been considered as suggested in the aCGH R package ( 
Fridlyand 2008). Probe tiling is another issue we should consider. Even though 
sometimes it is difficult to design probes at specific regions due to some sequence 
structure reasons, we still try to design array probes evenly across all chromosomes in 




probabilities of assigning probes on both short and long arms of each chromosome to 
50%. In addition to this, the simulation function of snapCGH also has the option to 
specify the minimum and maximum probe distances and the probabilities of each 
segment of chromosomes being tiled. In order to mimic the noise level of real data 
set, Gaussian noise with mean zero and varying variance were added based on the 
suggestion of Willenbrock and Fridlyand (2004). The standard deviation of each state 
is random sampled from uniform distribution of 0.1 to 0.2 as been observed from real 
data set (Fridlyand et al., 2004).  
The ratio profiles for the simulated data set are generated based on the 145 
real tumor samples in order to emulate the complexity of real tumor profile ( 
Fridlyand et al., 2004). Briefly, the mean values of segments were binned into the 
interval between -0.2 and 0.2 and length for normal level were sampling from the 
level [-0.2, 0.2] bin. The altered segments values are sampled from other bins contain 
other segmentation values. This simulated dataset is considered as the known dataset 
with known breakpoints. The HHMM and CBS algorithms were applied to the 
simulated dataset estimated and known breakpoints were compared and the false 
discovery rate was returned.   
For this study, all the simulated data sets are generated under the “default” 
condition (except otherwise specified) and then followed by HHMM and CBS 
segmentation processes. The default is the conditions that try to mimic the real data 
condition while still considering the limitation of simulation situation. For instance, 
the probability of probe tiles on both arms of each chromosome is 50% even though 




default standard deviation of the simulated data in each of the states is randomly 
sampled uniformly between 0.1 and 0.2. The lower limit for the distance between 
adjacent clones in non-tiled region is 0.9Mb and upper limit is 1.1Mb. Sex 
chromosomes are always excluded from simulation due to their special situation.  
For the remaining 22 pairs of chromosomes, about 8000 probes are generated 
in each simulated sample file. Since we have more than 170 hybridizations in this 
study, we first generated the simulated data set with 170 samples. Figure 4.1 shows 
the density plots of the generated log2(Ratio) from all 170 simulated samples. The left 
panel represents the “observed” log2(Ratio) and the right panel represents the “true” 
log2(Ratio). After segmentation with HHMM and CBS algorithms, we can compare 
the observed breakpoints and the true breakpoints and further derive the false 
discovery rate. First of all, we tested whether the sample size could affect the false 
discovery rate. Simultaneously, we also test whether the data quality has big effects to 
the false discovery rate (Figure 4.2). The R code is given in Appendix B.  
 
Figure 4.1 Density plot of the simulated log2(Ratio) from all 170 simulated sample set. The 
left panel represents the simulated “observed” log2(Ratio) and the right panel represents the 





Figure 4.2 Comparison of HHMM (read color) and CBS (blue color) segmentation methods 
using simulated data set. The top two figures show the false discovery rate of similarly 
simulated data set but with different sample size (sample size number 20 vs 170). The two 
panels below indicate the false discovery rate of the two segmentation methods from the 
simulated data sets with the same sample sizes (sample numbers are 20) and different data 
quality (standard deviations 0.1 and 1 respectively). 
First, within each panel of Figure 4.2, we can clearly see that the CBS 
segmentation method  (blue color) generates more reliable results with relatively low 
false discovery rates. For the CBS segmentation method, the FDR for the CBS 
segmentation method is around 0.1, while for HHMM (red color) segmentation 




and 170 here), the FDRs for the same segmentation method are quite similar. For data 
sets with low quality, the ability to correctly find the breakpoints for both CBS and 
HHMM segmentation methods dropped significantly, reflected in the higher False 
Discovery Rate in the right figure of the lower panel. In summary, the results above 
clearly indicate that data segmented using the CBS method gives low false discovery 
rate in general even though it was suggested that HHMM surpass CBS in detecting 
the short segments (Willenbrock and Fridlyand, 2005). Of course, increasing the data 
variations could significantly increase the false discovery rate for both methods. This 
is also easy to understand, since the increasing of the variability of the data sets will 














Chapter 5:  Data processing and analyzing 
 
For the array-based experiment, there are several significant features compared to 
the traditional karyotyping experiments. The first feature is large data volume. 
Specifically in this study there are 236,381 probes on each chip that will generate the 
same volume of ratio values. Considering all the tumor data from 170 patients, the 
total data volume is tremendous. In order to derive reliable analytical results from this 
massive data set, we set up the following steps to process the data as shown in Figure 
5.1.  
 
Figure 5.1 Array CGH data processing procedures. After segmentation, the data 







5.1 Raw data 
After hybridization, the chips are scanned and the intensities and backgrounds 
from both channels for all probes were recorded. This information will be used for 
further data processing.  
5.2 Quality control (QC) analysis 
As in many other experiments, data quality is vital to the reliability of the 
results generated. In microarrays, data quality of array CGH can be affected by many 
factors starting from the sample collection to the final chip scanning.   Some of these 
factors include, but are not limited to, tissue quality, genomic DNA quality, and 
hybridization techniques as well as others. Good data quality will maximize the 
information we can get from each study. For the array CGH, one of the very 
important quality parameters to access the final data quality is Derivative Log Ratio 
spread (DLRs). Derivative Log Ratio (DLR) calculates the log2(Ratio) differences 
between consecutive probes on the chromosomes. Based on the inter-quartile range 
(IQR) of all DLR values on each chip data set, we can derive the DLRs with 
comparable robust standard deviation. DLRs value estimates probe-to-probe noise 
from the array itself calculated from the log2(Ratio). High DLRs values could result 
in low discrimination of different copy number variation.  Figure 5.2.1 shows QC 
information of two hybridizations with different DLRs values. Clearly low DLRs 





Figure 5.2.1 The relations between DLRs and the noise level in the array CGH experiments. 
The upper figure shows the probe expression levels for one array CGH experiment with very 
high DLRs value. This figure is generated based on real data set from different study. Clearly 
no chromosome aberration patterns can be observed if they exist. On the contrary, for the 
array CGH data with low DLRs illustrated in the lower figure, we can see clear chromosome 
gains and losses patterns across the whole genome. The yellow line represents the “center” or 
baseline. The black line represents the segments values for individual segments. 
Table 5.2.1 list all the DLRs values for 170 hybridizations used in this part of 
the analysis. From this table, we can see that the DLRs values for most of the 
hybridizations are very low. Based on many experimental results and also the 








Patients DLRs Patients DLRs Patients DLRs Patients DLRs 
TCGA-08-0386 0.14 TCGA-02-0102 0.19 TCGA-02-0338 0.21 TCGA-02-0007 0.24 
TCGA-08-0358 0.14 TCGA-06-0178 0.19 TCGA-02-0333 0.21 TCGA-06-0139 0.24 
TCGA-06-0146 0.15 TCGA-02-0258 0.19 TCGA-02-0106 0.21 TCGA-08-0373 0.24 
TCGA-06-0175 0.16 TCGA-08-0520 0.19 TCGA-12-0616 0.21 TCGA-02-0079 0.24 
TCGA-08-0518 0.16 TCGA-02-0057 0.19 TCGA-08-0510 0.21 TCGA-06-0132 0.24 
TCGA-06-0394 0.16 TCGA-02-0446 0.19 TCGA-08-0521 0.21 TCGA-02-0011 0.24 
TCGA-06-0194 0.16 TCGA-08-0514 0.19 TCGA-02-0028 0.21 TCGA-02-0456 0.24 
TCGA-08-0509 0.16 TCGA-02-0080 0.19 TCGA-12-0620 0.21 TCGA-06-0122 0.24 
TCGA-08-0512 0.16 TCGA-02-0071 0.19 TCGA-08-0531 0.21 TCGA-06-0176 0.24 
TCGA-08-0352 0.17 TCGA-02-0430 0.19 TCGA-02-0451 0.21 TCGA-02-0037 0.24 
TCGA-06-0648 0.17 TCGA-06-0185 0.19 TCGA-06-0158 0.21 TCGA-02-0281 0.24 
TCGA-02-0330 0.17 TCGA-06-0646 0.19 TCGA-06-0209 0.21 TCGA-02-0083 0.24 
TCGA-02-0439 0.17 TCGA-12-0618 0.19 TCGA-02-0034 0.21 TCGA-02-0006 0.25 
TCGA-08-0349 0.17 TCGA-02-0113 0.19 TCGA-02-0432 0.21 TCGA-06-0148 0.25 
TCGA-06-0164 0.17 TCGA-02-0324 0.19 TCGA-06-0214 0.21 TCGA-02-0260 0.25 
TCGA-02-0422 0.18 TCGA-06-0162 0.19 TCGA-06-0208 0.21 TCGA-02-0058 0.25 
TCGA-06-0414 0.18 TCGA-02-0326 0.20 TCGA-02-0060 0.21 TCGA-06-0145 0.25 
TCGA-06-0213 0.18 TCGA-02-0332 0.20 TCGA-06-0128 0.21 TCGA-02-0024 0.25 
TCGA-06-0168 0.18 TCGA-02-0055 0.20 TCGA-02-0111 0.21 TCGA-02-0089 0.25 
TCGA-06-0195 0.18 TCGA-02-0074 0.20 TCGA-06-0237 0.21 TCGA-06-0211 0.25 
TCGA-06-0238 0.18 TCGA-02-0047 0.20 TCGA-02-0337 0.22 TCGA-06-0189 0.25 
TCGA-06-0402 0.18 TCGA-02-0069 0.20 TCGA-06-0171 0.22 TCGA-06-0169 0.25 
TCGA-02-0269 0.18 TCGA-06-0179 0.20 TCGA-06-0413 0.22 TCGA-06-0133 0.25 
TCGA-02-0075 0.18 TCGA-08-0517 0.20 TCGA-06-0182 0.22 TCGA-02-0116 0.26 
TCGA-06-0149 0.18 TCGA-08-0524 0.20 TCGA-06-0166 0.22 TCGA-02-0317 0.26 
TCGA-02-0321 0.18 TCGA-06-0127 0.20 TCGA-06-0173 0.22 TCGA-02-0010 0.26 
TCGA-02-0107 0.18 TCGA-02-0084 0.20 TCGA-08-0345 0.22 TCGA-02-0021 0.27 
TCGA-06-0409 0.18 TCGA-02-0052 0.20 TCGA-02-0001 0.22 TCGA-02-0003 0.27 
TCGA-06-0197 0.18 TCGA-06-0152 0.20 TCGA-02-0009 0.22 TCGA-06-0174 0.27 
TCGA-06-0157 0.18 TCGA-06-0210 0.20 TCGA-06-0156 0.22 TCGA-06-0126 0.27 
TCGA-08-0511 0.18 TCGA-02-0266 0.20 TCGA-08-0529 0.22 TCGA-06-0125 0.27 
TCGA-08-0516 0.18 TCGA-02-0038 0.20 TCGA-06-0190 0.22 TCGA-06-0147 0.28 
TCGA-02-0114 0.18 TCGA-02-0271 0.20 TCGA-02-0086 0.23 TCGA-06-0137 0.28 
TCGA-06-0397 0.18 TCGA-02-0033 0.20 TCGA-02-0339 0.23 TCGA-06-0141 0.28 
TCGA-02-0325 0.18 TCGA-06-0412 0.20 TCGA-02-0046 0.23 TCGA-06-0221 0.28 
TCGA-02-0054 0.18 TCGA-06-0184 0.20 TCGA-06-0177 0.23 TCGA-06-0154 0.29 
TCGA-02-0085 0.18 TCGA-02-0440 0.20 TCGA-06-0129 0.23 TCGA-02-0014 0.29 
TCGA-06-0241 0.19 TCGA-02-0289 0.20 TCGA-06-0124 0.23 TCGA-06-0138 0.29 
TCGA-06-0645 0.19 TCGA-02-0064 0.20 TCGA-02-0290 0.23 TCGA-02-0027 0.29 
TCGA-12-0619 0.19 TCGA-02-0087 0.20 TCGA-06-0187 0.23 TCGA-06-0188 0.31 
TCGA-02-0099 0.19 TCGA-06-0644 0.21 TCGA-02-0043 0.23 TCGA-02-0285 0.33 
TCGA-02-0115 0.19 TCGA-06-0143 0.21 TCGA-08-0522 0.23     
TCGA-08-0525 0.19 TCGA-06-0410 0.21 TCGA-06-0130 0.24     




Other data quality metrics include signal to noise ratio, signal intensities and 
background noise information for both red and green channels. Since there are also 
1000 replicated biological features printed on each chip, for each channel, 
reproducibility is assessed by calculating the median percent coefficient of variation 
of background-subtracted signal for replicate non-control probes. Figure 5.2.2 
summarizes the data distributions of all these data quality metrics including the DLRs 
presented as box plots. Exact values of these quantities are given in supplementary 
Table S5.2.1. Based on the manufacturer’s guidelines (Table 5.2.2), all experiments 
have reasonably good quality and therefore all will be used for further data analysis.  
Metric Excellent Good Poor 
BackgroundNoise <5 5-10 >10 
Signal Intensity >150 50-150 <50 
Signal to Noise >100 30-100 <30 
Reproducibility <0.05 0.05-0.2 >0.2 
DLRspread <0.2 0.2-0.3 >0.3 
 





Figure 5.2.2 data quality metrics and their value information from all hybridizations 
used in this study. The y-axis values are log10 scaled. Since there are two color channels 
(Green and red for two samples, tumor and reference, separately), the qualities of each 
channel are accessed independently except for the DLRs. The reproducibility values shown 
here are the percentage values. 
 
5.3 Background subtraction 
Traditionally, background intensities are subtracted from the foreground 




this method is that the foreground signal intensities might be smaller than the 
corresponding background intensities in many cases. So the subtraction will result in 
“negative” intensities for some probes, which could cause further computational 
problems when performing log transformation. In this analysis, we use “minimum” 
background subtraction in which the background intensity is subtracted from 
foreground intensity of each probe unless the resulting intensity is zero or negative 
value. In this case, half the value of foreground intensity will be used. Using this 
“minimum” background subtraction can avoid generating either negative or zero 
value intensities and facilitate the computerization of the data processing steps. 
5.4 Combination of intensities 
As with many other Microarray platforms, duplicates or replicates of many 
probes are printed on the chip in order to access the data quality or the variability of 
each array experiment. The intensities from these replicates are normally merged into 
one value, mostly by mean or median, based on the unique ID. On the Agilent array 
platform – Human Genome CGH 244k chips, more than a thousand probes spotted on 
the chips are replicated. These replicates are averaged into the single final value for 
each probe. 
5.5 Segmentation and Merging 
As mentioned above, all the data are processed using both HHMM and CBS 
segmentation methods. Since HHMM and CBS are based on different statistical 
models, it is reasonably to expect that both the segmentation results should not be 
exactly same. Subtle differences in the mean log2(Ratio) values of two segments are 




complex. In this case, merging of these segments values with insignificant statistical 
differences becomes necessary especially when segments are located on different 
chromosomes. In this analysis, this process is performed by applying Willenbrock 
and Fridlyand’s (2005) merging method. Briefly, the predicted levels of segments 
were merged into the same level if the differences between them were not significant 
according to the Wilcoxon rank test or less than the specific threshold generated by 
using the Ansari-Bradley 2-sample test (for details see Section 3.3).  
 
 
Figure 5.5.1 Boxplot of segmentation numbers result from HHMM and CBS methods 




Figure 5.5.1 shows the segmentation and merging results from both the 
HHMM and CBS analyzing methods. The original segmentation numbers are listed in 
Supplementary Table S5.5.1. First, within each segmentation method, the merging 
process did reduce the segments numbers. Second, the two segmentation methods 
generate dramatically different segment numbers. For the CBS segmentation method, 
the mean segment numbers from 170 patients’ samples after merging is 198, while as 
for HHMM segmentation method, this number increased to 2495. Density plots of the 
merged segmentation results also show subtle differences between the HHMM and 
CBS segmentation methods. Figure 5.5.2 is from two pairs of typical density plots 
from the same patient (patient TCGA-02-0001). From these two figures, we can see 
that the general patterns of the density plots generated from HHMM and CBS 
segmentation methods are quite similar, even though we can still see subtle 






Figure 5.5.2 Density plot of segmented values after performing merging steps for sample 
TCGA-02-0001. The x-axis represents the log2(Ratio) values of all probes after performing 
the merging. From these two figures, we can see that the general patterns of the density plots 
generated from HHMM and CBS segmentation methods are quite similar, even though we 








Figure 5.6.1 Log2(Ratio) values of the modes of the density plots from all 170 patients 
samples (CBS segmentation methods). For most of the hybridizations, the mode of the 
density plot is shifted quite far from value and need to be adjusted accordingly. 
 
 
As discussed previously, for the array CGH study, all the copy number 
changes (gains or losses) are relative to the unchanged copy number. If the segment 
shows no aberration, we expect to see the ratio of tumor sample and control sample 
equal to one (or log2(Ratio) = 0). In this study, we assume the mode of densities for 
each patient sample represents the center of the log2(Ratio) values and all the 
log2(Ratio) values in each array CGH are shifted accordingly. The density plots in 
Figure 5.5.2 clearly show the shift of the mode of segments for one typical patient 
sample. Figure 5.6.1 shows the log2(Ratio) of the modes from all 170 patients by 




segmentation and the plot is posted as supplementary figure (Figure S5.6.1). Since 
most of the modes from the density plots of all 170 hybridizations are quite far away 
from zero, all the log2(Ratio) data should be adjusted. So, centering is necessarily in 
order to make all the experiments comparable. Figure 5.6.2 shows the density plots 
from the same patients as in Figure 5.5.2 after performing the centering (based on the 
CBS segmentation result). 
 
Figure 5.6.2 comparison of density plots before and after centering for one specific patient 
sample TCGA-02-0001. The left figure shows the density plot before the centering, and the 










Chapter 6:  Experimental results 
 
6.1 Breakpoint identification of HHMM and CBS methods 
Regardless of which segmentation algorithms we are using, the most 
important thing is that we can reliably identify those segments with copy number 
variation or identify the break points. Based on the simulated data set, we know CBS 
can identify breakpoints fairly reliably with low false discovery rate compared to the 
HHMM algorithm. For the real data set in this study, we also want to know whether 
CBS or HHMM segmentation methods can find the breakpoints reliably. By checking 
the chromosome aggregation plots (not included due to huge file sizes (10Gb)), we 
observed that the HHMM segmentation method failed to pick up many obvious 
change points as shown in one example in Figure 6.1.1, while CBS could. On the 
other hand, the HHMM segmentation method identified many single probe aberration 
change points, while the CBS algorithm failed to do so.  
Detailed analysis of the length of all the segments reveals that HHMM 
identified many single probe aberrations while the CBS method failed to do so. The 
histogram of the lengths of all segments clearly shows this pattern (Figure 6.1.2). In 
this figure, the segments lengths, which are plotted along the x-axis, are log2 
transformed. For the HHMM segmentation, in addition to a sharp peak at a short 
length position, there is another main peak around 15 to 20. But for the CBS 





Figure 6.1.1 Breakpoint identification by using CBS and HHMM algorithms. Only two 
typical patient samples are displayed here, with only chromosome 11 for sample TCGA-02-
0037 and chromosome 17 for sample TCGA-02-0038. Panels (A) and (C) are generated 
based on the CBS algorithm, and (B) and (D) are based on HHMM segmentation method. For 
the CBS algorithm, significant copy number loss at position around 40Mb is clearly identified 
in (A), while for the HHMM method, this segment is missing in (B). On the contrary, the 
HHMM algorithm identify many single probe aberration in (D), while CBS algorithm failed 





Figure 6.1.2 Density plots of all segment lengths (without merging) from both CBS and 
HHMM segmentation methods. The segments lengths are log2 transformed. The mode of the 
segments lengths densities of CBS segmentation methods are around 20 to 25, while as for 
the HHMM segmentation method, this mode is around 15 to 20.  
 
Considering the absolute segmentation numbers from all 170 samples, for the 
CBS segmentation method, only 4 single probe aberrations are identified from the 
total 36,553 segments of all 170 samples. On average, only 215 segments are 
identified in each sample. For the HHMM segmentation method, the total number of 
segments from all samples was 472,656, or an average of 2,780 segments per sample. 
Of these 472,656 segments, 117,653 segments are single probe aberrations, or an 
average of 692 single probe aberrations identified per hybridization.  
Since there are so many single probe aberrations identified by using the 
HHMM segmentation algorithm, the next question we would like to ask is how the 




make all the data comparable, the predicted values from centralized (after merging) 
segments are used. Figure 6.1.3 shows the density plots of all the predicted 
log2(Ratio) values of all single probe aberration segments. Most of these 100k single 
probe aberration segments have relatively small chromosome variations. Nevertheless 
there are still 1000 single probe segments (not including segments on the sex 
chromosomes) having absolute log2(Ratio) values greater than 1 (For details see 
supplementary Table S6.1.1). 
 
Figure 6.1.3 Density of log2(Ratio) of all single probe aberration segments. All the 
predicted log2(Ratio) values are from centralized segments. For the CBS algorithm, only four 
segments are single probe aberrations. But for the HHMM algorithm, 102,580 single probe 
segments are identified. Most of the segments have relatively small predicted log2(Ratio) 
values. 
 
If we think DLRs reflects the noise information for each experiment, then the 




variation. In this analysis, 1.5 times DLRs (1.5xDLRs) was used as cutoff threshold 
to identify the segments with copy number variations. The histogram of the segment 
lengths (log2 transformed) in Figure 6.1.4 shows that there are more “big” segments 
when using CBS while HHMM tends to identify short length segments. Again, in the 
segment profiles with 1.5xDLRs cutoff, HHMM identified a total of 47114 single 
probe segments out of 106,868 segments. On the contrary, CBS identified only four. 
For the segment length distribution, we can also see that CBS tends to identify big 
segments while HHMM fails to do so. 
Even though we can’t say that all the single probe aberration identified by 
HHMM are biologically relevant, failure to identify these segments when using CBS 
segmentation methods clearly leads to the incomplete data analysis results. Similar 
conclusion could be drawn to the HHMM segmentation method that fails to identify 






Figure 6.1.4 Density plots of all segments lengths (log2 transformed) from segments with 
copy number variation. The cutoff thresholds for the predicted segmentation values are 
1.5xDLRs. Many segments with big length are identified in the CBS algorithm while HHMM 
segmentation method tends to find the small segments. 
 
6.2 Segment analysis 
Even though in many cases, copy number variation can lead to the 




also our poor understanding basically of all cancers, we should not expect all patients 
to have the same chromosome aberration patterns. In order to identify the underlying 
biological causes of Glioblastoma, we focus the analysis on the following two areas. 
The first area is to use frequency method to identify chromosome regions that show 
frequent copy number variations in many patients The second area is to focus on each 
individual patient and find those regions that clearly show high copy number gain or 
loss and to elucidate the relations of those genes within these segments to their 
biological phenotype (discussed in section 6.4). 
6.2.1 Frequency analysis of copy number variation 
 
Frequency analysis is attempts to identify those chromosome regions that 
show frequent aberrations (amplifications or deletions) in most of the disease patient 
samples. Regardless of which segmentation method is used, the frequency plots in 
Figure 6.2.1 clearly indicates that more than 60% of the patients have chromosome 
amplification of chromosome 7 and massive copy number losses of chromosomes 10 
and 9p. About fourth of the patients have copy number losses on chromosome 13, 14 
and 22 and/or copy number gain on chromosome 19, 20. Similar data processing and 
analyzing of 24 normal samples show no chromosome aberration at these regions 
(Figure 6.2.2). From the aberration plots, we can also see that for the HHMM 
segmentation algorithm, the data look more noise than the aberration plot generated 
based on CBS segmentation algorithm. This “noisy” pattern of HHMM frequency 






Figure 6.2.1 Frequency plots of all segments from 170 patients samples. Top figure generated 






Figure 6.2.2 Frequency plot of all segments from 24 normal tissue samples. The segmentation 
is based on CBS algorithm. For the HHMM segmentation algorithm, a similar result was 
obtained 
Table 6.2.1 shows the aberration regions with frequencies 25% or higher 
segmented by using the CBS algorithm method. For the HHMM segmentation 
algorithm, quite similar results are derived (see supplementary Table S6.2.1). We 
could notice from both table that some genes gain copy numbers in some patients 
(ADAM5P and ADAM3A at p11.23 of chromosome 8 in Table 6.2.1) while they lose 
copy numbers in other patients. The polymorphism properties of these genes (or other 







aberration pattern chrom start end cytoband gene num 
Gain chr1 71641212 72520865 p31.1 1 
Loss chr1 71641212 72520865 p31.1 1 
Loss chr1 149370786 149385728 q21.2 1 
Gain chr1 149579739 149586393 q21.2 1 
Loss chr1 238719495 238842085 q43 1 
Loss chr1 245069024 245148302 q44 1 
Loss chr3 196933423 196950211 q29 1 
Gain chr4 69546931 69570979 q13.2 1 
Loss chr4 69546931 70396215 q13.2 2 
Loss chr5 848719 904101 p15.33 1 
Loss chr6 32593131 32719407 p21.32 4 
Loss chr6 165660767 165995574 q27 1 
Gain chr7 288051 158630410 p22.3-q36.3 964 
Loss chr7 141517438 141567562 q34 1 
Loss chr8 7408720 7791647 p23.1 14 
Gain chr8 39291338 39499627 p11.23 2 
Loss chr8 39291338 39499627 p11.23 2 
Loss chr9 111037 33029062 p24.3-p13.3 114 
Loss chr10 170642 135341873 p15.3-q26.3 782 
Loss chr11 5755465 5756440 p15.4 1 
Loss chr11 55127492 55190148 q11 4 
Gain chr12 56374152 56462591 q14.1 8 
Loss chr13 35241122 101852125 q13.3-q33.1 158 
Loss chr14 18447593 92225087 q11.1-q32.12 13 
Loss chr15 18997107 19915749 q11.2 8 
Loss chr16 54352011 54366325 q12.2 1 
Loss chr17 41463128 41605371 q21.31 1 
Gain chr19 232043 63722733 p13.3-q13.43 784 
Loss chr19 56837617 56841944 q13.33 1 
Gain chr20 16350 62378023 p13-q13.33 567 
Loss chr20 1493029 1548689 p13 1 
Gain chr22 22670594 22731899 q11.23 4 
Loss chr22 22703116 22714284 q11.23 2 
Loss chr22 37683472 37718729 q13.1 2 
 
Table 6.2.1 Segmentation result generated based on CBS segmentation algorithm. All the 




6.3 Functional impact of candidate genes or related pathways in the 
development of Glioblastoma tumor 
PTEN has been found to be a tumor suppressor gene and the mutation or 
deletion of this gene is associated with the development of many cancers. PTEN has 
also been deleted in 60% -- 70% of high-grade Glioblastoma patients’ tumors 
(Johnston, et al. 2006). In this study, PTEN was deleted in around 100 patients out of 
all 170 patient samples (depending on the segmentation method; see Table 6.3.1 for 
detailed information). The pathway involving PI3K/PTEN/AKT has been suggested 
in previous studies (Fan, et al. 2007, Furnari, et al. 2007). Deletion of the tumor 
suppressor gene PTEN could result in uncontrolled PI3K signaling (Knobbe and 
Reifenberger 2003, Ohgaki, et al. 2004). Many regulatory subunits of PI3K have been 
identified, which include PIK3CA, PIK3CB and PIK3CD. Copy number gains of 
PIK3CA, PIK3CB and PIK3CD in some patient samples indicate the potential 
involvement of this pathway. In our study, we also observed that more than 90 
patients’ samples contain copy number gains of PIK3CG. PIK3CG has been shown to 
interact with PIK3CD (Vanhaesebroeck, et al. 1997). Amplification of PIK3CG 
probably also involves the PI3K/PTEN/AKT signal pathways. Other PI3K subunits 
including PIK3R2 (gain in about 40 samples), PIK3AP1 (losses in 95 patients 
samples) were also identified in our study.  
Some other genes acting as “induction of programmed cell death” are deleted 
in most of the patient samples. These genes include FAS, TIAL1, SMNDC1, BNIP3 
and CUL2. FAS belongs to TNF-receptor superfamily and has been shown to activate 
NF-kappa-B and MAPK3/ERK1 pathways. NF-kappa-B has been linked to 




the patients have NF-kappa-B2 deleted. Since this gene is also located on 
chromosome 10, whether the deletion of this gene is a causal factor for the disease or 
is simply an involuntary deletion is unclear. FAS contains a death domain and is 
shown to play a central role in programmed cell death. Human leukocyte antigen 
(HLA) variants have been shown associated to be with the onset and prognosis of 
adult Glioblastoma multiforme (Tang, et al. 2005), in this analysis with CBS 
segmentation algorithm, HLA-DRB5 has been deleted in 109 patients samples and 
HLA-DRB6 been deleted in 78 patients. There are also 38 patients see the deletion of 
HLA-DRB1 in the tumor samples.  
Epidermal growth factor receptor (EGFR) is a cell surface receptor. It has 
been shown that amplification of EGFR occurs in about 40% of Glioblastoma patients 
(Furnari, et al. 2007). In our study, about 100 patients have amplified EGFR. Matrix 
metallopeptidase 9 (MMP9) is involved in the breakdown of extracellular matrix. 
Amplified MMP9 might facilitate tumor cell growth and migration. More than 30 
patients also displayed the elevated expression level of this gene. 
P53 is another tumor suppressor gene acting as a check point regulator at the 
G1 to S phase. Loss of p53 could be either through point mutations or chromosome 
deletions whereas point mutation is inaccessible by using the array CGH method.  But 
in this study, there are also 11 patients who have copy number deletion for this gene. 
It has also been shown that the protein encoded by CDKN2A is an important 
accessory to p53 activation under conditions of oncogenic stress due to its 
neutralization of the p53 ubiquitin ligase, MDM2 (Kamijo, et al. 1998, Pomerantz, et 




suppressor gene CDKN2A on chromosome 9 in about 100 patient samples 
suggestions a potential pathway of development of Glioblastoma tumor involving p53 
regulation. Concordantly, MDM2 has been detected amplified in 25 patient samples 
when segmented based on CBS algorithm. We also observed that only 8 patients 
samples show amplification when data were analyzed by the HHMM algorithm. This 
suggests that there is a potential discrepancy between the CBS and HHMM 
algorithms. It is the best idea to consider all possibilities in order to get a better 
picture of the result. MDM4 could inhibit p53 transcription and enhances the 
ubiquitin ligase activity of MDM2 (Furnari, et al. 2007). We also noticed that 14 
patients samples have amplified MDM4. 
Retinoblastoma protein (Rb1) is another tumor suppressor protein frequently 
found deleted in many types of cancer (Murphree, et al. 1984). It has been shown that 
Rb1 can block the proliferation of tumor cells by binding to the E2F family of 
transcription factors (Sherr and McCormick 2002). Amplification of CDK4 and 
CDK6 accounts for the inactivation of Rb1 in many patient samples (Serrano, 
Hannon and Beach 1993). In this study, 99 patient samples have amplified copy 
numbers of CDK6. Copy number gains of CDK6 probably at least partially contribute 
to the inactivation of Rb1. We observed 41 patient sample deletions using the CBS 
segmentation algorithm and 49 sample deletions using HHMM segmentation method. 
P16 (or CDKN2A) is another tumor suppressor gene, which functions as an inhibitor 
of CDK4. In 104 patient samples, copy number losses of p16 were observed based on 
the CBS segmentation algorithm and 90 patients showed similar patterns based on the 




dependent kinase inhibitor, which forms a complex with CDK4 or CDK6. We 
observed 103 and 89 patients with copy number losses of CDKN2B from the CBS 
and HHMM segmentation algorithms respectively. 
DMTF1 functions as negative regulation of cell cycles. Gene expression level 
of DMTF1 was amplified in at least 93 patient samples. Other cell cycle regulating 
genes that have been amplified in at least half of the patient samples include RINT1, 
MAD1L1, HUS1, CDC2L5, INHBA and ASNS and all of them are located on 
chromosome 7. 
DMBT1 is a “Deleted in Malignant Brain Tumors 1” protein and the deletion 
of this gene has been associated with the progression of human cancers. DMBT1 was 
originally isolated based on the deletion in a medulloblastoma cell line, but was also 
later found deleted in many cases of Glioblastoma tumor. In this study, from HHMM 
segmentation analysis with 1.5xDLRs cutoff threshold, 121 patients have DMBT1 
deleted, and 105 patients have the same gene deleted based on the CBS segmentation 
method. Other genes that involve cell cycle regulating are BUB3, KIF20B, BCCIP, 
ZWINT, PDCD4, RASSF4, ZMYND11, CDC123, GTPBP4. All these genes were 
deleted in more than half of the patient sample.  
 









Gene Ontology Biological 
Process 
ASNS 87 4 90 2 chr7q21.3 
asparagine biosynthetic process; 
positive regulation of mitotic cell 
cycle 
BCCIP 4 97 4 95 chr10q26.1 regulation of cyclin-dependent protein kinase activity; cell cycle 
BNIP3 4 93 8 90 chr10q26.3 cell death; negative regulation of survival gene product expression 
BUB3 4 98 4 94 chr10q26 
mitotic sister chromatid 














Gene Ontology Biological 
Process 
CDC123 10 84 9 83 chr10p13 
cell cycle arrest; regulation of 
mitotic cell cycle; positive 
regulation of cell proliferation 
CDC2L5 89 4 92 2 chr7p13 positive regulation of cell proliferation 
CDK4 37 3 15 1 chr12q14 
G1/S transition of mitotic cell 
cycle; positive regulation of cell 
proliferation  
CDK6 99 4 93 2 chr7q21-q22 G1 phase of mitotic cell cycle; negative regulation of cell cycle 
CDKN2A 6 104 7 90 chr9p21 
cell cycle checkpoint; G1/S 
transition of mitotic cell cycle; 
induction of apoptosis 
CDKN2B 6 103 7 89 chr9p21 
negative regulation of cell 
proliferation ; G1/S transition 
checkpoint  
CUL2 6 89 6 86 chr10p11.21 
G1/S transition of mitotic cell 
cycle; negative regulation of cell 
proliferation  
DMBT1 4 99 4 105 chr10q26.13 
multicellular organismal 
development; epithelial cell 
differentiation 
DMTF1 94 4 93 2 chr7q21 cell cycle 
EGFR 112 7 96 3 chr7p12 
activation of MAPKK activity; 
negative regulation of mitotic cell 
cycle 
FAS 4 97 4 96 chr10q24.1 induction of apoptosis; positive regulation of necrotic cell death 
GTPBP4 10 82 8 80 chr10p15-p14 regulation of cyclin-dependent protein kinase activity 
HLA-
DRB1 7 38 5 23 chr6p21.3 immune response 
HLA-
DRB5 10 109 10 47 chr6p21.3 immune response 
HLA-
DRB6 9 78 8 33 chr6p21.3 --- 
HUS1 89 4 91 3 chr7p13-p12 DNA damage checkpoint 
INHBA 88 4 91 2 chr7p15-p13 
G1/S transition of mitotic cell 
cycle; negative regulation of cell 
cycle 
KIF20B 4 96 4 93 chr10q23.31 M phase of mitotic cell cycl; cell cycle arrest 
MAD1L1 90 4 94 5 chr7p22 mitotic cell cycle checkpoint  
MDM2 25 4 8 2 chr12q14.3-q15 negative regulation of transcription from RNA polymerase II promote 
MDM4 14 0 9 0 chr1q32 
negative regulation of transcription 
from RNA polymerase II promote; 
G0 to G1 transition 
MMP9 37 0 38 0 chr20q11.2-q13.1 positive regulation of apoptosis 
NFKB2 5 91 5 72 chr10q24 regulation of transcription, DNA-dependent 













Gene Ontology Biological 
Process 
PIK3CA 8 2 11 4 chr3q26.3 negative regulation of apoptosis 
PIK3CB 6 5 10 4 chr3q22.3 activation of MAPK activity 
PIK3CD 8 17 8 5 chr1p36.2 B cell homeostasis  
PIK3CG 90 4 92 2 chr7q22.3 negative regulation of apoptosis 
PTEN 4 98 4 97 chr10q23.3 
regulation of cyclin-dependent 
protein kinase activity; negative 
regulation of apoptosis 
RASSF4 3 92 3 88 chr10q11.21 cell cycle 
RB1 1 41 6 48 chr13q14.2 cell cycle checkpoint 
RINT1 91 4 92 2 chr7q22.3 G2/M transition DNA damage checkpoint 
SMNDC
1 4 93 4 92 chr10q23 induction of apoptosis 
TIAL1 4 98 4 97 chr10q induction of apoptosis; positive regulation of cell proliferation 
ZMYND
11 10 82 8 83 chr10p14 
negative regulation of transcription 
from RNA polymerase II promoter; 
cell cycle 
ZWINT 5 91 5 88 chr10q21-q22 cell cycle; phosphoinositide-mediated signaling 
 
Table 6.3.1 Gene information discussed in this section. In the column of Gene Oncology 
biological process, only partial GO terms are listed. All these GO terms are annotated based 
on Affymetrix gene chip annotation table downloaded from Affymetrix website 
(http://www.affymetrix.com). 
6.4 Genes that show significant variation in individual patients 
 Many genes show very big gene expression variation within individual 
samples. For instance, 951 genes have at least four-fold ratio differences between the 
tumor samples and the reference control within all 170 tumor samples.  Among these 
genes, 245 of them have at least 16-fold aberration. As discussed before, EGFR plays 
a very important role in the Glioblastoma development. In 50 tumor samples out of 
170 patients samples, EGFR is amplified at least 16 folds. Even though, for many 
genes, the biological function involving the development of Glioblastoma remains 




before suggests the importance of these genes. Table 6.4.1 shows the partial gene list 
that has at least four-fold aberrations. The full list is given in supplementary Table 
S6.4.1.     
genes chrom sample number pattern genes chrom 
sample 
number pattern 
K03193 7 62 Gain AJ001612 7 15 Gain 
EGFR 7 62 Gain MBD6 12 15 Gain 
SEC61G 7 42 Gain DDIT3 12 14 Gain 
LANCL2 7 32 Gain GEFT 12 14 Gain 
AK128355 7 25 Gain DTX3 12 14 Gain 
CDK4 12 25 Gain SLC35E3 12 14 Gain 
CENTG1 12 25 Gain SLC26A10 12 14 Gain 
TSPAN31 12 25 Gain KIF5A 12 14 Gain 
ECOP 7 24 Gain FLJ44060 7 13 Gain 
38784 12 24 Gain DCTN2 12 13 Gain 
CYP27B1 12 24 Gain B4GALNT1 12 13 Gain 
AK093897 12 24 Gain PIP5K2C 12 13 Gain 
DKFZP586D0919 12 24 Gain MARS 12 13 Gain 
METTL1 12 24 Gain NUP107 12 13 Gain 
CR613464 7 23 Gain GSH2 4 12 Gain 
BC045679 7 23 Gain PDGFRA 4 12 Gain 
MGC33530 7 22 Gain AY229892 4 12 Gain 
TSFM 12 22 Gain LOC402176 4 12 Gain 
AVIL 12 21 Gain CHIC2 4 12 Gain 
OS9 12 20 Gain BC094796 7 12 Gain 
CTDSP2 12 20 Gain ZNF713 7 11 Gain 
AF119871 12 19 Gain ARHGAP9 12 11 Gain 
MDM2 12 18 Gain CR590495 7 10 Gain 
CPM 12 18 Gain MRPS17 7 9 Gain 
BC032840 12 17 Gain GBAS 7 9 Gain 
XRCC6BP1 12 17 Gain CPSF6 12 9 Gain 
CR602022 12 16 Gain GLI1 12 9 Gain 
AK096400 12 16 Gain DDX5 17 9 Gain 
AF109294 9 37 Loss KLHL9 9 19 Loss 
CDKN2B 9 36 Loss IFNA14 9 18 Loss 
CDKN2A 9 36 Loss IFNE1 9 18 Loss 
HLA-DRB5 6 35 Loss BTNL3 5 15 Loss 
AJ007770 7 34 Loss IFNW1 9 14 Loss 
X89654 8 31 Loss ELAVL2 9 14 Loss 
LOC651362 8 30 Loss CR627240 9 14 Loss 
MTAP 9 26 Loss BC042393 9 14 Loss 




genes chrom sample number pattern genes chrom 
sample 
number pattern 
LOC647353 7 25 Loss U06641 4 13 Loss 
BC003593 6 24 Loss AK127991 22 12 Loss 
AK092601 9 22 Loss GSTT1 22 12 Loss 
DMRTA1 9 22 Loss BC043197 13 11 Loss 
AK124391 9 21 Loss BC019327 3 10 Loss 
IFNA8 9 19 Loss KIAA1797 9 10 Loss 
IFNA2 9 19 Loss OR4P4 11 10 Loss 
V00541 9 19 Loss CR593785 11 10 Loss 
 
Table 6.4.1 Partial gene list that have either more than 4 folds gains or homozygous deletions 
with log2(Ratio) more than 2 in at least 9 or 10 patients’ samples. 
 
   MDM2 is potentially involved in p53 tumor suppressor pathway. Similar to 
EGFR and CDK4, MDM2 helps to regulate the cell cycle process. The common GO 
term “regulation of Ras protein signal transduction” of GEFT, GENTG1 and also 
SLC26A10 indicate the potential involvement of the Ras signal transduction pathway 
in at least some patients. Since the maximum copy number losses are 2, the “high” 
copy number losses simply suggest the homozygous deletions of the gene.  
6.5 Survival analysis 
Even though Glioblastoma is a WHO grade IV tumor with very high mortality 
rate. From Table 2.1.1, we can still see that the survival times of individual patients 
are quite different, ranging from a few days to more than a hundred months after the 
diagnosis and treatment. In this analysis, in order to analyze the potential correlation 
of individual genes or segments of chromosome to the survival information, the log 
rank test (or Chi square test) is performed to compare the differences of two groups 
(the gene (or segment) amplified or deleted vs unchanged within all samples). Table 




method. In Table 6.5.1, all the “segments” have amplified copy number aberration, 
while Table 6.5.2 shows the survival analysis results of “segments” and genes with 
copy number deletion aberration.  
 
Chrom Start End Genes pvalue 
Chr7 5312948 5429703 TNRC18 0.000775179 
Chr7 28305464 28832036 CREB5 0.000944061 
Chr7 29200645 30763743 CHN2 PRR15 CRHR2 INMT 0.000611761 
Chr7 30777557 31714593 FLJ22374 AQP1 GHRHR…… 0.000983259 
Chr7 31795771 32077516 PDE1C 0.00094093 
Chr7 32491469 32736120 LSM5 AVL9 LOC441208 0.000983259 
Chr7 32874302 32949307 KBTBD2 RP9P 0.000611761 
Chr7 32963529 33612205 FKBP9 NT5C3 RP9 BBS9 0.000924488 
Chr7 53070842 53072112 DKFZp564N2472 0.000828016 
Chr7 54236410 54237608 HPVC1 8.52E-05 
Chr7 54577512 54604442 VSTM2A 0.000614989 
Chr7 54787433 55242525 SEC61G EGFR 0.000458793 
Chr7 55400634 55468929 LANCL2 0.000566615 
Chr7 55505799 55607694 ECOP 0.000829675 
Chr7 55680805 55682137 LOC442308 0.000895219 
Chr7 55828730 55897976 SEP14 0.000349342 
Chr7 55947824 55975927 ZNF713 0.000685318 
chr17 20970849 21035428 DHRS7B 0.00011957 
chr17 24107122 24357207 C17orf63 ERAL1… 0.000676561 
chr17 37718868 37794039 STAT3 0.000168583 
chr17 37807993 38105536 PTRF ATP6V0A1 NAGLU …… 0.00045271 
chr17 38306340 38318912 G6PC 1.22E-05 
chr17 42283966 42873676 WNT9B GOSR2 RPRML…… 0.000106719 
chr17 43373887 45633999 PNPO ATAD4 CDK5RAP3 …… 0.000206057 
chr17 45706831 46553225 TMEM92 XYLT2 MRPL27…… 2.53E-06 
chr17 46585918 51209747 NME1-NME2 NME1…… 0.000206057 
chr17 63144522 63799000 NOL11 BPTF C17orf58…… 0.000966895 
chr17 78494955 78646011 B3GNTL1 METRNL 0.000825796 
chr10 7837372 14412872 KIN ATP5C1 TAF3 …… 0.000339128 
chr10 14600564 14856902 FAM107B 0.000195038 
chr10 14901256 15801776 ARMETL1 HSPA14 SUV39H2 …… 0.000339128 
chr10 15860180 15942525 C10orf97 0.000562784 
chr10 16518972 17283687 PTER C1QL3 RSU1 CUBN TRDMT1 0.000339128 
chr22 21731592 21990224 RTDR1 GNAZ RAB36 BCR 0.000326071 
chr22 41226539 41245752 SERHL RRP7A 0.000381544 




Chrom Start End Genes pvalue 
Chr5 70366706 70399253 GTF2H2 2.67E-05 
Chr5 70366932 70399233 GTF2H2D 0.000226356 
Chr5 70405174 70424653 OCLN LOC647859 2.67E-05 
Chr5 129268421 135720972 CHSY3 TRPC7 0.00075346 
chr16 11255774 11353118 SOCS1 TNP2 PRM3….. 4.73E-06 
 
Table 6.5.1 Survival analysis of segments with amplified copy number aberration based on 
the CBS segmentation result. Only segments with p value less than 0.001 are shown here. 
Due to space limitation, for some segments, only a partial gene list is shown. The segment 
information generate here is different from the segments from CGH segmentation. For each 
individual gene a log rank test was performed, and then all the gene on the same 
chromosome, located near each other, and most importantly having the exact same gain and 
no change patterns across all 170 samples (so with the same p value) are combined together 

























Chrom Start End Genes pvalue 
chr3 37259741 47029961 GOLGA4 C3orf35 ITGA9… 0.003403045 
chr3 47032903 47180471 SETD2 0.002168912 
chr3 47244520 51509041 KIF9 KLHL18 PTPN23 … 0.003403045 
chr8 35212516 35771722 UNC5D 0.004481786 
chr1 793319 869824 FAM41C LOC100130417 SAMD11 0.003662627 
chr1 869445 1041599 NOC2L KLHL17 PLEKHN1 HES4 ISG15 AGRN C1orf159 0.00135508 
chr1 1099148 1171965 TTLL10 TNFRSF18 TNFRSF4 SDF4 B3GALT6 FAM132A 0.002042499 
chr1 1179154 1500125 UBE2J2 SCNN1D ACAP3 … 0.004211136 
chr1 158352143 158379996 ATP1A2 0.003451951 
chr1 239005439 239587101 RGS7 0.003109638 
chr10 42598264 43224702 BMS1 RET CSGALNACT2 RASGEF1A FXYD4 HNRNPF 0.004732608 
chr10 43252579 43464332 ZNF487 ZNF239 ZNF485 ZNF32 0.0040157 
chr10 43602865 43605871 HNRNPA3P1 0.002556484 
chr10 44185610 45410360 CXCL12 TMEM72 RASSF4… 0.001861497 
chr10 45431044 45488257 ANUBL1 0.002811846 
chr10 47128239 47171452 ANTXRL 0.003682633 
chr10 52420950 53725280 PRKG1 0.004829294 
Table 6.5.2 Survival analysis of segments with deleted copy number aberration based on the 
CBS segmentation result. Only segments with p value less than 0.005 are shown here. Due to 
space limitation, for some segments, only partial gene list is shown. Similar to Table 6.5.1, 
the segments information generate here is different to the segments from CGH segmentation. 
A log rank test is performed on each individual gene; then all the genes on the same 
chromosome, located near each other, and most importantly having the exact same deletion 
and no change patterns across all 170 samples (so with the same p value) are combined 
together to generate this table. 
Even though Tables 6.5.1 and 6.5.2 clearly show significant differences based 
on the log rank test, we can’t tell from the table whether the copy number aberration 
helps survival or works in an opposite way. Kaplan-Meier plots can reveal this kind 
of information visually. Figure 6.5.1 shows several typical Kaplan-Meier plots of the 
analysis from amplified segments based on the CBS segmentation. From these plots, 
basically there are two different patterns; one is that amplified copy numbers helps 




some genes located at Chr10:14901256-15801776 (p value: 0.00034), 
Chr10:15860180-15942525 (p value: 0.00056), and Chr10:14600564-
14856902(pvalue: 0.00020). Although for most patients’ samples, chromosome 10 
suffers massive copy number deletion, for instance, the gene PTER is deleted in 88 
patients’ samples, but still in 11 patients’ samples, the copy number of this gene is 
actually amplified. Some other genes with this pattern and within above segments 
include FAM107B, ARMETL1, HSPA14, SUV39H2, C10orf97, PTER, C1QL3, 
RSU1, CUBN, TRDMT1, et al. 
Another set of genes actually does more damage than good to the patients. 
Many of them located on Chromosome 17, for instance, Chr17: 45706831-46553225 
(p value: 2.5e-06), Chr17: 78494955-78646011 (p value: 0.00083) and Chr17: 
37807993-38105536 (p value: 0.00045). Some genes located at these regions include 
B3GNTL1, METRNL, TMEM92, XYLT2, MRPL27, PTRF, ATP6V0A1, NAGLU, 
et al. For the other genes or segments with significant log rank p value (p<0.0001), 
amplifications of these genes in these segments won’t help or damage too much to the 
survival as shown on the rest of the Kaplan-Meier plots Figure 6.5.1, even though, 
statistically both groups (patients with amplified genes and patients with no gene 





Figure 6.5.1 Typical Kaplan-Meier plots of survival analysis results based on the genes or 
segments with amplified copy number aberration based on the CBS segmentation analyzing 
result. In the figures, the y-axis represents the survival probability and the x-axis represents 
the survival time in months. In the legend, “change” represents that the specific gene or 
segment has amplified copy numbers and “no change” indicates no copy number aberration 
observed for this specific gene or segments in the patient sample. Here only show part of the 





Figure 6.5.2 Typical Kaplan-Meier plots of survival analysis results based on the genes or 
segments with deleted copy number aberration based on the CBS segmentation analyzing 
result. In the figures, the y-axis represents the survival probability and the x-axis represents 
the survival time in months. In the legend, “change” represents that the specific gene or 
segment has amplified copy numbers and “no change” indicate no copy number aberration 
observed for this specific gene or segments in the patient sample. Here only show part of the 
Kaplan-Meier plots, but the rest plots are quite similar. 
For those genes with deleted copy number aberration as shown in Table 6.5.2, 
Kaplan-Meier survival analysis (Figure 6.5.2) also shows patterns similar to Figure 




value: 0.0037), Chr1: 869445-1041599 (p value: 0.0014), Chr1: 1099148-1171965 (p 
value: 0.0020), Chr1: 1179154-1500125 (p value: 0.0042), and Chr3: 3725941-
51509047 (p value: 0.0021 and 0.0034), deletion of these genes actually correlate to 
extended survival of patients. 
6.6 Fisher exact test 
As discussed before, 1.5xDRLs is applied to identify those segments with 
copy number variation. Each gene within these segments could be assigned either 
gain or loss depending on the patterns of the copy number variation of each individual 
segments. For those segments with amplified copy number variation from all 170 
tumor samples, each individual gene is assigned either gain or no gain. There are also 
24 normal samples in which the same gene could also be assigned to gain or no gain. 
One-tail Fisher exact tests are performed for all genes (each gene has one 2x2 
contingency table) and p values are derived for each gene. Similarly, for those 
segments with copy number deletion, each individual gene within these segments 
could also form a 2x2 contingency table and each table could apply Fisher exact test. 
After the testing, the adjusted p values for multiple comparisons are calculated based 
on the method of Benjamin and Hochberg (1995)and the result is shown in Figure 
6.6.1. Many other genes, some of which were discussed in Section 6.3, also show 
significant p values. These genes include HUS1, CDC2L5, DMTF1, RINT1, EGFR, 
CDK6, MAD1L1, INHBA, PIK3CG, ASNS, and CDKN2B. All these genes have 
adjusted p values less than 0.05, and except for CDKN2B, all of them have gained 







Figure 6.6.1 Fisher exact test based on the CBS segmentation result. Top figure is derived 
from the genes with copy number gains and the lower figure is from those genes with copy 
number deletion. Genes are grouped based on the same adjusted p value, and each group is 
located on the same segment. The log2 transformed adjusted p values (less than 0.05) are 








Chapter 7 Discussion 
 
This thesis includes two main parts; the first part discussed the raw data 
processing and the second part mainly focused on biological aspects from the 
analysis. Through out the entire analysis, extensive statistical methods are used, 
which include, but are not limited to, Hidden Markov Chain, log rank test, Fisher 
exact test, as well as many others. Briefly, in the data processing part, even though 
there are more than ten different data processing algorithms available, many of them 
are gradually becoming obsolete due to various reasons. HHMM and CBS are the two 
data processing algorithms that stand up among all methods. In this thesis, both 
HHMM and CBS algorithms are used and their performances are compared using the 
data set generated from real tumor samples. From the analysis we can see CBS tends 
to identify the relatively big segments, but HHMM tends to identify more single 
probe aberrations while missing many obvious big segments. Simply based on the 
current CGH experiments, it is hard to tell whether single probe aberrations represent 
true biological copy number variation. One potential solution to verify whether the 
single probe aberrations really represent the copy number variation is to increase the 
resolutions of the CGH array. Moreover, the biological significance of each copy 
number aberration needs to be verified based on the laboratory bench work. 
Ideally, the copy number variation could easily be calculated mathematically 




experiment, we seldom can apply the ideal mathematic values in Table 3.1.1 to find 
the copy number changes. Instead, the noise level (DRLs) of each array experiment is 
calculated and an arbitrary 1.5x(DRLs) cutoff is applied to individual hybridization. 
All the segments with the absolute predicted log2(Ratio) values greater than this 
cutoff are treated as segments with copy number variation.  
Frequency plots also show (Figure 6.2.1) that copy number gains on the whole 
or most part of chromosome 7 and losses on whole or part of chromosome 10 are the 
signatures of Glioblastoma. Other than these two whole chromosome copy number 
aberrations, other chromosomes also contain various copy number aberrations with 
various segment lengths as shown in Table 6.2.1. We also observed from the 
frequency plots that there is no single segment whose copy number variation is shared 
by all patients. Gene level analysis (Fisher test) also yields the same conclusion. This 
suggests that even though all patients suffered from the same or similar WHO grade 
IV Glioblastoma, the genotypes of these patients are similar but not identical. This 
also implies that the Glioblastoma in individual patients many not have the same 
causation at the genome level.  
In this analysis, we also noticed that many tumor suppression genes are 
deleted and the copy numbers of many cell cycle related genes are changed. Some of 
the well-known tumor suppression genes identified in this study include, but are not 
limited to, PTEN, TP53, CDKN2A and RB1. Many of these genes are involved in the 
cell cycle checkpoints. Deletion of any of these tumor suppression genes in the tumor 




From the segmentation results, we can also confirm some signal transduction 
pathways that are involved in the development of Glioblastoma. One of these 
pathways is PI3K/PTEN/AKT. EGFR has been found amplified in the tumors of 
more than half of the patients, which is consistent with published results. The NF-
kappa-B involved signal transduction pathway has been linked to inflammatory 
events associated with many diseases. In this study, identification of some 
components involving this pathway suggests the importance of NF-kappa-B and 
MAPK3/ERK1signal transduction pathways in tumor development.  
Due to the individual variation of each patient, the causations of the same 
disease are also very different. Even though we can generate a signature pattern for 
this disease using frequency plots as shown in Figure 6.2.1, the gene level fingerprints 
of each individual patients could also reveal the importance of many genes or 
segments to each individual patient, especially when the copy number variation is 
significantly changed (homozygous deletion or multi-fold copy number gains). This 
part of the analysis will clearly benefit us in the personalized gene therapy or 
personalized drug development study in the future. 
Even though the mortality rate of the grade IV Glioblastoma disease is very 
high, survival analysis using the log rank test clearly shows the differences of some 
segments or genes to the survival rate. In this analysis, amplification of some genes at 
specific segments for instance Chr10: 14600564-15942525 or deletion of copy 
number of Chr1: 793319-1500152 and Chr3: 3725941-51509047, may help to extend 
the life expectation of some Glioblastoma patients. Even though many genes within 




are actually not quite clear and array CGH can’t answer this question. The only 
solution to this question is laboratory bench work for each individual gene. But at 

























Appendix A   Supplementary Tables and Figures 
 
Table S2.1.1 Detailed patients' information downloaded from public available sources. Due to descripancy of two 
difference data sources, there are two vital status of each patient 
 


























TCGA-02-0001 FEMALE Yes DECEASED DEAD -16179 353 358 null 137 Rec 45 45 
TCGA-02-0003 MALE No DECEASED DEAD -18340 144 144 null 40 No 50 50 
TCGA-02-0006 FEMALE No DECEASED DEAD -20516 558 558 null 302 No 56 58 
TCGA-02-0007 FEMALE Yes DECEASED DEAD -14805 705 705 518 null Rec 42 43 
TCGA-02-0009 FEMALE No DECEASED DEAD -22456 322 322 264 null No 61 62 
TCGA-02-0010 FEMALE Yes DECEASED DEAD -7451 1077 1077 351 null Sec 22 23 
TCGA-02-0011 FEMALE No DECEASED DEAD -6926 630 630 144 null No 19 20 
TCGA-02-0014 MALE No DECEASED DEAD -9369 2511 2511 -1409 null Rec 25 32 
TCGA-02-0021 FEMALE Yes DECEASED DEAD -16035 2361 2361 254 null Rec 44 50 
TCGA-02-0024 MALE Yes DECEASED DEAD -13116 1614 1614 null 1400 Rec 39 40 
TCGA-02-0027 FEMALE No DECEASED DEAD -12369 370 315 257 null No 34 35 
TCGA-02-0028 MALE Yes DECEASED DEAD -14303 2755 2755 1921 null Sec 46 46 
TCGA-02-0033 MALE No DECEASED DEAD -20070 86 86 32 null No 55 55 
TCGA-02-0034 MALE No DECEASED DEAD -22166 430 430 386 null No 61 62 
TCGA-02-0037 FEMALE No DECEASED DEAD -27063 109 109 37 null No 74 74 
TCGA-02-0038 FEMALE No DECEASED DEAD -17749 326 326 238 null No 49 50 
TCGA-02-0043 FEMALE Yes DECEASED DEAD -19882 556 556 282 null Rec 56 56 
TCGA-02-0046 MALE No DECEASED DEAD -22417 208 208 194 null No 61 62 
TCGA-02-0047 MALE No DECEASED DEAD -28759 447 447 57 null No 79 80 
TCGA-02-0052 MALE No DECEASED DEAD -18060 383 383 204 null No 50 51 
TCGA-02-0054 FEMALE No DECEASED DEAD -16223 199 199 72 null No 44 45 
TCGA-02-0055 FEMALE No DECEASED DEAD -22798 76 76 6 null No 62 62 
TCGA-02-0057 FEMALE Yes DECEASED DEAD -24139 604 604 473 null Rec 67 68 
TCGA-02-0058 FEMALE No DECEASED DEAD -10517 254 254 171 null Rec 29 29 
TCGA-02-0060 FEMALE No DECEASED DEAD -24150 183 183 183 null No 66 66 






























TCGA-02-0069 FEMALE No LIVING DEAD -11668 null 873 873 null No 31 34 
TCGA-02-0071 MALE No DECEASED DEAD -19425 167 167 8 null No 53 54 
TCGA-02-0074 FEMALE No DECEASED DEAD -24906 310 310 154 null No 68 69 
TCGA-02-0075 MALE No DECEASED DEAD -23205 634 634 336 null No 63 65 
TCGA-02-0079 MALE No DECEASED DEAD -21173 828 828 797 null No 56 58 
TCGA-02-0080 MALE Yes DECEASED DEAD -10309 2729 2729 2339 null Rec 34 35 
TCGA-02-0083 FEMALE Yes DECEASED DEAD -21626 691 691 462 null Rec 61 62 
TCGA-02-0084 FEMALE No DECEASED DEAD -13263 384 7 null null No 34 37 
TCGA-02-0085 FEMALE No DECEASED DEAD -23289 1560 1560 976 null No 66 69 
TCGA-02-0086 FEMALE No DECEASED DEAD -16763 268 268 97 null No 46 47 
TCGA-02-0087 FEMALE No LIVING DEAD -10185 null 1757 null 1757 No 28 30 
TCGA-02-0089 MALE Yes DECEASED DEAD -19233 515 515 358 null Rec 54 54 
TCGA-02-0099 MALE Yes DECEASED DEAD -17080 106 106 null null Rec 46 47 
TCGA-02-0102 MALE Yes DECEASED DEAD -15660 821 821 450 null Sec 44 45 
TCGA-02-0106 MALE No DECEASED DEAD -19883 355 355 null 195 No 55 55 
TCGA-02-0107 MALE Yes DECEASED DEAD -20557 537 537 null 146 Rec 57 58 
TCGA-02-0111 MALE No DECEASED DEAD -20813 704 704 74 null No 57 59 
TCGA-02-0113 FEMALE Yes LIVING DEAD -15836 null 2817 null 1559 Rec 49 51 
TCGA-02-0114 FEMALE Yes DECEASED DEAD -13681 3040 3040 null 2296 Sec 45 46 
TCGA-02-0115 MALE No DECEASED DEAD -19257 476 476 91 null No 53 54 
TCGA-02-0116 MALE Yes DECEASED DEAD -18656 1489 1489 1231 null Rec 54 55 
TCGA-02-0258 FEMALE No DECEASED DEAD -13268 503 503 null 503 No 36 37 
TCGA-02-0260 MALE No DECEASED DEAD -19956 514 514 null null No 54 56 
TCGA-02-0266 MALE No DECEASED DEAD -5303 538 538 293 null No 15 16 
TCGA-02-0269 MALE No DECEASED DEAD -25194 327 327 99 null No 69 70 
TCGA-02-0271 MALE No DECEASED DEAD -9578 440 440 0 null No 26 27 
TCGA-02-0281 FEMALE No DECEASED DEAD -28695 121 121 0 null No 78 79 
TCGA-02-0285 FEMALE No DECEASED DEAD -18353 422 422 0 null No 50 52 
TCGA-02-0289 MALE No DECEASED DEAD -21031 432 432 244 null No 57 59 






























TCGA-02-0317 MALE No DECEASED DEAD -14636 372 372 238 null No 40 41 
TCGA-02-0321 MALE No DECEASED DEAD -27125 300 300 73 null No 15 15 
TCGA-02-0324 FEMALE No DECEASED DEAD -25352 234 234 163 null No 69 70 
TCGA-02-0325 MALE No DECEASED DEAD -22598 323 323 284 null No 62 63 
TCGA-02-0326 FEMALE No DECEASED DEAD -30159 223 374 5 null No 83 84 
TCGA-02-0330 FEMALE No DECEASED DEAD -18654 484 484 120 null No 51 52 
TCGA-02-0332 FEMALE No DECEASED DEAD -17021 782 782 438 null No 47 47 
TCGA-02-0333 FEMALE No DECEASED DEAD -28449 133 133 4 null No 78 78 
TCGA-02-0337 MALE No DECEASED DEAD -17642 764 764 691 null No 48 50 
TCGA-02-0338 MALE No DECEASED DEAD -15231 322 322 167 null No 42 43 
TCGA-02-0339 MALE No DECEASED DEAD -24524 377 377 148 null No 67 68 
TCGA-02-0422 MALE No DECEASED DEAD -18367 441 441 125 null No 50 51 
TCGA-02-0430 FEMALE No DECEASED DEAD -24641 321 321 null null No 68 68 
TCGA-02-0432 MALE No DECEASED DEAD -13260 1433 1433 1053 null No 37 41 
TCGA-02-0439 FEMALE No DECEASED DEAD -25623 20 20 13 null No 70 70 
TCGA-02-0440 MALE No DECEASED DEAD -22955 345 345 212 null No 63 64 
TCGA-02-0446 MALE No DECEASED DEAD -22541 281 281 null 15 No 61 62 
TCGA-02-0451 FEMALE No DECEASED DEAD -22662 492 492 null 427 No 62 63 
TCGA-02-0456 FEMALE No DECEASED DEAD -24796 102 102 null 12 No UNK 68 
TCGA-06-0122 FEMALE No DECEASED DEAD -30967 187 8 null null No 85 86 
TCGA-06-0124 MALE No DECEASED DEAD -24591 619 123 null null No 67 69 
TCGA-06-0125 FEMALE No DECEASED DEAD -23343 1448 1439 797 null No 64 68 
TCGA-06-0126 MALE No DECEASED DEAD -31627 210 3 null null No 86 87 
TCGA-06-0127 MALE No DECEASED DEAD -24502 120 108 90 null No 68 68 
TCGA-06-0128 MALE No DECEASED DEAD -24217 691 691 189 null No 66 68 
TCGA-06-0129 MALE No DECEASED DEAD -11284 1024 988 147 null No 31 33 
TCGA-06-0130 MALE No DECEASED DEAD -19811 394 320 244 null No 54 55 
TCGA-06-0133 MALE No DECEASED ALIVE -23402 435 428 78 null No 64 64 
TCGA-06-0137 FEMALE No DECEASED DEAD -23273 812 701 487 null No 63 66 






























TCGA-06-0139 MALE No DECEASED DEAD -14728 362 327 152 null No 41 42 
TCGA-06-0141 MALE No DECEASED DEAD -22925 313 280 145 null No 63 64 
TCGA-06-0143 MALE No DECEASED DEAD -21386 357 357 null 264 No 58 59 
TCGA-06-0145 FEMALE No DECEASED DEAD -19660 71 71 null null No 54 54 
TCGA-06-0146 FEMALE No DECEASED DEAD -12252 611 611 530 null No 33 35 
TCGA-06-0147 FEMALE No DECEASED DEAD -18742 541 508 null null No 52 53 
TCGA-06-0148 MALE No DECEASED DEAD -27842 307 298 188 null No 76 77 
TCGA-06-0149 FEMALE No DECEASED DEAD -27315 261 238 203 null No 75 75 
TCGA-06-0152 MALE No DECEASED DEAD -24844 375 359 299 null No 68 69 
TCGA-06-0154 MALE No DECEASED DEAD -20018 423 389 207 null No 55 56 
TCGA-06-0156 MALE No DECEASED DEAD -20931 178 164 null null No 57 57 
TCGA-06-0157 FEMALE No DECEASED DEAD -23127 97 97 null null No 63 63 
TCGA-06-0158 MALE No DECEASED DEAD -26855 329 166 90 null No 74 74 
TCGA-06-0162 FEMALE No DECEASED DEAD -17272 104 78 null null No 47 48 
TCGA-06-0164 MALE No DECEASED DEAD -17510 1730 1729 1428 null No 47 52 
TCGA-06-0166 MALE No DECEASED DEAD -18902 178 161 66 null No 52 52 
TCGA-06-0168 FEMALE No DECEASED DEAD -21776 598 579 461 null No 60 62 
TCGA-06-0169 MALE No DECEASED DEAD -25127 100 95 92 null No 69 69 
TCGA-06-0171 MALE No DECEASED DEAD -24085 399 396 117 null No 66 67 
TCGA-06-0173 FEMALE No DECEASED DEAD -26548 136 7 null null No 73 74 
TCGA-06-0174 MALE No DECEASED DEAD -19824 98 67 47 null No 54 54 
TCGA-06-0175 MALE No DECEASED DEAD -25558 123 83 39 null No 70 71 
TCGA-06-0176 MALE No LIVING ALIVE -12777 null 1561 41 null No 35 37 
TCGA-06-0177 MALE No DECEASED DEAD -23498 126 60 null null No 65 65 
TCGA-06-0178 MALE No LIVING ALIVE -14235 null 1642 192 null No 39 42 
TCGA-06-0179 MALE No DECEASED DEAD -23449 616 578 250 null No 64 66 
TCGA-06-0182 MALE null DECEASED DEAD -27963 111 77 null null No 77 77 
TCGA-06-0184 MALE No LIVING ALIVE -23317 null 1228 null null No 64 66 
TCGA-06-0185 MALE No LIVING ALIVE -19922 null 1126 711 null No 54 57 






























TCGA-06-0188 MALE No LIVING ALIVE -26079 null 866 null null No 72 73 
TCGA-06-0189 MALE No DECEASED DEAD -20296 469 454 null null No 55 56 
TCGA-06-0190 MALE No DECEASED DEAD -22835 317 313 88 null No 62 63 
TCGA-06-0194 FEMALE No DECEASED DEAD -13852 142 142 125 null No 38 38 
TCGA-06-0195 MALE No DECEASED DEAD -23131 225 214 147 null No 64 64 
TCGA-06-0197 FEMALE No DECEASED DEAD -24095 168 79 47 null No 66 67 
TCGA-06-0208 FEMALE No DECEASED DEAD -19108 255 166 148 null No 53 53 
TCGA-06-0209 MALE No DECEASED DEAD -27877 231 118 null null No 77 77 
TCGA-06-0210 FEMALE No DECEASED DEAD -26600 225 151 67 null No 73 74 
TCGA-06-0211 MALE No DECEASED DEAD -17514 360 360 53 null No 48 49 
TCGA-06-0213 FEMALE No DECEASED DEAD -20134 16 6 null null No 55 55 
TCGA-06-0214 MALE No DECEASED DEAD -24187 457 378 48 null No 66 67 
TCGA-06-0221 MALE No DECEASED DEAD -11332 603 548 260 null No 31 32 
TCGA-06-0237 FEMALE No DECEASED ALIVE -27735 415 314 null null No 75 77 
TCGA-06-0238 MALE No DECEASED ALIVE -17037 404 359 311 null No 47 48 
TCGA-06-0241 FEMALE No LIVING ALIVE -24101 null 455 null 196 No 66 67 
TCGA-06-0394 MALE No DECEASED DEAD -18913 329 313 87 null No 51 52 
TCGA-06-0397 FEMALE No DECEASED DEAD -20997 121 15 null null No 57 58 
TCGA-06-0402 MALE No DECEASED DEAD -26059 8 8 null null No 71 71 
TCGA-06-0409 MALE No DECEASED DEAD -16023 2201 2145 334 null No 44 50 
TCGA-06-0410 FEMALE No DECEASED DEAD -28084 142 142 null 7 No 77 77 
TCGA-06-0412 FEMALE No DECEASED DEAD -20618 291 245 130 null No 56 57 
TCGA-06-0413 FEMALE No DECEASED DEAD -28433 96 5 null null No 77 78 
TCGA-06-0414 MALE No DECEASED DEAD -23215 1068 1065 null 1013 No 64 67 
TCGA-06-0644 MALE No LIVING ALIVE -26246 null 375 null 85 No 72 73 
TCGA-06-0645 FEMALE No DECEASED ALIVE -20448 175 98 null null No 56 57 
TCGA-06-0646 MALE No DECEASED ALIVE -22272 175 136 90 null No 61 62 
TCGA-06-0648 MALE No DECEASED ALIVE -28477 297 293 201 null No 78 79 
TCGA-08-0345 FEMALE null DECEASED DEAD -25960 53 53 null null No 71 72 






























TCGA-08-0352 MALE No DECEASED DEAD -29106 39 39 null null No 80 80 
TCGA-08-0358 MALE No DECEASED DEAD -18383 678 593 null 263 No 51 52 
TCGA-08-0373 MALE No DECEASED DEAD -25273 134 134 null null No 69 69 
TCGA-08-0386 MALE No DECEASED DEAD -27053 548 478 null 427 No 74 76 
TCGA-08-0509 MALE No DECEASED DEAD -23273 382 17 null null No 63 65 
TCGA-08-0510 MALE No DECEASED DEAD -27675 129 106 null 89 No 76 76 
TCGA-08-0511 MALE No DECEASED DEAD -25299 235 235 null null No 69 70 
TCGA-08-0512 MALE No DECEASED DEAD -17821 1282 358 231 null No 49 53 
TCGA-08-0514 FEMALE No DECEASED DEAD -25457 337 259 null null No 70 71 
TCGA-08-0516 MALE No DECEASED DEAD -5308 596 561 40 null No 15 17 
TCGA-08-0517 FEMALE Yes DECEASED DEAD -12771 1785 1770 null 1024 Rec UNK 40 
TCGA-08-0518 FEMALE No DECEASED DEAD -21995 588 39 134 null No 60 62 
TCGA-08-0520 MALE No DECEASED DEAD -25766 326 326 null 105 No 70 71 
TCGA-08-0521 MALE No DECEASED DEAD -6376 146 146 125 null No 18 18 
TCGA-08-0522 MALE No DECEASED DEAD -22413 635 555 266 null No 61 63 
TCGA-08-0524 FEMALE No DECEASED DEAD -6464 220 198 61 null No 17 18 
TCGA-08-0525 MALE Yes DECEASED DEAD -19012 486 486 343 null Sec UNK 54 
TCGA-08-0529 FEMALE No DECEASED DEAD -20556 559 526 null 328 No 56 58 
TCGA-08-0531 MALE No DECEASED DEAD -23481 230 168 null null No 65 65 
TCGA-12-0616 FEMALE No DECEASED DEAD -13451 447 438 397 null No 37 38 
TCGA-12-0618 MALE No DECEASED DEAD -18071 394 49 null null No 50 51 
TCGA-12-0619 MALE No DECEASED DEAD -21920 1062 316 203 null No 60 63 
TCGA-12-0620 MALE No DECEASED DEAD -21068 318 181 null null No 58 59 
TCGA-06-0132 MALE   ALIVE      No 50 51 
  
 
Table S5.2.1 QC parameters and their value information from all hybridizations used in 
this study. Since there are two color channels (Green and red for each sample, including 
both tumor and reference), the qualities of each channel are accessed independently 
except for the DLRspread. The reproducibility values shown here are the percentage 
values. 
 

























TCGA-02-0001 0.21 207.2 166.3 630.5 516.2 3 3.1 14 13.2 
TCGA-02-0003 0.26 201.6 157.3 527.4 422 2.6 2.7 10.7 11.9 
TCGA-02-0006 0.24 126.7 100.3 657 490.7 5.2 4.9 12.7 13.8 
TCGA-02-0007 0.23 220.2 163.1 539 397.8 2.4 2.4 6.9 7.2 
TCGA-02-0009 0.22 154.3 117.8 684.1 524.9 4.4 4.5 9.7 10.3 
TCGA-02-0010 0.26 157.6 130.3 570.1 459.3 3.6 3.5 12.2 12.4 
TCGA-02-0011 0.23 100.2 82.4 648.4 534 6.5 6.5 13.2 12.6 
TCGA-02-0014 0.27 121.9 94.5 552 401.4 4.5 4.2 9.4 12.8 
TCGA-02-0021 0.26 158.9 122.3 585.8 436.3 3.7 3.6 9.8 11.9 
TCGA-02-0024 0.24 174 136.5 515.2 377.8 3 2.8 7.3 8.3 
TCGA-02-0027 0.28 178.4 124.9 558.2 350.8 3.1 2.8 9.5 9.7 
TCGA-02-0028 0.2 131 109.2 584.4 587 4.5 5.4 8.3 8.9 
TCGA-02-0033 0.2 212.3 178.7 591.3 606.6 2.8 3.4 9.8 10.2 
TCGA-02-0034 0.2 169.5 156.6 539.4 597.9 3.2 3.8 9.4 9.9 
TCGA-02-0037 0.22 196 173.3 567.1 549.1 2.9 3.2 8.6 10.2 
TCGA-02-0038 0.2 150.8 125.6 680.7 657 4.5 5.2 10.9 9.9 
TCGA-02-0043 0.22 33.4 34.6 590.5 615.3 17.7 17.8 14.2 12.9 
TCGA-02-0046 0.22 42.3 44.4 523.6 544.2 12.4 12.3 12 12.3 
TCGA-02-0047 0.19 244.2 187.9 597.6 622.8 2.4 3.3 9.5 9.1 
TCGA-02-0052 0.2 203.5 149.9 658.1 628.9 3.2 4.2 8.2 8.1 
TCGA-02-0054 0.18 122.9 98.2 709.9 801.2 5.8 8.2 9.1 8.9 
TCGA-02-0055 0.19 232.3 178.8 623.9 645.3 2.7 3.6 10.3 10.1 
TCGA-02-0057 0.19 126.1 101.3 711 715.1 5.6 7.1 9.1 9.1 
TCGA-02-0058 0.23 213.2 137.6 830.4 395.3 3.9 2.9 7.9 10.6 
TCGA-02-0060 0.19 208.1 154.7 796.8 479.1 3.8 3.1 8.2 10.7 
TCGA-02-0064 0.19 108 136.7 747.3 597.7 6.9 4.4 8.5 9.1 
TCGA-02-0069 0.19 70.2 114.7 574.3 596 8.2 5.2 8.8 7.5 
TCGA-02-0071 0.18 67.3 71.2 784.5 703.4 11.7 9.9 8.7 9 
TCGA-02-0074 0.18 84.7 153.8 638 674.8 7.5 4.4 9 8.8 
TCGA-02-0075 0.17 91.2 116.1 656.6 656.3 7.2 5.7 5.3 5 
TCGA-02-0079 0.19 39.4 63.3 108.2 239.4 2.7 3.8 14 14.8 
TCGA-02-0080 0.17 88.2 91.2 713.4 754.8 8.1 8.3 9.4 9.1 
TCGA-02-0083 0.21 107.2 125.3 753.7 489.7 7 3.9 8.7 10.5 
TCGA-02-0084 0.19 59.7 52.2 196.9 362.7 3.3 7 12.9 12.4 
TCGA-02-0085 0.17 78.1 77.7 847.8 885.2 10.9 11.4 8.8 8.2 
TCGA-02-0086 0.2 108.3 143.1 662 464 6.1 3.2 8.6 11.6 
TCGA-02-0087 0.2 184.6 171.2 549.4 580 3 3.4 12.7 14.2 
TCGA-02-0089 0.2 76.6 94.4 735 541.2 9.6 5.7 7.7 12.2 





























TCGA-02-0102 0.17 97.3 108.9 766.3 784.2 7.9 7.2 8 8 
TCGA-02-0106 0.2 190.9 167.2 550 502 2.9 3 7.9 8.6 
TCGA-02-0107 0.17 71.5 88.6 718.6 665 10.1 7.5 5.1 4.7 
TCGA-02-0111 0.2 170.6 142.7 548.6 554.6 3.2 3.9 11.2 11.3 
TCGA-02-0113 0.18 82.2 98.1 719.1 782 8.8 8 12.2 11.5 
TCGA-02-0114 0.18 99.3 117 755.9 784.2 7.6 6.7 9.6 9.4 
TCGA-02-0115 0.17 74.9 81.4 753.5 752.3 10.1 9.2 10.8 10.2 
TCGA-02-0116 0.2 80 98.9 733.3 564.6 9.2 5.7 8.9 10.9 
TCGA-02-0258 0.18 186.7 190.6 549 628.6 2.9 3.3 11.2 12.2 
TCGA-02-0260 0.24 176.3 144.3 700.7 647.3 4 4.5 10.3 9.1 
TCGA-02-0266 0.2 100 96.2 642.2 781.9 6.4 8.1 13.6 13.3 
TCGA-02-0269 0.17 171.8 164.7 628.8 707.1 3.7 4.3 8.9 9.7 
TCGA-02-0271 0.2 154.9 159.2 594.2 631.7 3.8 4 13.5 13.5 
TCGA-02-0281 0.24 218.7 203.1 487.4 468.4 2.2 2.3 10.7 11.4 
TCGA-02-0285 0.32 233.2 201.3 514.3 460.7 2.2 2.3 12.8 14.5 
TCGA-02-0289 0.2 192.7 218 518.8 738.9 2.7 3.4 11.1 11.1 
TCGA-02-0290 0.22 256 239 594.5 667.2 2.3 2.8 8.2 7.7 
TCGA-02-0317 0.25 223.9 193.4 614.4 599.4 2.7 3.1 12.7 12.7 
TCGA-02-0321 0.17 184.8 161.6 653.3 675.9 3.5 4.2 10.2 10.4 
TCGA-02-0324 0.19 109.6 129.2 434.2 533.1 4 4.1 9.5 10.2 
TCGA-02-0325 0.18 115.6 112 629.3 682.1 5.4 6.1 13.8 13.8 
TCGA-02-0326 0.19 179.9 173.8 638.9 653.9 3.6 3.8 13.1 12.3 
TCGA-02-0330 0.17 188.8 209.9 477.2 596.3 2.5 2.8 7.3 7.3 
TCGA-02-0332 0.19 192 180.8 683.6 746.6 3.6 4.1 11.4 10.6 
TCGA-02-0333 0.2 184.4 146 810.3 771.9 4.4 5.3 9.6 9.7 
TCGA-02-0337 0.21 116.2 109.9 587.3 688.2 5.1 6.3 8.2 9 
TCGA-02-0338 0.2 120.7 101.6 688.2 690.3 5.7 6.8 14 13.9 
TCGA-02-0339 0.22 199.8 171.2 678.6 553.3 3.4 3.2 11.2 11.8 
TCGA-02-0422 0.17 184.6 186.7 617.7 741.8 3.3 4 7.2 7.8 
TCGA-02-0430 0.18 149 149.8 577.4 625.4 3.9 4.2 11 10.9 
TCGA-02-0432 0.2 199.5 207.6 578.4 588.8 2.9 2.8 10.8 10.6 
TCGA-02-0439 0.16 128.8 127.9 526.6 570.8 4.1 4.5 8.2 7.7 
TCGA-02-0440 0.19 125 111.7 607.8 690.5 4.9 6.2 12.7 10.5 
TCGA-02-0446 0.18 104.7 103.5 586.2 635.5 5.6 6.1 7.8 8.6 
TCGA-02-0451 0.21 217 193.6 614.3 604.5 2.8 3.1 14.2 14.1 
TCGA-02-0456 0.23 217.8 193.4 578.7 562.5 2.7 2.9 11.4 11.3 
TCGA-06-0122 0.23 265.9 163.1 806.7 508.6 3 3.1 7 8.7 
TCGA-06-0124 0.22 208.6 135.6 834.1 457.2 4 3.4 10 11.7 
TCGA-06-0125 0.26 200 126.6 982.7 505.9 4.9 4 8.4 9.6 
TCGA-06-0126 0.25 286.5 162.5 872.9 432.9 3 2.7 9.2 13.2 
TCGA-06-0127 0.19 42 45 143.5 370 3.4 8.2 11.1 11.3 
TCGA-06-0128 0.2 231.1 178.5 774 595.3 3.3 3.3 8.7 10.1 
TCGA-06-0129 0.22 286.4 176.6 766.1 630.2 2.7 3.6 8.1 9.1 
TCGA-06-0130 0.22 379.6 205.6 785.8 534.3 2.1 2.6 12.7 13.3 
TCGA-06-0132 0.21 202.4 202.5 654.7 534.5 3.2 2.6 11.1 11 
TCGA-06-0133 0.22 264.5 151.3 829.8 424 3.1 2.8 8.9 13.3 





























TCGA-06-0138 0.25 271.4 59 379.2 70.5 1.4 1.2 8.9 12.4 
TCGA-06-0139 0.23 346.8 233.6 704.6 611.3 2 2.6 9.2 8.4 
TCGA-06-0141 0.25 258.2 169.7 713.5 493.8 2.8 2.9 12.8 15.7 
TCGA-06-0143 0.2 116.7 90.3 540.6 460.7 4.6 5.1 12.4 13 
TCGA-06-0145 0.23 305.8 182.3 698.9 467.5 2.3 2.6 9.7 9.9 
TCGA-06-0146 0.15 217.6 248 590.4 698 2.7 2.8 10.1 9.8 
TCGA-06-0147 0.25 307.8 152.2 800.2 385.4 2.6 2.5 9.6 12.7 
TCGA-06-0148 0.23 189.9 127.9 876.9 483 4.6 3.8 8.2 7.9 
TCGA-06-0149 0.16 239 268.7 443.7 561.4 1.9 2.1 8.6 8.8 
TCGA-06-0152 0.19 70.2 57.9 189.3 319.1 2.7 5.5 10.2 10.6 
TCGA-06-0154 0.24 235 159.5 695.1 340.7 3 2.1 9.9 12.7 
TCGA-06-0156 0.22 162.8 128.5 735.5 569.2 4.5 4.4 10.7 12.3 
TCGA-06-0157 0.18 118.7 105.4 797.7 995.1 6.7 9.4 9.7 10.3 
TCGA-06-0158 0.19 199.9 161.9 617.3 581.1 3.1 3.6 8.1 9.1 
TCGA-06-0162 0.19 197.9 206.3 529.6 648.2 2.7 3.1 8.6 9.3 
TCGA-06-0164 0.16 168.3 179.3 532.9 616.9 3.2 3.4 9 8.5 
TCGA-06-0166 0.21 150.5 120.4 842.7 759.5 5.6 6.3 10.6 11.9 
TCGA-06-0168 0.17 180.4 145.5 810.5 914.1 4.5 6.3 8.8 9.4 
TCGA-06-0169 0.24 190.7 135.9 730 506.2 3.8 3.7 9.6 9.6 
TCGA-06-0171 0.2 240.4 210.4 585.4 555.6 2.4 2.6 9.1 9.6 
TCGA-06-0173 0.21 290.1 221.8 582.5 520.3 2 2.3 9.1 12 
TCGA-06-0174 0.24 210.6 109.4 680.2 228.6 3.2 2.1 9.7 10.9 
TCGA-06-0175 0.15 164.2 154.1 644.7 704.3 3.9 4.6 11.5 10.1 
TCGA-06-0176 0.23 186.9 150.7 940.6 780.7 5 5.2 9 10.9 
TCGA-06-0177 0.22 117.5 118.5 610 745.3 5.2 6.3 10.1 11.1 
TCGA-06-0178 0.18 165.2 165.4 922.7 1079.5 5.6 6.5 10.9 11.9 
TCGA-06-0179 0.2 173.8 143.9 459.2 432.7 2.6 3 8.2 8.8 
TCGA-06-0182 0.21 234.1 207.7 474.3 459.2 2 2.2 12.8 12.1 
TCGA-06-0184 0.2 119.9 100.7 935.3 808.3 7.8 8 9.9 10.1 
TCGA-06-0185 0.19 237.2 225.8 570 632 2.4 2.8 10.8 10.4 
TCGA-06-0187 0.22 166.4 177.3 566 519.2 3.4 2.9 8.7 11.4 
TCGA-06-0188 0.26 322.4 87.2 635 107.7 2 1.2 9.4 15.1 
TCGA-06-0189 0.23 171.3 121.6 421.9 334.4 2.5 2.7 12.7 12.9 
TCGA-06-0190 0.21 250 193.2 740.3 636 3 3.3 10 11.4 
TCGA-06-0194 0.16 205.2 236.5 587.1 752.6 2.9 3.2 10.2 11 
TCGA-06-0195 0.17 176.4 149.9 905.9 1014.6 5.1 6.8 12.2 13 
TCGA-06-0197 0.18 316.3 252.1 757.3 911.2 2.4 3.6 11.9 12.6 
TCGA-06-0208 0.21 180.6 140.6 880.6 748.9 4.9 5.3 10.6 11.4 
TCGA-06-0209 0.2 163.6 154.6 415.3 469.8 2.5 3 11.2 11.3 
TCGA-06-0210 0.19 126.4 106.3 457.4 482.1 3.6 4.5 12.6 13.1 
TCGA-06-0211 0.22 127.9 168 743.4 599.4 5.8 3.6 10.6 9 
TCGA-06-0213 0.17 135.8 111.3 938.4 1080.3 6.9 9.7 9 9.5 
TCGA-06-0214 0.2 133.1 113.1 873.3 611.1 6.6 5.4 11.7 12.5 
TCGA-06-0221 0.23 272.4 149.2 716.3 272.7 2.6 1.8 7.7 12.2 
TCGA-06-0237 0.2 168.8 134.2 351.2 315.9 2.1 2.4 13.2 13 
TCGA-06-0238 0.17 63.8 72.7 194.5 359.1 3 4.9 9.8 9.7 





























TCGA-06-0394 0.15 289.7 285.6 510.1 581.5 1.8 2 11.5 11.4 
TCGA-06-0397 0.17 161.8 143.4 692.7 675.7 4.3 4.7 11.9 11.2 
TCGA-06-0402 0.17 218.4 212.8 538.5 645.2 2.5 3 11.2 10.9 
TCGA-06-0409 0.17 112.4 118.8 628.6 692.4 5.6 5.8 10.1 8.8 
TCGA-06-0410 0.2 171.3 165.4 532.3 591.8 3.1 3.6 11.2 10 
TCGA-06-0412 0.2 208.9 180.7 583.1 624.1 2.8 3.5 11.9 11.9 
TCGA-06-0413 0.21 197.9 172.4 554.4 490 2.8 2.8 11.3 12.6 
TCGA-06-0414 0.17 240.9 250.6 550.8 657 2.3 2.6 9.5 9.8 
TCGA-06-0644 0.2 56.6 58.4 164 356.5 2.9 6.1 12.7 10.8 
TCGA-06-0645 0.17 64.1 71.8 163.6 297.5 2.6 4.1 11.9 11.2 
TCGA-06-0646 0.19 48.4 102.5 168.5 281 3.5 2.7 11.8 11.9 
TCGA-06-0648 0.17 54.7 67.2 180.6 385.8 3.3 5.7 10 8.8 
TCGA-08-0345 0.21 49.5 40.9 177.2 334.5 3.6 8.2 7.8 7.7 
TCGA-08-0349 0.16 73.7 74.4 201.8 337.2 2.7 4.5 10.2 10.3 
TCGA-08-0352 0.15 70.9 79 179.9 324.2 2.5 4.1 9.9 11 
TCGA-08-0358 0.12 80.9 87.4 205.5 307.4 2.5 3.5 9.9 11 
TCGA-08-0373 0.22 40.3 72.1 106.2 232.7 2.6 3.2 12.6 14.5 
TCGA-08-0386 0.13 57.1 57 247 338 4.3 5.9 11.4 11.7 
TCGA-08-0509 0.15 200.1 203.9 546.9 654.7 2.7 3.2 9.2 8.9 
TCGA-08-0510 0.19 173.3 161.2 680.9 712.7 3.9 4.4 11.4 11.2 
TCGA-08-0511 0.17 140 128.8 564.1 696.3 4 5.4 10.3 9.2 
TCGA-08-0512 0.16 162.9 170.3 558.7 761.7 3.4 4.5 11.4 10.9 
TCGA-08-0514 0.19 75.8 69.5 674.1 722.2 8.9 10.4 11.5 11.5 
TCGA-08-0516 0.18 348.1 320.9 554.4 555 1.6 1.7 13.6 13.8 
TCGA-08-0517 0.19 141.6 119.9 697.9 632.2 4.9 5.3 12 11.8 
TCGA-08-0518 0.15 177.8 191.4 535.3 683.9 3 3.6 9 8 
TCGA-08-0520 0.18 303.4 299.4 625.4 695.3 2.1 2.3 10.6 9.4 
TCGA-08-0521 0.2 267.6 246.1 623.5 636.2 2.3 2.6 10.3 9.7 
TCGA-08-0522 0.23 244.8 186.8 724.4 649.4 3 3.5 8 7.7 
TCGA-08-0524 0.19 125.4 128.9 613.2 680.3 4.9 5.3 9.7 9.3 
TCGA-08-0525 0.18 167.7 165 674.6 710.8 4 4.3 13 12.4 
TCGA-08-0529 0.22 206.9 184.7 404.6 380.1 2 2.1 10 10 
TCGA-08-0531 0.19 266.2 243.4 611.5 552.3 2.3 2.3 12.9 10.6 
TCGA-12-0616 0.2 53 48.1 251.1 511.3 4.7 10.6 10.5 9.4 
TCGA-12-0618 0.18 67.8 62 183.4 298.7 2.7 4.8 10.6 11.1 
TCGA-12-0619 0.18 64.8 69.3 170.6 323.3 2.6 4.7 11 10 











Table S5.5.1 Segment numbers before and after merging processes for both CBS and 
HHMM segmentation methods. Both CBS merged and HHMM merged represent 
numbers after merging while as CBS and HHMM represent numbers before the 
merging. 
 
probe CBS CBS Merged HHMM 
HHMM 





TCGA-02-0085 163 161 3387 3336  TCGA-06-0412 176 171 1361 1219 
TCGA-02-0014 294 245 3060 2729  TCGA-02-0055 175 162 1084 1055 
TCGA-06-0210 179 166 1290 1135  TCGA-02-0064 149 129 2645 2010 
TCGA-02-0338 161 151 3983 3121  TCGA-02-0324 238 235 3141 2848 
TCGA-06-0132 119 113 600 512  TCGA-02-0439 247 226 2232 1999 
TCGA-02-0332 220 208 2291 1899  TCGA-02-0006 232 217 1512 1333 
TCGA-06-0164 243 202 995 906  TCGA-02-0339 236 218 1450 1389 
TCGA-06-0168 220 205 1053 1006  TCGA-06-0141 394 364 2294 1637 
TCGA-06-0145 220 210 527 224  TCGA-08-0345 282 280 8280 8116 
TCGA-02-0330 273 259 1634 1470  TCGA-06-0179 152 139 1026 952 
TCGA-06-0133 144 138 1925 1845  TCGA-02-0071 150 144 1648 1536 
TCGA-02-0001 163 152 1124 1061  TCGA-12-0620 416 409 10979 10254 
TCGA-08-0349 183 177 6268 5860  TCGA-08-0531 185 167 758 668 
TCGA-02-0317 128 123 3202 3084  TCGA-08-0510 237 195 1582 1347 
TCGA-06-0171 187 159 581 506  TCGA-02-0432 165 130 1423 1133 
TCGA-06-0182 284 251 876 593  TCGA-08-0516 206 194 722 686 
TCGA-06-0166 271 239 2270 1719  TCGA-06-0127 207 207 18063 17867 
TCGA-02-0446 159 147 2279 1753  TCGA-02-0037 145 134 1869 1627 
TCGA-06-0402 432 380 553 430  TCGA-06-0126 119 113 3029 2044 
TCGA-06-0238 236 234 9595 9344  TCGA-08-0386 291 272 3166 3063 
TCGA-02-0266 406 344 2751 2366  TCGA-02-0028 167 166 1879 1867 
TCGA-06-0154 147 141 2997 2091  TCGA-02-0083 208 176 4954 4151 
TCGA-02-0033 115 111 1181 1128  TCGA-02-0116 111 108 3449 2971 
TCGA-02-0281 278 265 3413 3153  TCGA-06-0175 300 278 1523 1155 
TCGA-02-0052 134 130 1535 1305  TCGA-02-0011 159 140 3319 3218 
TCGA-06-0156 223 182 1107 683  TCGA-02-0038 209 205 1536 1317 
TCGA-08-0529 245 237 973 843  TCGA-06-0648 283 283 10903 10486 
TCGA-08-0522 141 136 1220 860  TCGA-02-0054 167 155 1076 1044 
TCGA-02-0113 175 166 3932 2944  TCGA-02-0440 166 164 1405 1282 
TCGA-02-0069 332 281 2619 2061  TCGA-02-0456 145 137 2993 2755 
TCGA-02-0074 187 177 3476 3171  TCGA-06-0148 196 177 1147 874 
TCGA-08-0514 330 309 2821 2145  TCGA-06-0194 198 191 1265 1222 
TCGA-02-0087 183 163 1628 1588  TCGA-02-0325 289 246 1993 1640 
TCGA-06-0162 351 316 1952 1368  TCGA-06-0130 150 138 644 588 
TCGA-06-0129 934 781 2889 2242  TCGA-06-0125 192 180 2151 1637 
TCGA-06-0195 169 160 1526 1481  TCGA-02-0115 197 181 2784 2524 
TCGA-02-0034 194 185 1304 1156  TCGA-02-0009 257 241 2178 1691 
TCGA-02-0084 198 197 9592 8706  TCGA-06-0122 177 153 1300 1266 
TCGA-06-0158 145 136 1364 1342  TCGA-02-0080 269 216 2095 1610 




probe CBS CBS Merged HHMM 
HHMM 





TCGA-08-0525 213 192 1156 978  TCGA-02-0422 235 208 1215 1166 
TCGA-02-0269 408 334 959 710  TCGA-02-0285 119 117 2765 2350 
TCGA-02-0099 236 212 2583 1687  TCGA-08-0352 284 278 5494 4850 
TCGA-02-0089 138 127 2150 1924  TCGA-06-0176 147 143 2649 2208 
TCGA-06-0187 160 148 1714 1056  TCGA-06-0147 125 117 2175 1634 
TCGA-02-0058 148 120 1205 894  TCGA-02-0114 257 238 4835 4608 
TCGA-02-0111 154 144 870 688  TCGA-06-0146 510 460 1494 1322 
TCGA-06-0209 177 161 1270 1074  TCGA-02-0075 147 142 3491 2963 
TCGA-06-0185 188 173 761 698  TCGA-06-0177 255 254 6457 5811 
TCGA-06-0178 108 106 2151 2096  TCGA-08-0521 148 145 2533 2359 
TCGA-06-0197 167 164 1390 1179  TCGA-06-0169 128 120 1792 1676 
TCGA-08-0518 296 274 1706 1113  TCGA-02-0102 141 134 1183 931 
TCGA-06-0644 184 176 12523 12341  TCGA-02-0260 232 213 3211 2822 
TCGA-08-0517 305 267 853 730  TCGA-06-0137 191 152 1244 1085 
TCGA-06-0128 194 170 2189 1986  TCGA-06-0397 195 181 1787 1696 
TCGA-02-0010 275 224 1278 1202  TCGA-06-0237 262 234 1091 1044 
TCGA-08-0511 235 219 1222 1166  TCGA-02-0046 162 152 2762 2486 
TCGA-06-0645 206 203 10923 10692  TCGA-06-0409 159 154 879 817 
TCGA-02-0024 215 171 898 865  TCGA-06-0124 150 139 1213 1085 
TCGA-06-0241 287 274 2455 2096  TCGA-02-0326 169 159 1356 1130 
TCGA-06-0410 245 236 2817 2726  TCGA-06-0174 119 104 1909 1835 
TCGA-06-0213 225 199 2121 1662  TCGA-02-0271 135 126 2380 2092 
TCGA-02-0003 125 117 929 842  TCGA-06-0184 205 188 832 795 
TCGA-02-0107 112 110 1741 1468  TCGA-08-0358 459 422 3100 2805 
TCGA-06-0190 165 157 1136 957  TCGA-02-0057 146 134 3056 2603 
TCGA-12-0619 253 246 10186 9357  TCGA-06-0189 103 101 1930 1892 
TCGA-06-0221 207 177 1295 772  TCGA-06-0149 223 215 1066 913 
TCGA-06-0188 114 104 2690 2263  TCGA-06-0157 193 187 1743 1392 
TCGA-06-0211 168 156 1140 689  TCGA-02-0289 164 164 4172 3450 
TCGA-02-0007 175 159 1984 1626  TCGA-02-0079 283 269 7998 7711 
TCGA-08-0512 149 145 1515 1291  TCGA-06-0208 227 212 1301 782 
TCGA-02-0027 131 125 2957 2906  TCGA-02-0430 263 236 1678 1518 
TCGA-02-0047 131 124 1149 1077  TCGA-02-0321 236 223 542 469 
TCGA-02-0106 246 205 1133 932  TCGA-06-0414 154 149 1745 1608 
TCGA-02-0021 193 186 2367 2287  TCGA-06-0214 259 236 1162 890 
TCGA-06-0394 180 161 1191 1103  TCGA-08-0524 274 241 1398 1266 
TCGA-12-0618 166 165 10075 8880  TCGA-02-0258 383 294 1186 1077 
TCGA-12-0616 298 294 16256 15933  TCGA-02-0333 311 293 2191 1747 
TCGA-08-0509 180 180 920 782  TCGA-06-0173 243 232 1539 1295 
TCGA-06-0143 227 219 1828 1625  TCGA-02-0086 134 128 2255 2053 
TCGA-06-0139 420 350 1508 1129  TCGA-02-0290 149 148 6011 4658 
TCGA-06-0138 115 97 1128 1078  TCGA-06-0152 249 246 12700 12581 
TCGA-06-0413 178 177 1762 1711  TCGA-08-0520 206 193 568 473 
TCGA-02-0060 304 260 1620 1536  TCGA-06-0646 248 244 10156 9754 







Figure S5.6.1 Log2(Ratio) values of the modes of the density plots from all 170 patients 
samples (HHMM segmentation method). For most of the hybridizations, the mode of the 













Table S6.1.1 Single probe segments with absolute predicted log2(Ratio) great than one 
identified by using HHMM segmentation algorithm. 
 
sample chr start end segval genes  sample chr start end segval genes 
TCGA-06-0124 1 149390893 149390952 -2.47   TCGA-02-0451 10 32885520 32885579 -1.28 CCDC7 
TCGA-02-0058 1 245054641 245054700 -2.27   TCGA-02-0451 10 66951636 66951695 -1.28  




1 -1.28  
TCGA-02-0028 1 5548432 5548490 -1.31   TCGA-08-0509 10 7480070 7480129 -1.26 SFMBT2 
TCGA-02-0028 1 14971358 14971417 -1.31 KIAA1026  TCGA-08-0509 10 55814784 55814843 -1.26 PCDH15 
TCGA-02-0028 1 37554771 37554830 -1.31   TCGA-08-0509 10 81766470 81766529 -1.26  
TCGA-02-0028 1 50942883 50942942 -1.31 FAF1  TCGA-08-0509 10 97984467 97984526 -1.26 BLNK 
TCGA-02-0028 1 104018651 104018710 -1.31   TCGA-06-0188 10 7739585 7739644 -1.24 ITIH5 
TCGA-02-0028 1 120923696 120923755 -1.31 AK128714  TCGA-06-0188 10 14709241 14709300 -1.24 FAM107B 
TCGA-02-0028 1 177906433 177906492 -1.31   TCGA-06-0188 10 18548400 18548459 -1.24 CACNB2 
TCGA-06-0124 1 149394958 149395017 -1.28   TCGA-06-0188 10 70334318 70334377 -1.24 DDX50 
TCGA-06-0124 1 149579637 149579696 -1.28   TCGA-02-0089 10 13517548 13517607 -1.22  
TCGA-06-0124 1 197596962 197597021 -1.28 C1orf106  TCGA-02-0089 10 90985518 90985577 -1.22 LIPA 




8 -1.22  
TCGA-12-0618 1 796956 797005 -1.18   TCGA-06-0648 10 1058642 1058692 -1.20 IDI2 
TCGA-12-0618 1 1116011 1116057 -1.18 BC028014  TCGA-06-0648 10 3167933 3167992 -1.20 PFKP 
TCGA-12-0618 1 1161026 1161070 -1.18 TTLL10  TCGA-06-0648 10 12437331 12437390 -1.20 CAMK1D 
TCGA-12-0618 1 1201344 1201388 -1.18 SDF4  TCGA-06-0648 10 26332271 26332330 -1.20 MYO3A 
TCGA-12-0618 1 1285365 1285409 -1.18 PUSL1  TCGA-06-0648 10 44193364 44193409 -1.20 CXCL12 
TCGA-12-0618 1 19410882 19410937 -1.18 CAPZB  TCGA-06-0648 10 45534651 45534696 -1.20  
TCGA-12-0618 1 22001371 22001430 -1.18 HSPG2  TCGA-06-0648 10 49955253 49955306 -1.20 C10orf72 
TCGA-12-0618 1 33988075 33988134 -1.18 CSMD2  TCGA-06-0648 10 69627248 69627307 -1.20 FLJ14437 
TCGA-12-0618 1 59618935 59618994 -1.18 FLJ10986  TCGA-06-0648 10 89199763 89199822 -1.20  
TCGA-12-0618 1 112964625 112964684 -1.18 AF338193  TCGA-06-0648 10 89615644 89615703 -1.20 PTEN 
TCGA-12-0618 1 147836482 147836541 -1.18 C1orf56  TCGA-06-0648 10 90291257 90291316 -1.20 C10orf59 
TCGA-12-0618 1 198567488 198567547 -1.18 IPO9  TCGA-06-0648 10 90651370 90651429 -1.20 STAMBPL1 
TCGA-12-0618 1 199154489 199154548 -1.18 PPP1R12B  TCGA-06-0648 10 90685095 90685154 -1.20 ACTA2 
TCGA-12-0618 1 219503635 219503694 -1.18 DISP1  TCGA-06-0648 10 99324268 99324325 -1.20 ANKRD2 




7 -1.20 SPFH1 




6 -1.20  




7 -1.20 NFKB2 




2 -1.20 NEURL 




3 -1.20 TCERG1L 
TCGA-06-0152 1 2614922 2614970 -1.03   TCGA-02-0006 10 66951636 66951695 -1.19  
TCGA-06-0152 1 19410882 19410937 -1.03 CAPZB  TCGA-02-0006 10 70947915 70947974 -1.19  
TCGA-06-0152 1 26288909 26288954 -1.03 CCDC21  TCGA-02-0006 10 89256027 89256086 -1.19 MINPP1 
TCGA-06-0152 1 30687222 30687281 -1.03   TCGA-02-0006 10 96842251 96842310 -1.19  
TCGA-06-0152 1 33988075 33988134 -1.03 CSMD2  TCGA-06-0152 10 1386766 1386810 -1.16 ADARB2 
TCGA-06-0152 1 46410804 46410851 -1.03 C1orf190  TCGA-06-0152 10 3899933 3899992 -1.16  
TCGA-06-0152 1 59618935 59618994 -1.03 FLJ10986  TCGA-06-0152 10 7739585 7739644 -1.16 ITIH5 
TCGA-06-0152 1 72978376 72978435 -1.03   TCGA-06-0152 10 11674768 11674827 -1.16 D13644 
TCGA-06-0152 1 112964625 112964684 -1.03 AF338193  TCGA-06-0152 10 11953319 11953378 -1.16 C10orf47 




sample chr start end segval genes  sample chr start end segval genes 
TCGA-06-0152 1 176128016 176128075 -1.03 C1orf125  TCGA-06-0152 10 26030462 26030521 -1.16 AK096400 
TCGA-06-0152 1 219503635 219503694 -1.03 DISP1  TCGA-06-0152 10 29704220 29704279 -1.16  
TCGA-06-0152 1 233380409 233380468 -1.03 MTR  TCGA-06-0152 10 34438690 34438749 -1.16 AF196185 
TCGA-02-0057 1 85468110 85468169 1.01 AK125723  TCGA-06-0152 10 39018805 39018864 -1.16  
TCGA-02-0057 1 119942294 119942353 1.01   TCGA-06-0152 10 44193364 44193409 -1.16 CXCL12 
TCGA-02-0057 1 175227043 175227102 1.01 AK097518  TCGA-06-0152 10 49340053 49340111 -1.16 ARHGAP22 
TCGA-02-0057 1 230972236 230972295 1.01 BC040195  TCGA-06-0152 10 50178065 50178124 -1.16 C10orf71 
TCGA-02-0113 1 56126922 56126981 1.36   TCGA-06-0152 10 52945287 52945346 -1.16 PRKG1 
TCGA-02-0113 1 72489681 72489740 1.36   TCGA-06-0152 10 56071056 56071115 -1.16 PCDH15 
TCGA-02-0113 1 222038023 222038082 1.36 ENAH  TCGA-06-0152 10 59122592 59122651 -1.16  
TCGA-02-0071 1 72489681 72489740 1.50   TCGA-06-0152 10 63382145 63382204 -1.16 ARID5B 
TCGA-02-0071 1 199904886 199904945 1.50 X75546  TCGA-06-0152 10 69627248 69627307 -1.16 FLJ14437 
TCGA-08-0529 2 94950913 94950972 -1.16   TCGA-06-0152 10 71541910 71541969 -1.16 H2AFY2 
TCGA-08-0529 2 102195099 102195158 -1.16   TCGA-06-0152 10 72029378 72029434 -1.16 PRF1 
TCGA-08-0529 2 112717800 112717859 -1.16 ZC3H8  TCGA-06-0152 10 72324240 72324293 -1.16  
TCGA-08-0529 2 186437582 186437641 -1.16 FSIP2  TCGA-06-0152 10 72351591 72351650 -1.16  
TCGA-08-0529 2 200138001 200138060 -1.16 SATB2  TCGA-06-0152 10 74539893 74539952 -1.16  
TCGA-08-0529 2 231068830 231068889 -1.16 LOC93349  TCGA-06-0152 10 80668229 80668288 -1.16 RAI17 
TCGA-08-0529 2 241125726 241125781 -1.16 GPC1  TCGA-06-0152 10 98350765 98350824 -1.16 PIK3AP1 
TCGA-06-0169 2 27432096 27432155 -1.06 TRIM54  TCGA-06-0152 10 99369370 99369421 -1.16 C10orf83 




4 -1.16 NKX2-3 




3 -1.16 ABCC2 




7 -1.16 PEO1 




6 -1.16  




5 -1.16 KCNIP2 




7 -1.16 C10orf77 




5 -1.16 ARL3 




0 -1.16 AB209785 




2 -1.16 NEURL 




2 -1.16  




0 -1.16 ATRNL1 




2 -1.16 C10orf46 




0 -1.16 AB030073 




8 -1.16  




2 -1.16 CPXM2 




2 -1.16 MGMT 




3 -1.16 TCERG1L 




1 -1.16 ADAM8 
TCGA-02-0071 2 169668054 169668113 1.02 ABCB11  TCGA-06-0645 10 1058642 1058692 -1.07 IDI2 
TCGA-02-0071 2 205581237 205581296 1.02 ALS2CR19  TCGA-06-0645 10 1386766 1386810 -1.07 ADARB2 
TCGA-02-0071 2 210647216 210647275 1.02 AB058746  TCGA-06-0645 10 12437331 12437390 -1.07 CAMK1D 
TCGA-02-0071 2 240659146 240659205 1.02 NDUFA10  TCGA-06-0645 10 18949751 18949810 -1.07 NSUN6 
TCGA-02-0071 2 241724916 241724971 1.02 AK074062  TCGA-06-0645 10 26030462 26030521 -1.07 AK096400 
TCGA-02-0046 2 114719726 114719785 1.73   TCGA-06-0645 10 32821797 32821856 -1.07 CCDC7 
TCGA-02-0046 2 182746745 182746804 1.73 CR600208  TCGA-06-0645 10 34430998 34431057 -1.07  




sample chr start end segval genes  sample chr start end segval genes 
TCGA-02-0069 3 76799534 76799593 -1.50 AJ012503  TCGA-06-0645 10 45468415 45468474 -1.07 ANUBL1 
TCGA-02-0038 3 166528671 166528730 -1.22   TCGA-06-0645 10 49955253 49955306 -1.07 C10orf72 
TCGA-02-0038 3 167881635 167881694 -1.22   TCGA-06-0645 10 50178065 50178124 -1.07 C10orf71 
TCGA-02-0055 3 191208239 191208298 -1.17 LEPREL1  TCGA-06-0645 10 50485951 50486010 -1.07  
TCGA-02-0271 3 6006012 6006071 -1.12   TCGA-06-0645 10 69627248 69627307 -1.07 FLJ14437 
TCGA-02-0271 3 36193272 36193331 -1.12   TCGA-06-0645 10 72029378 72029434 -1.07 PRF1 
TCGA-02-0271 3 64325557 64325616 -1.12   TCGA-06-0645 10 72324240 72324293 -1.07  
TCGA-02-0271 3 111465930 111465989 -1.12   TCGA-06-0645 10 74692636 74692695 -1.07 TTC18 




2 -1.07 NEURL 
TCGA-02-0271 3 175704921 175704980 -1.12 AJ607399  TCGA-12-0620 10 5530640 5530688 -1.05 CALML5 
TCGA-02-0271 3 185573293 185573340 -1.12 THPO  TCGA-12-0620 10 7372309 7372368 -1.05 SFMBT2 
TCGA-02-0271 3 190368566 190368625 -1.12 BX641108  TCGA-12-0620 10 9864908 9864967 -1.05  
TCGA-06-0122 3 88797733 88797792 -1.07 M19503  TCGA-12-0620 10 17931709 17931760 -1.05 MRC1 
TCGA-02-0440 3 47209546 47209605 1.05 AK096853  TCGA-12-0620 10 33163680 33163739 -1.05 C10orf68 
TCGA-02-0440 3 99534264 99534323 1.05 BC104637  TCGA-12-0620 10 35450870 35450929 -1.05  
TCGA-02-0440 3 196258410 196258469 1.05   TCGA-12-0620 10 39018805 39018864 -1.05  
TCGA-08-0345 3 33514508 33514567 1.19 CLASP2  TCGA-12-0620 10 72029378 72029434 -1.05 PRF1 
TCGA-08-0345 3 48705552 48705611 1.19 IHPK2  TCGA-12-0620 10 72324240 72324293 -1.05  
TCGA-08-0345 3 49370234 49370284 1.19 GPX1  TCGA-12-0620 10 74692636 74692695 -1.05 TTC18 
TCGA-08-0345 3 56669849 56669908 1.19 C3orf63  TCGA-12-0620 10 79357832 79357891 -1.05 AF194537 
TCGA-08-0345 3 113831725 113831784 1.19 CCDC80  TCGA-12-0620 10 88690277 88690334 -1.05 MMRN2 
TCGA-08-0345 3 115523069 115523128 1.19   TCGA-12-0620 10 96987297 96987356 -1.05 PDLIM1 
TCGA-08-0345 3 128769344 128769403 1.19   TCGA-12-0620 10 99324268 99324325 -1.05 ANKRD2 




6 -1.05 HPSE2 




7 -1.05 PEO1 




9 -1.05 SFXN3 




8 -1.05  




7 -1.05 NFKB2 




2 -1.05 NEURL 




4 -1.05 KIAA1914 




6 -1.05 EMX2 
TCGA-02-0439 3 163987465 163987524 1.58 BC019327  TCGA-06-0410 10 37508402 37508461 -1.04 ANKRD30A 
TCGA-06-0148 4 41587341 41587400 -1.57 PHOX2B  TCGA-02-0034 10 80943483 80943542 -1.01 BC070048 
TCGA-06-0148 4 83995737 83995796 -1.57 SCD5  TCGA-02-0069 10 33177446 33177505 1.09 C10orf68 
TCGA-06-0148 4 173804227 173804286 -1.57 GALNT17  TCGA-02-0069 10 30701361 30701420 1.18 AL122121 
TCGA-06-0414 4 65081008 65081067 -1.42 SRD5A2L2  TCGA-02-0010 11 40145100 40145159 -3.42 LRRC4C 
TCGA-06-0176 4 6519210 6519269 -1.06 PPP2R2C  TCGA-02-0010 11 43385450 43385509 -3.42 TTC17 
TCGA-06-0176 4 142355308 142355367 -1.06 RNF150  TCGA-02-0010 11 43581380 43581439 -3.42  




3 -2.36  
TCGA-08-0358 4 2969303 2969362 1.01 TETRAN  TCGA-02-0010 11 5714298 5714357 -2.20 OR56B1 
TCGA-08-0358 4 78326484 78326543 1.01 CCNI  TCGA-02-0010 11 40138697 40138756 -2.20 LRRC4C 
TCGA-08-0358 4 88751976 88752035 1.01 SPARCL1  TCGA-02-0010 11 40636139 40636198 -2.20 DQ084202 
TCGA-08-0358 4 173814860 173814919 1.01 GALNT17  TCGA-02-0010 11 40875860 40875919 -2.20 DQ084202 
TCGA-02-0084 4 78326484 78326543 1.02 CCNI  TCGA-02-0010 11 41967473 41967532 -2.20  
TCGA-02-0084 4 83908026 83908085 1.02 SCD5  TCGA-02-0010 11 42320627 42320686 -2.20  
TCGA-02-0084 4 174684198 174684257 1.02 SCRG1  TCGA-02-0010 11 42441291 42441350 -2.20  




sample chr start end segval genes  sample chr start end segval genes 
TCGA-06-0169 4 20771524 20771583 1.13 KCNIP4  TCGA-02-0010 11 43369996 43370055 -2.20 TTC17 
TCGA-06-0169 4 173797255 173797314 1.13 GALNT17  TCGA-02-0010 11 43576127 43576185 -2.20  
TCGA-02-0069 4 119787238 119787297 1.25   TCGA-02-0010 11 66469412 66469471 -2.20 PC 
TCGA-08-0345 4 176930261 176930320 1.37 GPM6A  TCGA-02-0086 11 12730077 12730136 -1.81 AL833289 
TCGA-08-0373 4 75786041 75786100 1.38   TCGA-02-0116 11 4422151 4422209 1.13  
TCGA-08-0373 4 111021272 111021331 1.38 CFI  TCGA-02-0116 11 5039792 5039851 1.13  
TCGA-02-0446 4 56434374 56434433 2.10   TCGA-02-0116 11 50016006 50016065 1.13  
TCGA-06-0644 4 88751976 88752035 2.30 SPARCL1  TCGA-02-0116 11 62081604 62081658 1.13  




9 1.13 KIRREL3 
TCGA-02-0011 5 180351118 180351177 -2.75 BTNL3  TCGA-08-0510 12 22246157 22246216 -1.86 ST8SIA1 
TCGA-02-0439 5 763494 763553 -2.39 AF251188  TCGA-02-0075 12 6309670 6309724 -1.24 TNFRSF1A 
TCGA-02-0060 5 41270804 41270863 -1.42 BC035723  TCGA-02-0075 12 83250693 83250752 -1.24  
TCGA-02-0060 5 55994367 55994426 -1.42   TCGA-02-0432 12 20451634 20451693 -1.20 PDE3A 
TCGA-02-0069 5 15772846 15772905 -1.34 FBXL7  TCGA-02-0116 12 43930302 43930361 -1.17 TMEM16F 
TCGA-02-0069 5 154503127 154503186 -1.34   TCGA-02-0028 12 11077272 11077331 -1.05 BC071692 
TCGA-08-0516 5 72852165 72852224 -1.20   TCGA-02-0028 12 83250693 83250752 -1.05  
TCGA-02-0084 5 129005390 129005449 -1.16 ADAMTS19  TCGA-02-0060 12 45828785 45828844 1.13 BC072670 
TCGA-02-0084 5 175590732 175590791 -1.16   TCGA-02-0060 12 47147923 47147970 1.13  
TCGA-02-0084 5 175717047 175717106 -1.16 KIAA1191  TCGA-02-0060 12 54363637 54363688 1.13 METTL7B 
TCGA-08-0529 5 20776045 20776104 -1.04 AK093362  TCGA-02-0060 12 60982821 60982880 1.13 USP15 
TCGA-08-0529 5 69274433 69274492 -1.04 LOC153561  TCGA-02-0060 12 68301742 68301801 1.13  
TCGA-08-0529 5 72852165 72852224 -1.04   TCGA-02-0060 12 68612610 68612669 1.13 C12orf28 
TCGA-08-0529 5 117403380 117403439 -1.04   TCGA-02-0060 12 70516795 70516854 1.13  
TCGA-06-0141 5 28853748 28853807 -1.02   TCGA-02-0060 12 56445035 56445079 1.65 CYP27B1 
TCGA-02-0003 5 34407822 34407881 -1.01   TCGA-02-0060 12 68293939 68293998 1.65  
TCGA-02-0027 5 41541451 41541510 -1.01 PLCXD3  TCGA-02-0060 12 68627275 68627334 1.65 C12orf28 
TCGA-02-0027 5 60277014 60277061 -1.01 mimitin  TCGA-02-0060 12 69119002 69119061 1.65  
TCGA-02-0027 5 69274433 69274492 -1.01 LOC153561  TCGA-02-0060 12 73929394 73929453 1.65 AK093193 
TCGA-02-0027 5 100842157 100842216 -1.01   TCGA-02-0060 12 56449995 56450051 2.17 METTL1 
TCGA-02-0027 5 125801997 125802056 -1.01 GRAMD3  TCGA-06-0414 13 59499981 59500040 -2.75 AY750055 
TCGA-08-0521 5 34407822 34407881 -1.01   TCGA-02-0115 13 98277054 98277113 -1.43 DOCK9 




6 -1.36 MYR8 
TCGA-06-0414 5 34407822 34407881 -1.01   TCGA-02-0258 13 27564238 27564297 -1.22 FLT3 
TCGA-06-0414 5 55994367 55994426 -1.01   TCGA-02-0258 13 48770638 48770697 -1.22  
TCGA-06-0414 5 118719760 118719808 -1.01 TNFAIP8  TCGA-02-0258 13 49224565 49224624 -1.22 KPNA3 
TCGA-06-0178 6 153446065 153446124 -2.50 RGS17  TCGA-02-0258 13 50057943 50058002 -1.22 AJ412029 
TCGA-02-0011 6 110760400 110760459 -1.81 AK127146  TCGA-02-0258 13 51077617 51077676 -1.22 WDFY2 
TCGA-06-0410 6 32629848 32629907 -1.72 BC003593  TCGA-02-0258 13 58110118 58110177 -1.22  
TCGA-08-0516 6 32654432 32654491 -1.65 BC003593  TCGA-02-0258 13 66001904 66001963 -1.22 PCDH9 
TCGA-02-0324 6 109812732 109812791 -1.39   TCGA-02-0258 13 75553783 75553842 -1.22  
TCGA-02-0113 6 162554711 162554770 -1.27 PARK2  TCGA-02-0258 13 76189003 76189062 -1.22  
TCGA-02-0086 6 110760400 110760459 -1.23 AK127146  TCGA-08-0386 13 49085437 49085496 -1.13  
TCGA-06-0149 6 161002365 161002409 -1.10 LPA  TCGA-08-0386 13 51491170 51491229 -1.13 ALG11 
TCGA-06-0645 6 35866245 35866302 -1.09   TCGA-08-0386 13 73171121 73171180 -1.13 KLF12 




9 -1.13 AK025806 




6 -1.13  




sample chr start end segval genes  sample chr start end segval genes 
TCGA-06-0645 6 169461396 169461455 -1.09 THBS2  TCGA-12-0616 14 67387689 67387733 -1.66 RAD51L 
TCGA-06-0127 6 21704616 21704667 -1.02 SOX4  TCGA-12-0616 14 79742303 79742358 -1.66 DIO2 
TCGA-06-0127 6 22401348 22401407 -1.02 PRL  TCGA-12-0616 14 80737659 80737718 -1.66 GTF2A1 
TCGA-06-0127 6 33649670 33649716 -1.02 BAK1  TCGA-12-0616 14 92173663 92173722 -1.66 RIN3 
TCGA-06-0127 6 34509282 34509341 -1.02   TCGA-12-0616 14 99330427 99330486 -1.66 EML1 
TCGA-06-0127 6 35327326 35327385 -1.02 BX537875  TCGA-06-0646 14 96412034 96412093 -1.61 VRK1 
TCGA-06-0127 6 35479198 35479257 -1.02 PPARD  TCGA-02-0011 14 19397709 19397768 -1.49 BC020999 




0 -1.49 LOC652848 
TCGA-06-0127 6 39397697 39397752 -1.02 KCNK16  TCGA-08-0520 14 20418299 20418358 -1.26  
TCGA-06-0127 6 45623047 45623106 -1.02 RUNX2  TCGA-02-0258 14 55960336 55960395 -1.13  
TCGA-06-0127 6 63574775 63574834 -1.02   TCGA-06-0646 14 22765734 22765778 -1.11  
TCGA-06-0127 6 80042348 80042407 -1.02   TCGA-06-0646 14 31509284 31509343 -1.11  
TCGA-06-0127 6 80846877 80846936 -1.02   TCGA-06-0646 14 32544742 32544801 -1.11 NPAS3 
TCGA-06-0127 6 84706582 84706641 -1.02 CYB5R4  TCGA-06-0646 14 32975012 32975071 -1.11 NPAS3 
TCGA-06-0127 6 86406013 86406072 -1.02 SYNCRIP  TCGA-06-0646 14 33049437 33049496 -1.11 NPAS3 
TCGA-06-0127 6 104449055 104449114 -1.02   TCGA-06-0646 14 34063670 34063718 -1.11 C14orf11 
TCGA-06-0127 6 105918008 105918066 -1.02 PREP  TCGA-06-0646 14 52112020 52112079 -1.11 AK123953 
TCGA-06-0127 6 109466409 109466468 -1.02 SESN1  TCGA-06-0646 14 58891735 58891794 -1.11 DAAM1 
TCGA-06-0127 6 110408187 110408246 -1.02 GPR6  TCGA-06-0646 14 64965154 64965213 -1.11 FUT8 
TCGA-06-0127 6 117931629 117931680 -1.02 DCBLD1  TCGA-06-0646 14 67241027 67241086 -1.11  
TCGA-06-0127 6 118697288 118697347 -1.02 SLC35F1  TCGA-06-0646 14 67387689 67387733 -1.11 RAD51L1 
TCGA-06-0127 6 129614962 129615021 -1.02 LAMA2  TCGA-06-0646 14 71065782 71065838 -1.11 SIPA1L1 
TCGA-06-0127 6 143467919 143467978 -1.02 AIG1  TCGA-06-0646 14 76641904 76641954 -1.11 KIAA1737 
TCGA-06-0127 6 167767660 167767704 -1.02 TCP10  TCGA-06-0646 14 85586106 85586165 -1.11  
TCGA-06-0127 6 169461396 169461455 -1.02 THBS2  TCGA-06-0646 14 96404574 96404633 -1.11 VRK1 
TCGA-02-0266 6 31898633 31898692 1.02 BC011600  TCGA-06-0646 14 96417233 96417292 -1.11 VRK1 
TCGA-02-0266 6 44347885 44347941 1.02 C6orf137  TCGA-06-0646 14 99375657 99375716 -1.11 EML1 
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4 -1.11 AK125079 
TCGA-02-0084 6 18502918 18502977 1.16 IBRDC2  TCGA-06-0143 14 23523096 23523155 -1.09 AY616182 




2 -1.09 LOC652848 
TCGA-02-0084 6 122807669 122807728 1.16 SERINC1  TCGA-02-0099 14 21966870 21966929 -1.08 BC063432 
TCGA-02-0086 7 141985466 141985512 -1.16 LOC647353  TCGA-02-0034 14 37193624 37193683 -1.03 BC038110 
TCGA-02-0324 7 1263119 1263178 1.05 MICAL-L2  TCGA-02-0034 14 52247460 52247519 -1.03 PSMC6 
TCGA-02-0324 7 2333471 2333526 1.05 LFNG  TCGA-06-0152 14 46778735 46778794 -1.01 MAMDC1 
TCGA-02-0324 7 27000106 27000165 1.05 BC025338  TCGA-06-0152 14 80737659 80737718 -1.01 GTF2A1 
TCGA-02-0324 7 48477536 48477595 1.05   TCGA-06-0152 14 92173663 92173722 -1.01 RIN3 
TCGA-02-0324 7 75792244 75792291 1.05 UPK3B  TCGA-06-0152 14 99317055 99317107 -1.01  




6 -1.01 KIAA1446 
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TCGA-02-0324 7 129532549 129532608 1.05 CPA4  TCGA-02-0281 14 22385544 22385598 -1.01 MMP14 
TCGA-02-0324 7 129875106 129875151 1.05 KLF14  TCGA-02-0281 14 22439703 22439762 -1.01 BC106012 
TCGA-06-0154 7 51730660 51730719 1.13   TCGA-02-0281 14 57266951 57267010 -1.01  
TCGA-06-0154 7 52016452 52016511 1.13   TCGA-02-0281 14 64811144 64811203 -1.01  
TCGA-06-0154 7 53947391 53947450 1.13   TCGA-06-0648 15 30423192 30423251 -2.30  
TCGA-06-0154 7 55078607 55078666 1.13 K03193  TCGA-06-0648 15 80451436 80451495 -2.30 CR936602 
TCGA-06-0154 7 55412238 55412297 1.13 ECOP  TCGA-02-0011 15 28719136 28719195 -2.05 BC071990 
TCGA-06-0154 7 55739664 55739723 1.13 BC094796  TCGA-12-0618 15 19819961 19820020 -1.31 AY941978 
TCGA-06-0154 7 65931904 65931963 1.13 RSAFD1  TCGA-12-0618 15 19910867 19910926 -1.31 AY941978 
TCGA-06-0154 7 88764458 88764517 1.13   TCGA-12-0618 15 21610007 21610066 -1.31  
TCGA-06-0154 7 92632452 92632511 1.13 FLJ20097  TCGA-12-0618 15 22860025 22860075 -1.31 AL832758 
TCGA-06-0154 7 107423997 107424056 1.13 NRCAM  TCGA-12-0618 15 62292333 62292392 -1.31 CSNK1G1 
TCGA-06-0154 7 110498901 110498960 1.13 IMMP2L  TCGA-12-0618 15 63131441 63131496 -1.31 OSTbeta 
TCGA-06-0154 7 113575827 113575886 1.13 AK131266  TCGA-12-0618 15 80451436 80451495 -1.31 CR936602 
TCGA-06-0154 7 124008262 124008321 1.13   TCGA-12-0618 15 88619485 88619529 -1.31 AK125370 
TCGA-06-0154 7 127992874 127992933 1.13 CALU  TCGA-12-0618 15 98679517 98679576 -1.31 ADAMTS17 
TCGA-06-0154 7 129875106 129875151 1.13 KLF14  TCGA-06-0238 15 18722595 18722639 -1.18  
TCGA-06-0154 7 136947009 136947068 1.13 DGKI  TCGA-06-0238 15 22364310 22364369 -1.18 AK058147 
TCGA-06-0154 7 146110679 146110738 1.13 CNTNAP2  TCGA-06-0238 15 29640538 29640597 -1.18 OTUD7 
TCGA-06-0154 7 150772061 150772120 1.13 PRKAG2  TCGA-06-0238 15 30423192 30423251 -1.18  
TCGA-06-0154 7 150894557 150894616 1.13 PRKAG2  TCGA-06-0238 15 46005914 46005973 -1.18 BC023624 
TCGA-12-0620 7 810135 810191 1.18 MGC11257  TCGA-06-0238 15 47655530 47655589 -1.18 C15orf33 
TCGA-12-0620 7 13800963 13801022 1.18 ETV1  TCGA-06-0238 15 61329801 61329860 -1.18 RAB8B 
TCGA-12-0620 7 26003797 26003856 1.18 BX538099  TCGA-06-0238 15 73865562 73865606 -1.18  
TCGA-12-0620 7 101707816 101707862 1.18 POLR2J  TCGA-06-0402 15 40231199 40231256 -1.06 PLA2G4F 
TCGA-12-0620 7 107474529 107474588 1.18 NRCAM  TCGA-06-0402 15 54579631 54579690 -1.06  
TCGA-12-0620 7 111012308 111012367 1.18 DOCK4  TCGA-06-0402 15 55616161 55616220 -1.06 CGNL1 
TCGA-12-0620 7 121310523 121310582 1.18 AASS  TCGA-02-0439 15 19879661 19879720 -1.05 AY941978 
TCGA-12-0620 7 130634163 130634222 1.18 MKLN1  TCGA-02-0439 15 86225234 86225293 -1.05 NTRK3 
TCGA-12-0620 7 156017585 156017644 1.18 LMBR1  TCGA-06-0128 15 28441169 28441228 -1.00  
TCGA-02-0001 7 7362407 7362466 1.38   TCGA-06-0195 15 29272766 29272813 1.44  
TCGA-02-0001 7 65931904 65931963 1.38 RSAFD1  TCGA-08-0520 16 3100485 3100544 -1.01 BC001809 
TCGA-02-0001 7 82760953 82761012 1.38 SEMA3E  TCGA-08-0520 16 79670474 79670533 -1.01  
TCGA-02-0001 7 107423997 107424056 1.38 NRCAM  TCGA-02-0326 16 76938723 76938782 1.24 WWOX 
TCGA-02-0001 7 122705022 122705081 1.38 FLJ35834  TCGA-06-0184 17 31474518 31474577 -1.05  
TCGA-02-0001 7 129875106 129875151 1.38 KLF14  TCGA-12-0616 17 6532881 6532940 -1.03 SLC13A5 
TCGA-02-0001 7 141238383 141238442 1.38 MGAM  TCGA-12-0616 17 7318722 7318771 -1.03 ZBTB4 
TCGA-02-0001 7 141511878 141511937 1.38 AJ007770  TCGA-12-0616 17 7694620 7694679 -1.03 AB002344 
TCGA-02-0001 7 146116115 146116174 1.38 CNTNAP2  TCGA-12-0616 17 19522211 19522270 -1.03 FLJ31196 
TCGA-02-0086 7 20047659 20047718 1.57   TCGA-12-0616 17 20234571 20234630 -1.03  
TCGA-02-0086 7 62806412 62806471 1.57 BC029561  TCGA-12-0616 17 20625245 20625304 -1.03  
TCGA-02-0086 7 95236836 95236895 1.57 DYNC1I1  TCGA-12-0616 17 20684380 20684439 -1.03  
TCGA-02-0086 7 122705022 122705081 1.57 FLJ35834  TCGA-12-0616 17 21442476 21442522 -1.03  
TCGA-02-0086 7 141511878 141511937 1.57 AJ007770  TCGA-12-0616 17 25911485 25911529 -1.03 
DKFZP434O
047 
TCGA-02-0086 7 158617983 158618042 1.57   TCGA-12-0616 17 26501612 26501671 -1.03 NF1 
TCGA-02-0271 7 139642681 139642740 1.69   TCGA-12-0616 17 31486540 31486599 -1.03  




sample chr start end segval genes  sample chr start end segval genes 
TCGA-02-0116 7 54558881 54558940 2.71   TCGA-12-0616 17 39752508 39752560 -1.03 CGI-69 
TCGA-02-0451 7 53857835 53857894 2.80   TCGA-12-0616 17 41011530 41011589 -1.03 AK124512 
TCGA-08-0514 7 64701922 64701968 3.98   TCGA-12-0616 17 46260128 46260181 -1.03  
TCGA-02-0116 7 55862893 55862952 4.14 PSPH  TCGA-12-0616 17 55035194 55035253 -1.03 DHX40 
TCGA-02-0106 8 12276178 12276237 -2.25 BC032892  TCGA-12-0616 17 57983727 57983786 -1.03 TLK2 
TCGA-02-0084 8 7729311 7729370 -1.85 BC030211  TCGA-12-0616 17 59370192 59370251 -1.03 SCN4A 
TCGA-02-0107 8 1333233 1333292 -1.81   TCGA-12-0616 17 63739129 63739187 -1.03  
TCGA-02-0107 8 37907045 37907104 -1.81   TCGA-12-0616 17 69818169 69818228 -1.03 DNAI2 
TCGA-02-0107 8 101800174 101800233 -1.81 PABPC1  TCGA-12-0616 17 76068937 76068984 -1.03  
TCGA-02-0439 8 77057200 77057259 -1.48   TCGA-12-0616 17 76749430 76749479 -1.03 AK131529 
TCGA-02-0266 8 107602071 107602130 -1.38 AK124441  TCGA-12-0616 17 77041927 77041971 -1.03 AB040880 
TCGA-02-0266 8 133094826 133094885 -1.38 KIAA0143  TCGA-12-0616 17 77478901 77478945 -1.03 AF338198 
TCGA-06-0152 8 90816 90868 -1.22 BC071667  TCGA-12-0616 17 78653545 78653589 -1.03  
TCGA-06-0152 8 6929691 6929747 -1.22   TCGA-02-0079 17 1315406 1315465 -1.02 MYO1C 
TCGA-06-0152 8 31607545 31607604 -1.22   TCGA-02-0079 17 1877316 1877367 -1.02  
TCGA-06-0152 8 32141825 32141884 -1.22 NRG1  TCGA-02-0079 17 3727364 3727419 -1.02 CAMKK1 
TCGA-06-0152 8 33568440 33568487 -1.22 DUSP26  TCGA-02-0079 17 4424180 4424239 -1.02  
TCGA-06-0152 8 37913540 37913593 -1.22 GOT1L1  TCGA-02-0079 17 4789213 4789267 -1.02 RNF167 
TCGA-06-0152 8 39599448 39599507 -1.22 ADAM18  TCGA-02-0079 17 6871963 6872019 -1.02 BCL6B 
TCGA-06-0152 8 50776370 50776429 -1.22   TCGA-02-0079 17 7318722 7318771 -1.02 ZBTB4 
TCGA-06-0152 8 53424593 53424652 -1.22 ST18  TCGA-02-0079 17 7694620 7694679 -1.02 AB002344 
TCGA-06-0152 8 55138187 55138246 -1.22 LYPLA1  TCGA-02-0079 17 8052025 8052084 -1.02 AURKB 
TCGA-06-0152 8 75582884 75582943 -1.22   TCGA-02-0079 17 16370645 16370704 -1.02  
TCGA-06-0152 8 92307137 92307196 -1.22 BC060784  TCGA-02-0079 17 20625245 20625304 -1.02  
TCGA-06-0152 8 118601645 118601704 -1.22   TCGA-02-0079 17 23862418 23862477 -1.02 BC045622 
TCGA-06-0152 8 123979018 123979077 -1.22 ZHX2  TCGA-02-0079 17 26501612 26501671 -1.02 NF1 
TCGA-06-0152 8 131103860 131103919 -1.22   TCGA-02-0079 17 28177706 28177765 -1.02 MYO1D 
TCGA-06-0152 8 141106328 141106387 -1.22 NIBP  TCGA-02-0079 17 41459223 41459276 -1.02 MAPT 
TCGA-06-0152 8 144166141 144166185 -1.22 BC007589  TCGA-02-0079 17 44360021 44360080 -1.02 UBE2Z 
TCGA-06-0152 8 144203999 144204053 -1.22 C8orf31  TCGA-02-0079 17 45019015 45019071 -1.02  
TCGA-06-0152 8 144537484 144537534 -1.22 BC025767  TCGA-02-0079 17 46006096 46006155 -1.02 CACNA1G 
TCGA-06-0152 8 145533392 145533436 -1.22   TCGA-02-0079 17 69024557 69024616 -1.02 BC041474 
TCGA-02-0115 8 137160246 137160305 -1.13   TCGA-02-0079 17 69774078 69774137 -1.02  
TCGA-02-0046 8 140318249 140318308 -1.03   TCGA-02-0079 17 69890659 69890716 -1.02  
TCGA-12-0619 8 90816 90868 -1.03 BC071667  TCGA-02-0079 17 70367463 70367509 -1.02 GRIN2C 
TCGA-12-0619 8 974966 975025 -1.03 BC022082  TCGA-02-0079 17 70596987 70597031 -1.02 SLC16A5 
TCGA-12-0619 8 6929691 6929747 -1.03   TCGA-02-0079 17 77041927 77041971 -1.02 AB040880 
TCGA-12-0619 8 33568440 33568487 -1.03 DUSP26  TCGA-02-0258 17 3400142 3400201 -1.00 TRPV3 
TCGA-12-0619 8 39599448 39599507 -1.03 ADAM18  TCGA-02-0079 17 36351895 36351954 1.02  
TCGA-12-0619 8 50776370 50776429 -1.03   TCGA-02-0079 17 37744308 37744367 1.02 STAT3 
TCGA-12-0619 8 53424593 53424652 -1.03 ST18  TCGA-02-0079 17 72239339 72239398 1.02 CR599912 
TCGA-12-0619 8 66640572 66640631 -1.03   TCGA-06-0208 17 69926294 69926352 1.04  
TCGA-12-0619 8 86064843 86064902 -1.03   TCGA-06-0208 17 76449446 76449505 1.04 KIAA1303 
TCGA-12-0619 8 87405509 87405568 -1.03   TCGA-06-0208 17 78528645 78528704 1.04 B3GNTL1 
TCGA-12-0619 8 92307137 92307196 -1.03 BC060784  TCGA-06-0414 17 36534226 36534285 1.05  
TCGA-12-0619 8 106441121 106441180 -1.03 ZFPM2  TCGA-06-0644 17 22315936 22315983 1.09  




sample chr start end segval genes  sample chr start end segval genes 
TCGA-12-0619 8 132063081 132063140 -1.03 ADCY8  TCGA-06-0644 17 72239339 72239398 1.09 CR599912 
TCGA-12-0619 8 141106328 141106387 -1.03 NIBP  TCGA-06-0644 17 74381487 74381542 1.09 TIMP2 
TCGA-12-0619 8 144203999 144204053 -1.03 C8orf31  TCGA-02-0060 17 38398917 38398976 1.13 RUNDC1 
TCGA-12-0619 8 144537484 144537534 -1.03 BC025767  TCGA-06-0210 17 76449446 76449505 1.17 KIAA1303 
TCGA-12-0619 8 145695514 145695558 -1.03 PPP1R16A  TCGA-06-0188 17 23682723 23682782 1.21 IFT20 
TCGA-02-0266 8 144945861 144945906 1.31 SCRIB  TCGA-06-0188 17 23979594 23979653 1.21 KIAA0100 
TCGA-02-0043 9 23816193 23816243 -3.19 ELAVL2  TCGA-06-0188 17 25520058 25520117 1.21 CCDC55 
TCGA-02-0043 9 127262922 127262981 -3.19   TCGA-06-0188 17 29640471 29640530 1.21  
TCGA-06-0148 9 346079 346138 -3.04 DOCK8  TCGA-06-0188 17 33726698 33726757 1.21 MRPL45 
TCGA-06-0148 9 21179604 21179663 -3.04   TCGA-06-0188 17 36969988 36970044 1.21  
TCGA-06-0148 9 26913325 26913384 -3.04 PLAA  TCGA-06-0188 17 37513554 37513598 1.21 LGP2 
TCGA-06-0148 9 29245323 29245382 -3.04   TCGA-06-0188 17 38202283 38202338 1.21 WNK4 
TCGA-02-0009 9 36611606 36611665 -2.94 MELK  TCGA-06-0188 17 44212401 44212460 1.21 TTLL6 
TCGA-06-0125 9 110104594 110104653 -2.83   TCGA-06-0188 17 50986963 50987022 1.21  
TCGA-02-0021 9 23901804 23901863 -2.73   TCGA-06-0188 17 53747474 53747533 1.21 BZRAP1 
TCGA-02-0021 9 23971151 23971210 -2.73   TCGA-06-0188 17 57148071 57148123 1.21 BRIP1 
TCGA-02-0021 9 25195505 25195564 -2.73   TCGA-06-0188 17 67531059 67531118 1.21  
TCGA-02-0021 9 43378350 43378400 -2.73   TCGA-06-0188 17 68826587 68826646 1.21  
TCGA-02-0037 9 43378350 43378400 -2.45   TCGA-02-0107 18 24048647 24048706 -1.29  
TCGA-02-0430 9 43378350 43378400 -2.23   TCGA-02-0046 18 2382176 2382235 -1.07  
TCGA-06-0148 9 330083 330142 -2.19 DOCK8  TCGA-02-0046 18 17945381 17945440 -1.07  
TCGA-06-0148 9 629010 629069 -2.19 ANKRD15  TCGA-02-0046 18 22436502 22436561 -1.07 KCTD1 
TCGA-06-0148 9 20208937 20208996 -2.19   TCGA-02-0046 18 33015923 33015982 -1.07 KIAA1328 
TCGA-06-0148 9 20684462 20684521 -2.19 KIAA1797  TCGA-02-0046 18 56467989 56468048 -1.07  
TCGA-06-0148 9 20739288 20739347 -2.19 KIAA1797  TCGA-02-0439 18 64017240 64017299 -1.05  
TCGA-06-0148 9 20871870 20871926 -2.19 KIAA1797  TCGA-02-0024 18 14196224 14196283 -1.01  
TCGA-06-0148 9 21282858 21282917 -2.19   TCGA-02-0010 18 22442191 22442250 1.19 KCTD1 
TCGA-06-0148 9 21466463 21466522 -2.19 AK124391  TCGA-02-0271 18 42794580 42794639 1.22 KATNAL2 
TCGA-06-0148 9 21510354 21510413 -2.19 AK124391  TCGA-08-0373 18 22690074 22690133 1.44 AQP4 
TCGA-06-0148 9 21958041 21958099 -2.19 CDKN2A  TCGA-02-0271 19 737550 737609 -2.03 AK024373 
TCGA-06-0148 9 22723912 22723971 -2.19 AK092601  TCGA-06-0176 19 13199527 13199586 -1.31 CACNA1A 
TCGA-06-0148 9 25678698 25678757 -2.19   TCGA-06-0176 19 57038202 57038261 -1.31  
TCGA-06-0148 9 26104455 26104514 -2.19 FLJ16323  TCGA-06-0213 19 40543992 40544045 -1.28  
TCGA-06-0148 9 26123251 26123310 -2.19   TCGA-02-0086 19 61559132 61559191 -1.25 BC043232 
TCGA-06-0148 9 26613334 26613393 -2.19   TCGA-12-0616 19 1803379 1803438 -1.18 KLF16 
TCGA-06-0148 9 26821029 26821088 -2.19   TCGA-12-0616 19 3911050 3911095 -1.18 DAPK3 
TCGA-06-0148 9 28196294 28196353 -2.19 LRRN6C  TCGA-12-0616 19 4760281 4760340 -1.18  
TCGA-06-0148 9 29289692 29289751 -2.19   TCGA-12-0616 19 6155257 6155316 -1.18  
TCGA-06-0148 9 29358120 29358179 -2.19   TCGA-12-0616 19 7015859 7015918 -1.18  
TCGA-06-0148 9 30237394 30237453 -2.19   TCGA-12-0616 19 9861570 9861629 -1.18 OLFM2 
TCGA-06-0148 9 42913008 42913063 -2.19 BC031626  TCGA-12-0616 19 20099547 20099606 -1.18  
TCGA-02-0422 9 86952145 86952204 -2.13   TCGA-12-0616 19 20860538 20860597 -1.18  
TCGA-02-0290 9 35971395 35971454 -2.13   TCGA-12-0616 19 23221921 23221980 -1.18  
TCGA-02-0260 9 20431890 20431949 -2.11 MLLT3  TCGA-12-0616 19 40716218 40716265 -1.18 GAPDHS 
TCGA-02-0260 9 20684462 20684521 -2.11 KIAA1797  TCGA-12-0616 19 40944669 40944728 -1.18 LOC148137 
TCGA-02-0260 9 21282858 21282917 -2.11   TCGA-12-0616 19 48221641 48221700 -1.18 PSG11 




sample chr start end segval genes  sample chr start end segval genes 
TCGA-02-0260 9 21504931 21504990 -2.11 AK124391  TCGA-12-0616 19 52722417 52722476 -1.18 ZNF541 
TCGA-02-0260 9 21958041 21958099 -2.11 CDKN2A  TCGA-12-0616 19 55664690 55664734 -1.18 LOC112703 
TCGA-02-0260 9 22723912 22723971 -2.11 AK092601  TCGA-12-0616 19 57791741 57791800 -1.18 ZNF137 
TCGA-02-0260 9 22842920 22842979 -2.11   TCGA-12-0616 19 57929244 57929303 -1.18 BC056265 
TCGA-02-0260 9 23784955 23785014 -2.11 ELAVL2  TCGA-12-0616 19 58875960 58876019 -1.18  
TCGA-02-0116 9 34267524 34267583 -2.10   TCGA-12-0616 19 59492650 59492707 -1.18 LILRA6 
TCGA-06-0125 9 21114816 21114875 -2.08   TCGA-12-0616 19 59617971 59618024 -1.18 AF315098 
TCGA-06-0125 9 21282858 21282917 -2.08   TCGA-12-0616 19 63190370 63190429 -1.18 ZNF606 
TCGA-06-0125 9 21394289 21394347 -2.08   TCGA-12-0616 19 63676549 63676604 -1.18 ZNF324 
TCGA-06-0125 9 22723912 22723971 -2.08 AK092601  TCGA-06-0171 19 10432640 10432687 -1.11 PDE4A 
TCGA-06-0125 9 23704617 23704676 -2.08 ELAVL2  TCGA-06-0171 19 59492650 59492707 -1.11 LILRA6 
TCGA-06-0125 9 23784955 23785014 -2.08 ELAVL2  TCGA-08-0517 19 47574701 47574758 -1.08 SBP1 
TCGA-06-0125 9 25678698 25678757 -2.08   TCGA-08-0517 19 55146867 55146912 -1.08 SIGLEC11 
TCGA-06-0125 9 25969531 25969590 -2.08   TCGA-08-0517 19 56840346 56840401 -1.08 AY358369 
TCGA-06-0125 9 27430770 27430827 -2.08 MOBKL2B  TCGA-08-0517 19 57561995 57562054 -1.08 BC039903 
TCGA-06-0125 9 28196294 28196353 -2.08 LRRN6C  TCGA-12-0618 19 3911050 3911095 -1.05 DAPK3 
TCGA-06-0125 9 28294971 28295030 -2.08 LRRN6C  TCGA-12-0618 19 6155257 6155316 -1.05  
TCGA-06-0125 9 28335772 28335831 -2.08 LRRN6C  TCGA-12-0618 19 10074425 10074476 -1.05 AF230330 
TCGA-06-0125 9 41470116 41470175 -2.08   TCGA-12-0618 19 10420582 10420626 -1.05 AY593872 
TCGA-06-0125 9 110100386 110100445 -2.08   TCGA-12-0618 19 12889945 12889989 -1.05 CR620067 
TCGA-06-0125 9 120634700 120634746 -2.08 FBXW2  TCGA-12-0618 19 16858458 16858506 -1.05  
TCGA-08-0521 9 109690961 109691020 -1.97 PALM2  TCGA-12-0618 19 18400268 18400312 -1.05 SSBP4 
TCGA-08-0521 9 138301699 138301758 -1.97   TCGA-12-0618 19 20099547 20099606 -1.05  
TCGA-06-0412 9 109690961 109691020 -1.76 PALM2  TCGA-12-0618 19 20860538 20860597 -1.05  
TCGA-06-0154 9 113477324 113477383 -1.64   TCGA-12-0618 19 40716218 40716265 -1.05 GAPDHS 
TCGA-06-0210 9 21154498 21154557 -1.48   TCGA-12-0618 19 50609052 50609096 -1.05 ERCC1 
TCGA-06-0210 9 86952145 86952204 -1.48   TCGA-12-0618 19 52615730 52615789 -1.05  
TCGA-06-0143 9 41470116 41470175 -1.39   TCGA-12-0618 19 52722417 52722476 -1.05 ZNF541 
TCGA-08-0525 9 26821029 26821088 -1.35   TCGA-12-0618 19 53802678 53802732 -1.05 FAM83E 
TCGA-08-0525 9 26925960 26926019 -1.35 PLAA  TCGA-12-0618 19 54232133 54232177 -1.05 J00117 
TCGA-08-0525 9 27094550 27094609 -1.35   TCGA-12-0618 19 55664690 55664734 -1.05 LOC112703 
TCGA-08-0525 9 30524794 30524853 -1.35 BC022036  TCGA-12-0618 19 56018305 56018353 -1.05 KLK1 
TCGA-12-0620 9 32374264 32374323 -1.32   TCGA-12-0618 19 57791741 57791800 -1.05 ZNF137 
TCGA-12-0620 9 35467102 35467161 -1.32 BC031276  TCGA-12-0618 19 57929244 57929303 -1.05 BC056265 
TCGA-12-0620 9 94414166 94414225 -1.32 FBP2  TCGA-12-0618 19 59492650 59492707 -1.05 LILRA6 
TCGA-12-0620 9 108704113 108704159 -1.32 BC014610  TCGA-12-0618 19 59617971 59618024 -1.05 AF315098 
TCGA-02-0089 9 26491363 26491422 -1.24   TCGA-12-0618 19 63190370 63190429 -1.05 ZNF606 
TCGA-06-0646 9 23316739 23316798 -1.22   TCGA-12-0618 19 63676549 63676604 -1.05 ZNF324 
TCGA-06-0646 9 34703703 34703762 -1.22   TCGA-06-0214 19 40543992 40544045 -1.02  
TCGA-06-0646 9 36894709 36894768 -1.22 PAX5  TCGA-06-0214 19 59146487 59146540 -1.02 AB209671 
TCGA-06-0646 9 79490663 79490722 -1.22 TLE4  TCGA-06-0214 19 59492650 59492707 -1.02 LILRA6 
TCGA-06-0646 9 83312126 83312177 -1.22 FRMD3  TCGA-02-0106 19 57718358 57718417 -1.01 BC056265 
TCGA-06-0646 9 92816494 92816542 -1.22 FGD3  TCGA-08-0345 19 611954 612011 -1.00 RNF126 
TCGA-06-0646 9 93619886 93619945 -1.22   TCGA-08-0345 19 626534 626591 -1.00 AK024373 
TCGA-06-0646 9 94414166 94414225 -1.22 FBP2  TCGA-08-0345 19 807195 807247 -1.00 ELA2 
TCGA-06-0646 9 104697731 104697790 -1.22 ABCA1  TCGA-08-0345 19 2574069 2574116 -1.00 GNG7 
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TCGA-06-0646 9 114162328 114162387 -1.22   TCGA-08-0345 19 3935557 3935616 -1.00 EEF2 
TCGA-06-0646 9 115918913 115918972 -1.22   TCGA-08-0345 19 4245786 4245834 -1.00 MGC23244 
TCGA-06-0646 9 125747778 125747837 -1.22 PBX3  TCGA-08-0345 19 4760281 4760340 -1.00  
TCGA-06-0646 9 132117335 132117394 -1.22 NTNG2  TCGA-08-0345 19 5729696 5729750 -1.00 TMEM146 
TCGA-06-0646 9 133011339 133011393 -1.22 RALGDS  TCGA-08-0345 19 6155257 6155316 -1.00  
TCGA-06-0646 9 135648788 135648839 -1.22   TCGA-08-0345 19 7015859 7015918 -1.00  
TCGA-06-0646 9 136071499 136071558 -1.22 UBADC1  TCGA-08-0345 19 7498185 7498244 -1.00 MCOLN1 
TCGA-06-0646 9 136839806 136839850 -1.22 EGFL7  TCGA-08-0345 19 9800520 9800566 -1.00 UBL5 
TCGA-06-0646 9 137561971 137562015 -1.22 FLJ20433  TCGA-08-0345 19 11298922 11298976 -1.00 RAB3D 
TCGA-06-0646 9 138301699 138301758 -1.22   TCGA-08-0345 19 16858458 16858506 -1.00  
TCGA-06-0190 9 21359384 21359443 -1.17   TCGA-08-0345 19 18496572 18496624 -1.00  
TCGA-06-0190 9 21408944 21409003 -1.17   TCGA-08-0345 19 19922085 19922142 -1.00  
TCGA-06-0190 9 24160666 24160725 -1.17   TCGA-08-0345 19 20860538 20860597 -1.00  
TCGA-06-0210 9 20883453 20883512 -1.17 KIAA1797  TCGA-08-0345 19 22533332 22533391 -1.00  
TCGA-06-0210 9 21044957 21045016 -1.17   TCGA-08-0345 19 38504014 38504073 -1.00  
TCGA-06-0210 9 21114816 21114875 -1.17   TCGA-08-0345 19 40716218 40716265 -1.00 GAPDHS 
TCGA-06-0164 9 36353448 36353507 -1.13 RNF38  TCGA-08-0345 19 42396997 42397056 -1.00  
TCGA-06-0164 9 41470116 41470175 -1.13   TCGA-08-0345 19 43927527 43927583 -1.00  
TCGA-02-0269 9 114165838 114165888 -1.13 ORM1  TCGA-08-0345 19 49263677 49263736 -1.00 ZNF223 
TCGA-02-0064 9 11308830 11308889 -1.11   TCGA-08-0345 19 49950095 49950154 -1.00 BCL3 
TCGA-02-0064 9 43378350 43378400 -1.11   TCGA-08-0345 19 52615730 52615789 -1.00  
TCGA-06-0194 9 114165838 114165888 -1.09 ORM1  TCGA-08-0345 19 52722417 52722476 -1.00 ZNF541 
TCGA-08-0345 9 30134402 30134461 -1.01   TCGA-08-0345 19 55395280 55395334 -1.00 AK125082 
TCGA-08-0345 9 39355550 39355594 -1.01 CNTNAP3  TCGA-08-0345 19 55664690 55664734 -1.00 LOC112703 
TCGA-08-0345 9 68962739 68962798 -1.01   TCGA-08-0345 19 57791741 57791800 -1.00 ZNF137 
TCGA-08-0345 9 94414166 94414225 -1.01 FBP2  TCGA-08-0345 19 57929244 57929303 -1.00 BC056265 
TCGA-08-0345 9 104690871 104690930 -1.01 ABCA1  TCGA-08-0345 19 58003930 58003989 -1.00 ZNF28 
TCGA-02-0034 9 39131835 39131894 -1.00 CNTNAP3  TCGA-08-0345 19 58088740 58088799 -1.00 X78928 
TCGA-02-0034 9 43017845 43017904 -1.00   TCGA-08-0345 19 58875960 58876019 -1.00  
TCGA-02-0034 9 43948886 43948940 -1.00   TCGA-08-0345 19 59310832 59310881 -1.00 PRPF31 
TCGA-06-0133 9 85298838 85298897 1.14   TCGA-08-0345 19 59617971 59618024 -1.00 AF315098 
TCGA-06-0413 9 42913008 42913063 1.73 BC031626  TCGA-08-0345 19 63190370 63190429 -1.00 ZNF606 
TCGA-06-0126 9 137529571 137529630 2.20 FLJ20433  TCGA-02-0107 19 52823576 52823635 1.19 BC032065 
TCGA-06-0137 9 43410478 43410537 2.98 AY098593  TCGA-06-0174 19 5934511 5934570 1.21  
TCGA-02-0043 10 66951636 66951695 -3.03   TCGA-06-0174 19 13870803 13870862 1.21 MGC11271 
TCGA-02-0043 10 98125575 98125634 -3.03 TLL2  TCGA-06-0174 19 16406261 16406318 1.21 EPS15L1 
TCGA-02-0333 10 98125575 98125634 -2.79 TLL2  TCGA-06-0174 19 33356504 33356563 1.21  
TCGA-06-0414 10 51264997 51265056 -2.74 TIMM23  TCGA-06-0174 19 39614667 39614726 1.21 UBA2 
TCGA-06-0138 10 32885520 32885579 -2.29 CCDC7  TCGA-06-0174 19 44473559 44473615 1.21  
TCGA-06-0138 10 51581040 51581091 -2.29   TCGA-06-0174 19 49469272 49469331 1.21 ZNF233 
TCGA-06-0138 10 66951636 66951695 -2.29   TCGA-06-0174 19 52530292 52530351 1.21  
TCGA-06-0138 10 100678817 100678876 -2.29 HPSE2  TCGA-06-0174 19 60941502 60941556 1.21 NALP9 
TCGA-08-0520 10 118757869 118757928 -2.19   TCGA-06-0412 20 1528899 1528958 -1.71 SIRPB1 
TCGA-06-0648 10 45554717 45554776 -2.00 FAM21C  TCGA-02-0027 20 51513440 51513499 -1.27 TSHZ2 
TCGA-06-0414 10 3438109 3438168 -1.98 BC037918  TCGA-06-0156 20 51513440 51513499 -1.11 TSHZ2 
TCGA-06-0414 10 4104978 4105037 -1.98 AK055803  TCGA-06-0129 20 25839919 25839978 -1.09  
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TCGA-06-0414 10 4742025 4742084 -1.98   TCGA-06-0412 20 25885935 25885994 1.09 BC052952 
TCGA-06-0414 10 5154246 5154305 -1.98   TCGA-06-0402 20 4144452 4144506 1.14  
TCGA-06-0414 10 51306200 51306259 -1.98 AF005043  TCGA-06-0397 21 28368917 28368976 -1.80 AK093119 
TCGA-06-0414 10 89241227 89241286 -1.98   TCGA-02-0102 21 28368917 28368976 -1.51 AK093119 
TCGA-06-0414 10 89295627 89295686 -1.98 MINPP1  TCGA-02-0106 21 28368917 28368976 -1.28 AK093119 
TCGA-06-0414 10 89679976 89680035 -1.98 PTEN  TCGA-02-0432 21 28368917 28368976 -1.24 AK093119 
TCGA-06-0414 10 89879205 89879264 -1.98   TCGA-08-0531 21 28368917 28368976 -1.20 AK093119 
TCGA-06-0414 10 90051433 90051492 -1.98 C10orf59  TCGA-06-0209 21 28368917 28368976 -1.14 AK093119 
TCGA-06-0414 10 90174342 90174401 -1.98 C10orf59  TCGA-02-0043 21 39030818 39030877 -1.03  
TCGA-06-0414 10 97984467 97984526 -1.98 BLNK  TCGA-02-0043 21 40192300 40192359 -1.03 PCP4 
TCGA-06-0414 10 99548159 99548218 -1.98   TCGA-02-0043 21 42480546 42480605 -1.03  
TCGA-02-0083 10 60513350 60513409 -1.89   TCGA-02-0043 21 44856311 44856357 -1.03 C21orf29 
TCGA-02-0324 10 37508402 37508461 -1.78 ANKRD30A  TCGA-02-0079 21 32896034 32896092 1.13 C21orf59 
TCGA-02-0324 10 90976366 90976425 -1.78 LIPA  TCGA-12-0619 21 26175055 26175112 1.43 APP 
TCGA-02-0324 10 98125575 98125634 -1.78 TLL2  TCGA-06-0174 22 22672513 22672572 -4.08  
TCGA-12-0619 10 37508402 37508461 -1.64 ANKRD30A  TCGA-06-0188 22 22672513 22672572 -3.19  
TCGA-12-0619 10 89440846 89440905 -1.64 PAPSS2  TCGA-06-0188 22 24050904 24050963 -3.19  
TCGA-12-0619 10 90678178 90678237 -1.64 AB037794  TCGA-08-0349 22 22672513 22672572 -2.17  
TCGA-06-0646 10 9864908 9864967 -1.56   TCGA-06-0402 22 14504218 14504277 -2.15 BC016035 
TCGA-06-0646 10 25672743 25672802 -1.56 GPR158  TCGA-06-0402 22 45755429 45755488 -2.15 TBC1D22A 
TCGA-06-0646 10 33163680 33163739 -1.56 C10orf68  TCGA-02-0084 22 22672513 22672572 -1.89  
TCGA-06-0646 10 37508402 37508461 -1.56 ANKRD30A  TCGA-02-0084 22 49356005 49356052 -1.89 ARSA 
TCGA-06-0646 10 105290373 105290432 -1.56 NEURL  TCGA-06-0238 22 49356005 49356052 -1.78 ARSA 
TCGA-08-0520 10 5530640 5530688 -1.47 CALML5  TCGA-08-0345 22 49356005 49356052 -1.74 ARSA 
TCGA-08-0520 10 37523207 37523266 -1.47 ANKRD30A  TCGA-06-0175 22 31690525 31690584 -1.71 SYN3 
TCGA-08-0520 10 53695083 53695142 -1.47 PRKG1  TCGA-06-0175 22 47880174 47880233 -1.71  
TCGA-08-0520 10 55138890 55138949 -1.47 AF083130  TCGA-02-0325 22 36070350 36070409 -1.67 AK055475 
TCGA-08-0520 10 55384225 55384284 -1.47 PCDH15  TCGA-02-0057 22 27667173 27667232 -1.62 AB051436 
TCGA-08-0520 10 69688265 69688324 -1.47   TCGA-02-0060 22 49349292 49349344 -1.50  
TCGA-08-0520 10 90976366 90976425 -1.47 LIPA  TCGA-06-0188 22 22665928 22665976 -1.41 HS322B1A 
TCGA-08-0520 10 98125575 98125634 -1.47 TLL2  TCGA-06-0188 22 22676549 22676593 -1.41  
TCGA-08-0520 10 118752176 118752235 -1.47 KIAA1598  TCGA-06-0188 22 22690716 22690769 -1.41  
TCGA-02-0046 10 80943483 80943542 -1.45 BC070048  TCGA-06-0188 22 22719859 22719907 -1.41 AK127991 
TCGA-02-0046 10 99247798 99247854 -1.45 MMS19L  TCGA-06-0188 22 23978623 23978682 -1.41  
TCGA-02-0046 10 126834997 126835056 -1.45 CTBP2  TCGA-06-0188 22 24228038 24228097 -1.41 BC004918 
TCGA-06-0214 10 66951636 66951695 -1.45   TCGA-06-0188 22 31690525 31690584 -1.41 SYN3 
TCGA-06-0210 10 100678817 100678876 -1.42 HPSE2  TCGA-06-0152 22 17317314 17317358 -1.32  
TCGA-02-0071 10 42266351 42266410 -1.33 BC039000  TCGA-06-0152 22 17494609 17494663 -1.32 DGCR13 
TCGA-02-0071 10 69257482 69257541 -1.33 DNAJC12  TCGA-06-0152 22 18127109 18127159 -1.32 TBX1 
TCGA-02-0071 10 80943483 80943542 -1.33 BC070048  TCGA-06-0152 22 22672513 22672572 -1.32  
TCGA-02-0071 10 88203067 88203126 -1.33 WAPAL  TCGA-06-0152 22 25749756 25749815 -1.32  
TCGA-12-0618 10 11953319 11953378 -1.30 C10orf47  TCGA-06-0152 22 26468793 26468852 -1.32 MN1 
TCGA-12-0618 10 23014261 23014320 -1.30 PIP5K2A  TCGA-06-0152 22 28007348 28007405 -1.32 EWSR1 
TCGA-12-0618 10 25129184 25129243 -1.30   TCGA-06-0152 22 29594981 29595040 -1.32 OSBP2 
TCGA-12-0618 10 29704220 29704279 -1.30   TCGA-06-0152 22 30207655 30207714 -1.32 EIF4ENIF1 
TCGA-12-0618 10 33163680 33163739 -1.30 C10orf68  TCGA-06-0152 22 37730228 37730287 -1.32  
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TCGA-12-0618 10 49340053 49340111 -1.30 ARHGAP22  TCGA-06-0152 22 43210959 43211009 -1.32 LDOC1L 
TCGA-12-0618 10 50178065 50178124 -1.30 C10orf71  TCGA-06-0152 22 45818352 45818411 -1.32 TBC1D22A 
TCGA-12-0618 10 50485951 50486010 -1.30   TCGA-06-0152 22 48956760 48956818 -1.32 SELO 
TCGA-12-0618 10 54775509 54775568 -1.30   TCGA-06-0152 22 49356005 49356052 -1.32 ARSA 
TCGA-12-0618 10 60786104 60786163 -1.30 FAM13C1  TCGA-02-0058 22 21174548 21174607 -1.23 SUHW2 
TCGA-12-0618 10 69612724 69612783 -1.30 FLJ14437  TCGA-02-0058 22 48749925 48749984 -1.23 FLJ41993 
TCGA-12-0618 10 72324240 72324293 -1.30   TCGA-02-0111 22 17525955 17526014 -1.15  
TCGA-12-0618 10 88690277 88690334 -1.30 MMRN2  TCGA-06-0237 22 14504218 14504277 -1.12 BC016035 
TCGA-12-0618 10 99324268 99324325 -1.30 ANKRD2  TCGA-06-0237 22 22719859 22719907 -1.12 AK127991 
TCGA-12-0618 10 100789507 100789566 -1.30 HPSE2  TCGA-06-0237 22 47122623 47122682 -1.12  
TCGA-12-0618 10 101591744 101591803 -1.30 ABCC2  TCGA-06-0410 22 22719859 22719907 -1.08 AK127991 
TCGA-12-0618 10 101933488 101933542 -1.30 SPFH1  TCGA-06-0410 22 27754812 27754871 -1.08 AB051436 
TCGA-12-0618 10 103517472 103517526 -1.30   TCGA-06-0410 22 27884866 27884925 -1.08 AK056425 
TCGA-12-0618 10 104152486 104152530 -1.30 PSD  TCGA-06-0410 22 32067638 32067697 -1.08 LARGE 
TCGA-12-0618 10 105290373 105290432 -1.30 NEURL  TCGA-06-0410 22 38851943 38852002 -1.08 TNRC6B 
TCGA-12-0618 10 107411772 107411831 -1.30   TCGA-02-0102 22 18984101 18984160 1.33  
































Table S6.4.1 Genes that have at least four folds aberrations in at least one patient tumor 
sample. Count for the last column indicates the sample numbers that specific genes 
being identified having big aberrations 
 
Patient ID Chromosomal Location gene count 
TCGA-06-017 chr1q43-q44 SDCCAG8 1 
TCGA-06-015 chr1q32 SOX13 1 
TCGA-06-0412;TCGA-06-015 chr1q32.1 PPP1R15B 2 
TCGA-06-017 chr1q44 C1orf101 1 
TCGA-06-017 chr1q44-qter ZNF238 1 
TCGA-06-017 chr1q44 CEP170 1 
TCGA-06-015 chr1q32.1 ETNK2 1 
TCGA-06-0412;TCGA-06-015 chr1q32 PIK3C2B 2 
TCGA-06-015 chr1q32.1 GOLT1A 1 
TCGA-06-017 chr1q44 C1orf100 1 
TCGA-06-015 chr1q32.1 NFASC 1 
TCGA-06-015 chr1q32.1 PLEKHA6 1 
TCGA-06-017 chr1cen-q12 ADSS 1 
TCGA-06-0412;TCGA-06-015 chr1q32 MDM4 2 
TCGA-06-017 chr1q43-q44 AKT3 1 
TCGA-06-015 chr1q32 KISS1 1 
TCGA-06-015 chr1q32 REN 1 
TCGA-06-020 chr3q28 IL1RAP 1 
TCGA-06-020 chr3q28-q29 CLDN1 1 
TCGA-06-020 chr3q28 CLDN16 1 
TCGA-06-0241;TCGA-08-0524;TCGA-06-017 chr4q11-q12 KIT 3 
TCGA-06-017 chr4q12 SGCB 1 
TCGA-06-0241;TCGA-06-017 chr4q11-q12 KDR 2 
TCGA-02-0440;TCGA-06-017 chr4q12 SCFD2 2 
TCGA-06-017 chr4q12 LNX1 1 
TCGA-02-0440;TCGA-06-0241;TCGA-08-0524;TCGA-06-017 chr4q11 CHIC2 4 
TCGA-06-017 chr4q12 SPATA18 1 
TCGA-08-052 chr4p13 RPL9 1 
TCGA-02-0440;TCGA-06-0241;TCGA-08-0524;TCGA-06-017 chr4q11-q13 PDGFRA 4 
TCGA-06-017 chr4q12 DCUN1D4 1 
TCGA-06-0139;TCGA-06-013 chr4q13 UGT2B17 2 
TCGA-08-052 chr4p14 LIAS 1 
TCGA-06-017 chr4q12 USP46 1 
TCGA-06-017 chr4q12 RASL11B 1 
TCGA-02-0440;TCGA-06-017 chr4q12 FIP1L1 2 
TCGA-06-0210;TCGA-02-0285;TCGA-02-0321;TCGA-02-
0007;TCGA-06-0168;TCGA-02-0024;TCGA-02-043 chr5q35.3 BTNL3 7 
TCGA-06-0122;TCGA-02-0021;TCGA-06-018 chr7p12 GBAS 3 
TCGA-02-008 chr7q36.1 ACTR3B 1 
TCGA-06-018 chr7p11.2 CCT6A 1 




Patient ID Chromosomal Location gene count 






















chr7q31.1-q31.33 LANCL2 26 
TCGA-06-018 chr7p15.2-p15.1 PSPH 1 
TCGA-12-061 chr7p14.1 C7orf10 1 
TCGA-06-0209;TCGA-02-0021;TCGA-06-0211;TCGA-06-
0122;TCGA-06-018 chr7p11.2 ZNF713 5 










chr7p11.2 SEC61G 35 
TCGA-08-052 chr9q34 GTF3C5 1 
TCGA-08-052 chr9q34.13 C9orf98 1 
TCGA-08-052 chr9q34 TSC1 1 
TCGA-08-052 chr9q34.13-q34.3 GBGT1 1 
TCGA-08-052 chr9q34.3 CEL 1 
TCGA-08-052 chr9q34.3 RALGDS 1 
TCGA-08-052 chr9q34.13 GFI1B 1 
TCGA-08-052 chr9q34 C9orf9 1 
TCGA-06-017 chr12q12-q13 KRT6B 1 
TCGA-06-017 chr12q12-q13 KRT3 1 
TCGA-06-0129;TCGA-06-0209;TCGA-12-0616;TCGA-06-
0177;TCGA-06-0152;TCGA-06-018 chr12q14 CDK4 6 
TCGA-06-0209;TCGA-02-0052;TCGA-06-0152;TCGA-06-
0187;TCGA-06-0173;TCGA-06-0182;TCGA-02-010 chr12q15 SLC35E3 7 
TCGA-06-017 chr12q13 KRT8 1 
TCGA-06-017 chr12q14.3 WIF1 1 
TCGA-06-017 chr12q13.13 GRASP 1 
TCGA-06-0648;TCGA-06-018 chr12q14 CAND1 2 
TCGA-06-012 chr12q24.33 GLT1D1 1 
TCGA-06-017 chr12q13.3 HOXC11 1 




Patient ID Chromosomal Location gene count 
TCGA-12-061 chr12q21.32 CEP290 1 
TCGA-06-012 chr12q13.3 NDUFA4L2 1 
TCGA-06-012 chr12p13.3 CACNA1C 1 
TCGA-06-0129;TCGA-06-0209;TCGA-12-0616;TCGA-06-
0177;TCGA-06-0152;TCGA-06-018 chr12q13.3 TSPAN31 6 
TCGA-06-017 chr12q14.1 XRCC6BP1 1 
TCGA-06-017 chr12q13-q21 TAC3 1 
TCGA-06-020 chr12p12.3 AEBP2 1 
TCGA-06-017 chr12q14.2 DPY19L2 1 
TCGA-06-0209;TCGA-06-0152;TCGA-06-0187;TCGA-06-
0182;TCGA-02-010 chr12q15 CPSF6 5 
TCGA-06-0182;TCGA-02-010 chr12q15 PTPRR 2 
TCGA-06-018 chr12q13.2-q13.3 GLI1 1 
TCGA-06-017 chr12q13 ACVR1B 1 
TCGA-06-017 chr12q13 KRT18 1 
TCGA-06-017 chr12q13.3 RDH16 1 
TCGA-06-017 chr12q13.3 HOXC10 1 
TCGA-06-0152;TCGA-06-0187;TCGA-02-010 chr12q15 CCT2 3 
TCGA-06-0177;TCGA-06-018 chr12q14.1 LRIG3 2 
TCGA-06-0152;TCGA-06-0187;TCGA-06-018 chr12q15 CNOT2 3 
TCGA-06-0129;TCGA-06-0209;TCGA-06-0177;TCGA-06-
0152;TCGA-06-018 chr12q13.1-q13.3 CYP27B1 5 
TCGA-06-018 chr12q13.2-q13.3 DCTN2 1 
TCGA-06-017 chr12q12-q13 KRT4 1 
TCGA-12-061 chr12q21.32 TMTC3 1 
TCGA-06-0187;TCGA-06-018 chr12q KCNMB4 2 
TCGA-06-018 --- MBD6 1 








chr12q14.3 CPM 11 
TCGA-06-018 chr12q14.3 IRAK3 1 
TCGA-06-018 chr12q15 C12orf28 1 
TCGA-06-0129;TCGA-06-017 chr12q13.3 R3HDM2 2 
TCGA-06-0129;TCGA-06-0209;TCGA-06-017 chr12q13-q14 TSFM 3 
TCGA-06-018 chr12q13.3 INHBE 1 
TCGA-06-0177;TCGA-06-018 chr12q14.1 FAM19A2 2 
TCGA-06-0177;TCGA-06-018 chr12q14.3 RAB3IP 2 
TCGA-06-018 chr12q13.2 MARS 1 
TCGA-12-061 chr12q21.32 C12orf29 1 
TCGA-06-017 chr12q13-q15 CTDSP2 1 
TCGA-06-012 chr12q21.33 C12orf12 1 
TCGA-06-0209;TCGA-02-0052;TCGA-06-0152;TCGA-06-
0173;TCGA-06-0182;TCGA-02-010 chr12q15 NUP107 6 
TCGA-06-017 chr12q13.11 SLC38A1 1 
TCGA-06-017 chr12q12-q13 KRT7 1 




Patient ID Chromosomal Location gene count 
TCGA-06-017 chr12q13.2 WIBG 1 
TCGA-06-0209;TCGA-06-0152;TCGA-06-018 chr12q13-q15 YEATS4 3 
TCGA-06-0177;TCGA-06-0152;TCGA-06-0182;TCGA-02-010 chr12q14.2 SRGAP1 4 
TCGA-06-017 chr12q13.3 HOXC8 1 
TCGA-06-017 chr12q13.3 HOXC9 1 
TCGA-06-0129;TCGA-06-0209;TCGA-06-0177;TCGA-06-
0152;TCGA-06-018 chr12q13 METTL1 5 
TCGA-06-017 chr12q13.3 ZBTB39 1 
TCGA-06-0209;TCGA-06-0152;TCGA-06-0187;TCGA-02-010 chr12q15 FRS2 4 
TCGA-06-018 chr12q14 ARHGAP9 1 
TCGA-06-0209;TCGA-06-018 chr12q15 LYZ 2 
TCGA-06-018 chr12q15-q21 PTPRB 1 
TCGA-06-012 chr12q13.3 STAC3 1 
TCGA-06-015 chr12q14 LEMD3 1 
TCGA-06-017 chr12q13.3 HOXC4 1 
TCGA-06-014 chr14q32.33 PLD4 1 
TCGA-06-014 chr14q32.32|14q32.32 AKT1 1 
TCGA-06-014 chr14q32.33 KIAA0284 1 
TCGA-06-014 chr14q32.33 ADSSL1 1 
TCGA-06-018 chr22q11.23 GSTT1 1 














Appendix B   R code for data processing 
library(snapCGH); 
library(limma); 
targets <- readTargets("targets"); 




data = read.maimages(targets$FileName, columns=cols, source = 
'agilent') 
save(data, file = "data") 
save.image(file = "importeddata.RData") 
RG2 <- backgroundCorrect(data, method="minimum") 
RG3 <- RG2[grep("chr", data$genes$SystematicName),] 
RG3$genes$Chr <- gsub(":.+", "", RG3$genes$SystematicName)   
RG4 <- RG3[-grep("_random", RG3$genes$Chr),] 
RG4$genes$Chr <- gsub("chr", "", RG4$genes$Chr) 
RG4$genes$Chr <- gsub("X", "23", RG4$genes$Chr) 
RG4$genes$Chr <- gsub("Y", "24", RG4$genes$Chr) 
RG4$genes$Chr <- as.numeric(as.character(RG4$genes$Chr)) 
 
RG4$genes$Position <- gsub(".+:", "", 





RG4$genes$end <- gsub(".+-", "", RG4$genes$SystematicName) 
RG4$genes$end <- as.numeric(as.character(RG4$genes$end)) 
RG5 <- RG4[order(RG4$genes$Chr, RG4$genes$Position),] 
RG5$weights <- array(1, dim(RG5))     
RG5$weights[RG5$genes$chrom > 22,] <- 0 
colnames(RG5$weights) <- colnames(RG5$G) 
save(RG5, file = "RG5"); 




MA <- normalizeWithinArrays(RG5, bc.method="none", 
method="none")   
MA$targets <- readTargets("targets"); 
MA$design <- rep(1,dim(MA)[2])  
save(MA, file = "MA"); 
MA2 <- processCGH(MA, maxChromThreshold=24, 
method.of.averaging=mean, ID="ProbeName") 





Seg.CBS <- runDNAcopy(MA2) 
Seg.HHMM <- runHomHMM(MA2) 
save.image(file = "seg.RData");        gc(); 
Seg.CBS.merged <- mergeStates(Seg.CBS, MergeType=1) 
Seg.HHMM.merged <- mergeStates(Seg.HHMM, MergeType = 1) 
save(Seg.CBS.merged, Seg.CBS, file="SegCBS") 
save(Seg.HHMM.merged, Seg.HHMM, file = "SegHHMM") 
save.image(file = "mergesStates.RData") 
 
 




simu_data1 <- simulateData(nArrays = 4, seed = 1, output = 
TRUE) 
simu_data2 <- simulateData(nArrays = 20, seed = 1, output = 
TRUE) 
simu_data3 <- simulateData(nArrays = 50, seed = 1, output = 
TRUE) 
simu_data4 <- simulateData(nArrays = 100, seed = 1, output = 
TRUE) 
simu_data5 <- simulateData(nArrays = 170, seed = 1, output = 
TRUE) 
 
sim.HHMM1 <- runHomHMM(simu_data1) 
sim.DNAcopy1 <- runDNAcopy(simu_data1)  
sim.HHMM2 <- runHomHMM(simu_data2) 
sim.DNAcopy2 <- runDNAcopy(simu_data2) 
sim.HHMM3 <- runHomHMM(simu_data3) 
sim.DNAcopy3 <- runDNAcopy(simu_data3) 
sim.HHMM4 <- runHomHMM(simu_data4) 
sim.DNAcopy4 <- runDNAcopy(simu_data4) 
sim.HHMM5 <- runHomHMM(simu_data5) 
sim.DNAcopy5 <- runDNAcopy(simu_data5) 
 
comp1 <- compareSegmentations(simu_data1, offset = 0, 
sim.HHMM1, sim.DNAcopy1) 
comp2 <- compareSegmentations(simu_data2, offset = 0, 
sim.HHMM2, sim.DNAcopy2) 
comp3 <- compareSegmentations(simu_data3, offset = 0, 
sim.HHMM3, sim.DNAcopy3) 
comp4 <- compareSegmentations(simu_data4, offset = 0, 
sim.HHMM4, sim.DNAcopy4) 








boxplot(comp1$TPR ~ row(comp1$TPR), col = c("red", "blue"), 
main = "True Positive rate") 
boxplot(comp1$FDR ~ row(comp1$FDR), col = c("red", "blue"), 
main = "False Positive rate") 
boxplot(comp2$TPR ~ row(comp2$TPR), col = c("red", "blue"), 
main = "True Positive rate") 
boxplot(comp2$FDR ~ row(comp2$FDR), col = c("red", "blue"), 
main = "False Positive rate") 
boxplot(comp3$TPR ~ row(comp3$TPR), col = c("red", "blue"), 
main = "True Positive rate") 
boxplot(comp3$FDR ~ row(comp3$FDR), col = c("red", "blue"), 
main = "False Positive rate") 
boxplot(comp4$TPR ~ row(comp4$TPR), col = c("red", "blue"), 
main = "True Positive rate") 
boxplot(comp4$FDR ~ row(comp4$FDR), col = c("red", "blue"), 
main = "False Positive rate") 
boxplot(comp5$TPR ~ row(comp5$TPR), col = c("red", "blue"), 
main = "True Positive rate") 
boxplot(comp5$FDR ~ row(comp5$FDR), col = c("red", "blue"), 
main = "False Positive rate"); 
 





files <- list.files(pattern=".txt$"); 
pdf("survival_plot.pdf", width=8, height=10) 
par(mfrow=c(4,3)) 
for(i in files) { 
d <- read.table(i, header=TRUE, sep="\t"); 
fit <- survfit(Surv(d$suv, d$dead) ~d[,5], data = d) 
fit2 <- survdiff(Surv(d$suv, d$dead) ~d[,5], data = d) 
pval <- 1-pchisq(fit2$chisq, 1) 
f <- length(d[d[,5]==1,4]); 
 
p <- format(pval, digit = 2) 
title = paste("pvalue", ":", p) 
if((pval <0.005)&(f>3)){ 
write.table(pval, paste(i, c(".out"), sep=""), quote=FALSE, 
sep="\t", col.names = "pvalue");   
plot(fit, main = title, lty = c(1,3), xlab = "months", ylab = 
"Survival Prob") 










Glossary and abbreviation 
Aneuploidy: The occurrence of one or more extra or missing chromosomes leading to 
an unbalanced chromosome complement, or, any chromosome number that is 
not an exact multiple of the haploid number 
BioConductor: BioConductor represents the web site of www.bioconductor.org where 
hoses many R packages used for the microarray data processing and 
analyzing.  
CBS: Circular Binary Segmentation  
Cell cycle: The cell cycle, or cell-division cycle, is the series of events that takes 
place in a cell leading to its division and duplication (replication). In cells 
without a nucleus (prokaryotic), the cell cycle occurs via a process termed 
binary fission. In cells with a nucleus (eukaryotes), the cell cycle can be 
divided in two brief periods: interphase—during which the cell grows, 
accumulating nutrients needed for mitosis and duplicating its DNA—and the 
mitosis (M) phase, during which the cell splits itself into two distinct cells, 
often called "daughter cells". 
Centromere: The specialized region of a chromosome to which spindle fibers attach 
during cell division 
CGH: Comparative genomic hybridization 
Comparative genomic hybridization (CGH) is a technique that allows the detection of 
losses and gains in DNA copy number across the entire genome without prior 
knowledge of specific chromosomal abnormalities. Comparative genomic 
hybridization utilizes the hybridization of differentially labeled tumor and 
reference DNA to generate a map of DNA copy number changes in tumor 
genomes. Comparative genomic hybridization is an ideal tool for analyzing 
chromosomal imbalances in archived tumor material and for examining 




Chromosome: In prokaryotes, the intact DNA molecule containing the genome. In 
eukaryotes, a DNA molecule complexed with RNA and protein into a 
threadlike structure containing a linear array of genes. 
Chromosomal aberration: Any type of change in the chromosome structure or number 
(deficiencies, duplications, translocations, inversions, etc.). Although it can be 
a mechanism for enhancing genetic diversity, such alterations are usually fatal 
or ill-adaptive, especially in animals. 
CLAC: Cluster Along Chromosomes  
Diploid: The condition of having two of each chromosome. Somatic cells of higher 
plants and animals are normally diploid. 
DLRs: Derivative Log Ratio spread 
DNA: (deoxyribonucleic acid) The macromolecule that contains genetic information 
and comprises the genes. DNA consists of a chain of deoxyribonucleotides 
joined by phosphodiester linkages. Each deoxyribonucleotide consists of a 
nitrogenous base attached to the sugar deoxyribose, which in turn has a 
phosphate group attached at its 5' position. 
FISH: Fluorescent in situ hybridization 
Fluorescence in situ hybridization (FISH) is a laboratory technique for detecting and 
locating a specific DNA sequence on a chromosome. The technique relies on 
exposing chromosomes to a small DNA sequence called a probe that has a 
fluorescent molecule attached to it. The probe sequence binds to its 
corresponding sequence on the chromosome. 
Gene: The fundamental unit of heredity; a segment of DNA found at a fixed location 
on a chromosome that codes for a single polypeptide. 
Gene expression: The process of RNA and protein production by which genes exert 
their phenotypic effects on an organism. 
Genome: A genome is an organism’s complete set of DNA, including all of its genes. 
Each genome contains all of the information needed to build and maintain that 
organism. In humans, a copy of the entire genome—more than 3 billion DNA 




GLAD: Gain and Loss Analysis of DNA 
GO: Genome Ontology 
The Gene Ontology (GO) project is a collaborative effort to address the need for 
consistent descriptions of gene products in different databases. The GO 
collaborators are developing three structured, controlled vocabularies 
(ontologies) that describe gene products in terms of their associated biological 
processes, cellular components and molecular functions in a species-
independent manner.  
HHMM: Homogenous Hidden Markov Model 
Karyotypes: A photographic representation of the chromosomes of a single cell, cut 
and arranged in pairs based on their banding pattern and size according to a 
standard classification 
Microarray: Sets of miniaturized chemical reaction areas that may also be used to test 
DNA fragments, antibodies, or proteins, by using a chip having immobilised 
target and hybridising them with probed sample. the color we get from the 
chip after hybridisation is then scanned and the data is analysed by a soft ware 
to find the expression level. 
Ploidy: A term referring to the basic set of chromosomes or multiples of that set. 
QC: Quality Control 
Sex chromosome: A chromosome involved in sex determination. An example of this 
are the X and Y chromosomes of humans. 
TCGA: The Cancer Genome Atlas  
The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to 
accelerate our understanding of the genetics of cancer using innovative 
genome analysis technologies. 
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